WorldWideScience

Sample records for actinium d

  1. Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

    The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces ∼100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 GeV protons

  2. Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

    Harvey, James T.; Nolen, Jerry; Vandergrift, George; Gomes, Itacil; Kroc, Tom; Horwitz, Phil; McAlister, Dan; Bowers, Del; Sullivan, Vivian; Greene, John

    2011-12-30

    The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces {approx}100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 Ge

  3. Extraction of actinium with di-(2-ethylhexyl)phosphoric acid from hydrochloric and nitric acid solutions

    The extraction of actinium with HDEHP from Cl- and NO3- systems has been investigated. It was found that extraction of actinium from HCl solutions is much better than from HNO3 solutions. Stability constants of actinium complexes Ac(X-)+2 with Cl- and NO3- ligands were determined. Our results show that the actinium formed less stable complexes with Cl- than with NO3- ligands. 5 refs., 3 figs., 1 tab. (author)

  4. The sorption of polonium, actinium and protactinium onto geological materials

    This paper describes a combined experimental and modeling program of generic sorption studies to increase confidence in the performance assessment for a potential high-level radioactive waste repository in Japan. The sorption of polonium, actinium and protactinium onto geological materials has been investigated. Sorption of these radioelements onto bentonite, tuff and granodiorite from equilibrated de-ionized water was studied under reducing conditions at room temperature. In addition, the sorption of actinium and protactinium was investigated at 60 C. Thermodynamic chemical modeling was carried out to aid interpretation of the results

  5. Separation of Actinium 227 from the uranium minerals

    The purpose of this work was to separate Actinium 227, whose content is 18%, from the mineral carnotite found in Gomez Chihuahua mountain range in Mexico. The mineral before processing is is pre-concentrated and passed, first through anionic exchange resins, later the eluate obtained is passed through cationic resins. The resins were 20-50 MESH QOWEX and 100-200 MESH 50 X 8-20 in some cased 200-400 MESH AG 50W-X8, 1X8 in other cases. The eluates from the ionic exchange were electrodeposited on stainless steel polished disc cathode and platinum electrode as anode; under a current ODF 10mA for 2.5 to 5 hours and of 100mA for .5 of an hour. it was possible to identify the Actinium 227 by means of its descendents, TH-227 and RA-223, through alpha spectroscopy. Due to the radiochemical purity which the electro deposits were obtained the Actinium 227 was low and was not quantitatively determined. A large majority of the members of the natural radioactive series 3 were identified and even alpha energies reported in the literature with very low percentages of non-identified emissions were observed. We conclude that a more precise study is needed concerning ionic exchange and electrodeposit to obtain an Actinium 227 of radiochemical purity. (Author)

  6. Spectroscopic and computational investigation of actinium coordination chemistry.

    Ferrier, Maryline G; Batista, Enrique R; Berg, John M; Birnbaum, Eva R; Cross, Justin N; Engle, Jonathan W; La Pierre, Henry S; Kozimor, Stosh A; Lezama Pacheco, Juan S; Stein, Benjamin W; Stieber, S Chantal E; Wilson, Justin J

    2016-01-01

    Actinium-225 is a promising isotope for targeted-α therapy. Unfortunately, progress in developing chelators for medicinal applications has been hindered by a limited understanding of actinium chemistry. This knowledge gap is primarily associated with handling actinium, as it is highly radioactive and in short supply. Hence, Ac(III) reactivity is often inferred from the lanthanides and minor actinides (that is, Am, Cm), with limited success. Here we overcome these challenges and characterize actinium in HCl solutions using X-ray absorption spectroscopy and molecular dynamics density functional theory. The Ac-Cl and Ac-OH2O distances are measured to be 2.95(3) and 2.59(3) Å, respectively. The X-ray absorption spectroscopy comparisons between Ac(III) and Am(III) in HCl solutions indicate Ac(III) coordinates more inner-sphere Cl(1-) ligands (3.2±1.1) than Am(III) (0.8±0.3). These results imply diverse reactivity for the +3 actinides and highlight the unexpected and unique Ac(III) chemical behaviour. PMID:27531582

  7. Discovery of the actinium, thorium, protactinium, and uranium isotopes

    Fry, C; Thoennessen, M

    2012-01-01

    Currently, 31 actinium, 31 thorium, 28 protactinium, and 23 uranium isotopes have so far been observed; the discovery of these isotopes is discussed. For each isotope a brief summary of the first refereed publication, including the production and identification method, is presented.

  8. Production of high-purity radium-223 from legacy actinium-beryllium neutron sources.

    Soderquist, Chuck Z; McNamara, Bruce K; Fisher, Darrell R

    2012-07-01

    Radium-223 is a short-lived alpha-particle-emitting radionuclide with potential applications in cancer treatment. Research to develop new radiopharmaceuticals employing (223)Ra has been hindered by poor availability due to the small quantities of parent actinium-227 available world-wide. The purpose of this study was to develop innovative and cost-effective methods to obtain high-purity (223)Ra from (227)Ac. We obtained (227)Ac from two surplus actinium-beryllium neutron generators. We retrieved the actinium/beryllium buttons from the sources and dissolved them in a sulfuric-nitric acid solution. A crude actinium solid was recovered from the solution by coprecipitation with thorium fluoride, leaving beryllium in solution. The crude actinium was purified to provide about 40 milligrams of actinium nitrate using anion exchange in methanol-water-nitric acid solution. The purified actinium was then used to generate high-purity (223)Ra. We extracted (223)Ra using anion exchange in a methanol-water-nitric acid solution. After the radium was separated, actinium and thorium were then eluted from the column and dried for interim storage. This single-pass separation produces high purity, carrier-free (223)Ra product, and does not disturb the (227)Ac/(227)Th equilibrium. A high purity, carrier-free (227)Th was also obtained from the actinium using a similar anion exchange in nitric acid. These methods enable efficient production of (223)Ra for research and new alpha-emitter radiopharmaceutical development. PMID:22697483

  9. Radium, thorium, and actinium extraction from seawater using an improved manganese-oxide-coated fiber

    Laboratory experiments were conducted to determine the efficiency with which improved manganese-oxide-coated acrylic fibers extract radium, thorium, and actinium from seawater. Tests were made using surface seawater spiked with 227Ac, 227Th and 223Ra. For sample volumes of approximately 30 liters and flow rates up to 0.5 liters per minute, radium and actinium are removed quantitatively. Approximately 80-95% of the thorium is removed under these same conditions. (Auth.)

  10. Neutron-Induced Fission of Actinium-227, Protactinium-231 and Neptunium-237: Mass Distribution

    Results of radiochemical studies on the mass distribution in the neutron-induced fission of actinium-227, protactinium-231 and neptunium-237 have been presented. This work has been carried out as part of a programme to determine the mass distribution in the fission of heavy elements as a function of Z and A. All irradiations have been carried out in the core of the swimming-pool type reactor APSARA with cadmium shielding wherever necessary. Relative yields of several fission product nuclides have been obtained by a method involving a comparison of the fission product activities from the respective targets with those formed from uranium-235 simultaneously irradiated. Thermal-neutron fission yields of uranium-235 have been assumed. These results indicate a predominantly asymmetric mass distribution in all the three cases, and also a distinct though small symmetric peak in the case of actinium-227. (author)

  11. A new method for the determination of low-level actinium-227 in geological samples

    We developed a new method for the determination of 227Ac in geological samples. The method uses extraction chromatographic techniques and alpha-spectrometry and is applicable for a range of natural matrices. Here we report on the procedure and results of the analysis of water (fresh and seawater) and rock samples. Water samples were acidified and rock samples underwent total dissolution via acid leaching. A DGA (N,N,N',N'-tetra-n-octyldiglycolamide) extraction chromatographic column was used for the separation of actinium. The actinium fraction was prepared for alpha spectrometric measurement via cerium fluoride micro-precipitation. Recoveries of actinium in water samples were 80 ± 8 % (number of analyses n = 14) and in rock samples 70 ± 12 % (n = 30). The minimum detectable activities (MDA) were 0.017-0.5 Bq kg-1 for both matrices. Rock sample 227Ac activities ranged from 0.17 to 8.3 Bq kg-1 and water sample activities ranged from below MDA values to 14 Bq kg-1of 227Ac. From the analysis of several standard rock and water samples with the method we found very good agreement between our results and certified values. (author)

  12. Analysis of the gamma spectra of the uranium, actinium, and thorium decay series

    Momeni, M.H.

    1981-09-01

    This report describes the identification of radionuclides in the uranium, actinium, and thorium series by analysis of gamma spectra in the energy range of 40 to 1400 keV. Energies and absolute efficiencies for each gamma line were measured by means of a high-resolution germanium detector and compared with those in the literature. A gamma spectroscopy method, which utilizes an on-line computer for deconvolution of spectra, search and identification of each line, and estimation of activity for each radionuclide, was used to analyze soil and uranium tailings, and ore.

  13. Analysis of the gamma spectra of the uranium, actinium, and thorium decay series

    This report describes the identification of radionuclides in the uranium, actinium, and thorium series by analysis of gamma spectra in the energy range of 40 to 1400 keV. Energies and absolute efficiencies for each gamma line were measured by means of a high-resolution germanium detector and compared with those in the literature. A gamma spectroscopy method, which utilizes an on-line computer for deconvolution of spectra, search and identification of each line, and estimation of activity for each radionuclide, was used to analyze soil and uranium tailings, and ore

  14. In-source laser spectroscopy developments at TRILIS—towards spectroscopy on actinium and scandium

    Resonance Ionization Laser Ion Sources (RILIS) have become a versatile tool for production and study of exotic nuclides at Isotope Separator On-Line (ISOL) facilities such as ISAC at TRIUMF. The recent development and addition of a grating tuned spectroscopy laser to the TRIUMF RILIS solid state laser system allows for wide range spectral scans to investigate atomic structures on short lived isotopes, e.g., those from the element actinium, produced in uranium targets at ISAC. In addition, development of new and improved laser ionization schemes for rare isotope production at ISAC is ongoing. Here spectroscopic studies on bound states, Rydberg states and autoionizing (AI) resonances on scandium using the existing off-line capabilities are reported. These results allowed to identify a suitable ionization scheme for scandium via excitation into an autoionizing state at 58,104 cm − 1 which has subsequently been used for ionization of on-line produced exotic scandium isotopes.

  15. Developments towards in-gas-jet laser spectroscopy studies of actinium isotopes at LISOL

    Raeder, S.; Bastin, B.; Block, M.; Creemers, P.; Delahaye, P.; Ferrer, R.; Fléchard, X.; Franchoo, S.; Ghys, L.; Gaffney, L. P.; Granados, C.; Heinke, R.; Hijazi, L.; Huyse, M.; Kron, T.; Kudryavtsev, Yu.; Laatiaoui, M.; Lecesne, N.; Luton, F.; Moore, I. D.; Martinez, Y.; Mogilevskiy, E.; Naubereit, P.; Piot, J.; Rothe, S.; Savajols, H.; Sels, S.; Sonnenschein, V.; Traykov, E.; Van Beveren, C.; Van den Bergh, P.; Van Duppen, P.; Wendt, K.; Zadvornaya, A.

    2016-06-01

    To study exotic nuclides at the borders of stability with laser ionization and spectroscopy techniques, highest efficiencies in combination with a high spectral resolution are required. These usually opposing requirements are reconciled by applying the in-gas-laser ionization and spectroscopy (IGLIS) technique in the supersonic gas jet produced by a de Laval nozzle installed at the exit of the stopping gas cell. Carrying out laser ionization in the low-temperature and low density supersonic gas jet eliminates pressure broadening, which will significantly improve the spectral resolution. This article presents the required modifications at the Leuven Isotope Separator On-Line (LISOL) facility that are needed for the first on-line studies of in-gas-jet laser spectroscopy. Different geometries for the gas outlet and extraction ion guides have been tested for their performance regarding the acceptance of laser ionized species as well as for their differential pumping capacities. The specifications and performance of the temporarily installed high repetition rate laser system, including a narrow bandwidth injection-locked Ti:sapphire laser, are discussed and first preliminary results on neutron-deficient actinium isotopes are presented indicating the high capability of this novel technique.

  16. Groundwater seepage from the Ranger uranium mine tailings dam: radioisotopes of radium, thorium and actinium. Supervising Scientist report 106

    Monitoring of bores near the Ranger uranium mine tailings dam has revealed deterioration in water quality in several bores since 1983. In a group of bores to the north of the dam, increases have been observed of up to 500 times for sulphate concentrations and of up to 5 times for 226Ra concentrations. Results are presented here of measurements of members of the uranium, thorium and actinium decay series in borewater samples collected between 1985 and 1993. In particular, measurements of all four naturally-occurring radium isotopes have been used in an investigation of the mechanism of radium concentration changes. For the most seepage-affected bores the major findings of the study include: 228Ra/226Ra 223Ra /226Ra and 224Ra/228Ra ratios all increased over the course of the study; barium concentrations show high seasonal variability, being lower in November than May, but strontium concentrations show a steady increase with time. Calculations show that the groundwater is probably saturated with respect to barite but not with respect to celestite or anglesite; sulphide concentrations are low in comparison with sulphate, and are higher in November than in May; and 227Ac concentrations have increased with time, but do not account for the high 223Ra/226Ra ratios. It is concluded on the basis of these observations that increases in Ra isotope concentrations observed in a number of seepage-affected bores arise from increases in salinity leading to desorption of radium from adsorption sites in the vicinity of the bore rather by direct transport of radium from the tailings. Increased salinity is also causing the observed increases in 227Ac and strontium concentrations, while formation of a barite solid phase in the groundwater is causing the removal of some radium from solution. This is the cause of the increasing radium isotope ratios noted above

  17. origin of elements of the Uranium-235 family observed in the Ellez river near the EL-4 experimental nuclear reactor in dismantling (Monts d'Arree- Finistere department)

    In a previous study which concerned the catchment basin of the harbour of Brest, the A.C.R.O. put in evidence a marking by artificial radioelements around the power plant of Brennilis which can be imputed without ambiguities to the nuclear installation. It also put in evidence abnormalities concerning the natural radioactivity which justifies this new study. In the area of the Monts d'Arree, actinium 227 (227Ac), non born by its ascendents which are 235U and 231Pa is observed. This phenomenon is characterized by mass activities superior to these ones of 235U and able to reach these ones of 238U. Its presence corresponds with the drainage of the Ellez river since the former channel of radioactive effluents releases from the nuclear power plant EL-4 up to the reservoir Saint-Herblot situated 6 km downstream. The strongest values of radioactivity are registered near the disused power plant, at this place a relationship exists between the level of actinium 227 and this one of the artificial radioactivity as it exists a relationship with the decay products of radon exhaled from the subsoil (210Pb). But its presence is not limited to a part of the Ellez river, it is equally observed in terrestrial medium, in places in priori not influenced by the direct liquid effluents of the power plant. This place is situated at more than 4 km and without any connection with the Ellez waters. At this stage of the study, it is not possible to answer with certainty the question of the origin of this phenomenon. A new reorientation is considered indispensable to clarify definitively the origin of this unknown phenomenon in the scientific publications and the environmental monitoring. (N.C.)

  18. Geological disposal: security and R and D. Security of 'second draft for R and D of geological disposal'

    The second draft for R and D of geological disposal (second draft) was arranged in 1999. The idea of security of geological disposal in the second draft is explained. The evaluation results of the uncertainty analysis and an example of evaluation of the effect of separation nuclear transmutation on the geological disposal are shown. The construction of strong engineered barrier is a basic idea of geological disposal system. Three processes such as isolation, engineering countermeasures and safety evaluation are carried out for the security of geological disposal. The security of geological environment for a long time of 12 sites in Japan was studied by data. Provability of production and enforcement of engineered barrier were confirmed by trial of over pack, tests and the present and future technologies developed. By using the conditions of reference case in the second draft, the evaluation results of dose effects in the two cases: 1) 90 to 99% Cs and Sr removed from HLW (High Level radioactive Waste) and 2) high stripping ratio of actinium series are explained. (S.Y.)

  19. Origin of elements of the Uranium-235 family observed in the Ellez river near the EL-4 experimental nuclear reactor in dismantling (Monts d'Arree- Finistere department); Origine des elements de la famille de l'uranium-235 observes dans la riviere Ellez a proximite du reacteur nucleaire experimental EL4 en cours de demantelement (Mont d'Arree - departement du Finistere). Resultats et premiers constats annee 2006

    NONE

    2006-07-01

    In a previous study which concerned the catchment basin of the harbour of Brest, the A.C.R.O. put in evidence a marking by artificial radioelements around the power plant of Brennilis which can be imputed without ambiguities to the nuclear installation. It also put in evidence abnormalities concerning the natural radioactivity which justifies this new study. In the area of the Monts d'Arree, actinium 227 ({sup 227}Ac), non born by its ascendents which are {sup 235}U and {sup 231}Pa is observed. This phenomenon is characterized by mass activities superior to these ones of {sup 235}U and able to reach these ones of {sup 238}U. Its presence corresponds with the drainage of the Ellez river since the former channel of radioactive effluents releases from the nuclear power plant EL-4 up to the reservoir Saint-Herblot situated 6 km downstream. The strongest values of radioactivity are registered near the disused power plant, at this place a relationship exists between the level of actinium 227 and this one of the artificial radioactivity as it exists a relationship with the decay products of radon exhaled from the subsoil ({sup 210}Pb). But its presence is not limited to a part of the Ellez river, it is equally observed in terrestrial medium, in places in priori not influenced by the direct liquid effluents of the power plant. This place is situated at more than 4 km and without any connection with the Ellez waters. At this stage of the study, it is not possible to answer with certainty the question of the origin of this phenomenon. A new reorientation is considered indispensable to clarify definitively the origin of this unknown phenomenon in the scientific publications and the environmental monitoring. (N.C.)

  20. D and D projects trends

    This series of slides presents: 1 - the Various types of needs and types of operations in any D and D project, 2 - the strong variety of nuclear units to dismantle, 3 - the D and D dependence on nuclear operators' strategy (Immediate/Deferred dismantling), 4 - the demand for D and D services with respect to the ageing of the nuclear fleet, 5 - the impacts to come on the D and D environment due to the Fukushima accident, 6 - the geographical dependence of D and D demands, 7 - the different D and D choices from nuclear operators in the supply chain management, 8 - the key levers in a D and D project performance, 9 - Some key competencies in D and D, 10 - Risk management for both clients and suppliers in a D and D project, 11 - AREVA involvement in Fukushima project as a key demonstration of a critical D and D project management

  1. Vitamin D

    ... But foods made from milk, like cheese and ice cream, are usually not fortified. Vitamin D is added ... bone pain and muscle weakness. What are some effects of vitamin D on health? Vitamin D is being studied for its possible ...

  2. Vitamin D

    ... body needs to grow and develop normally. Vitamin D helps your body absorb calcium. Calcium is one ... building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis ...

  3. Vitamin D

    Vitamins are substances that your body needs to grow and develop normally. Vitamin D helps your body absorb calcium. Calcium is ... main building blocks of bone. A lack of vitamin D can lead to bone diseases such as ...

  4. Cathepsin D

    Fusek, M.; Mareš, Michael; Větvička, V.

    Amsterdam : Academic Press, 2013 - (Salvesen, G.), s. 54-63 ISBN 978-0-12-382219-2 R&D Projects: GA AV ČR IAA400550705 Institutional support: RVO:61388963 Keywords : cathepsin D * protease * aspartic peptidase * apoptosis * cancer Subject RIV: CE - Biochemistry

  5. Performerens død

    Kuhlmann, Annelis

    I den politiske performance Funus Imaginarium er graven et værested for identiteten og statsborgeren. Som en mise en abyme-konstruktion sætter den fokus på konsekvensen af sultekunstnerens iscenesatte autorbegreb: performerens død. Performancens mimede ritual udvider opfattelsen af forholdet mell...

  6. Vitamin D

    Grant, William B; Tangpricha, Vin

    2012-01-01

    Evidence that vitamin D reduces the risk of many types of disease is increasing exponentially. In 2011, 3,100 publications with “vitamin D” in the title or abstract were published, up from 2,606 in 2010, 1,303 in 2005, and 796 in 2000. A committee operating under the auspices of the Institute of Medicine (IOM) of the US National Academies reviewed the evidence for beneficial effects of vitamin D. Their report, issued at the end of 2010, 1 found what they considered to be strong evidence for o...

  7. Economic evaluation of D-T, D-3He, and catalyzed D-D fusion reactors

    Because the D-3He reaction generates no neutrons and the D-D reaction can use abundant fuel resources, these reactions are expected to be used in advanced fuel fusion reactors. Economic considerations and engineering problems are important for realizing such reactors as commercial plants. Therefore, we estimate and compare the cost of electricity (COE) from D-T, D-3He, and catalyzed D-D (cat D-D) fusion reactors. D-3He and cat D-D reactors have a low neutron wall load. Therefore, the D-3He reactor has no wall replacement cost. In addition, no tritium breeding system is needed for the D-3He reactor, but 3He gas is rare. Because the reaction rates of the D-3He and D-D reactions are less, D-3He and D-D reactors require highly efficient confinement properties and operation at high ion temperatures. Furthermore, the power densities of D-3He and D-D reactors are smaller than that of the D-T reactor; thus, D-3He and D-D reactors require a large plasma volume. Assuming a high ion temperature (= 60 keV) and high normalized beta (= 7-8), the COE of a D-3He reactor is expected to be similar to that of a D-T reactor. In terms of cost, cat D-D is disadvantageous in comparison with D-3He and D-T reactors. (author)

  8. D3+D6 solution and D4+D6 solution

    Shin Heiyoung E-mail: hyshin@physics.utexas.edu

    2001-04-16

    We make the supergravity solutions describing the branes (D3 branes and D4 branes) localized within the D6 branes in the near core region of D6 brane. From the D=11 solutions (M3 branes and M4 branes with the Z{sub N} identifications in the transverse space) we obtain the D=10 supergravity solutions of D3 branes localized within D6 branes and D4 branes localized within D6 branes by reducing the dimension down to D=10 along a circular direction of S{sup 3} part of the transverse space. M3 brane solution leads to D=10 background representing D3 branes localized on D6 branes in the region close to the D6 branes core. M4 branes lead to the D4 branes localized on D6 branes in the region close to the D6 brane core.

  9. D3+D6 solution and D4+D6 solution

    We make the supergravity solutions describing the branes (D3 branes and D4 branes) localized within the D6 branes in the near core region of D6 brane. From the D=11 solutions (M3 branes and M4 branes with the ZN identifications in the transverse space) we obtain the D=10 supergravity solutions of D3 branes localized within D6 branes and D4 branes localized within D6 branes by reducing the dimension down to D=10 along a circular direction of S3 part of the transverse space. M3 brane solution leads to D=10 background representing D3 branes localized on D6 branes in the region close to the D6 branes core. M4 branes lead to the D4 branes localized on D6 branes in the region close to the D6 brane core

  10. Color suppressed contributions to the decay modes B_{d,s} -> D_{s,d} D_{s,d}, B_{d,s} -> D_{s,d} D^*_{s,d}, and B_{d,s} -> D^*_{s,d} D^*_{s,d}

    Eeg, Jan O.; Fajfer, Svjetlana; Prapotnik, Anita

    2005-01-01

    The amplitudes for decays of the type $B_{d,s} \\to D_{s,d} D_{s,d}$, have no factorizable contributions, while $B_{d,s} \\to D_{s,d} D^*_{s,d}$, and $B_{d,s} \\to D^*_{s,d} D^*_{s,d}$ have relatively small factorizable contributions through the annihilation mechanism. The dominant contributions to the decay amplitudes arise from chiral loop contributions and tree level amplitudes which can be obtained in terms of soft gluon emissions forming a gluon condensate. We predict that the branching rat...

  11. Facts about Vitamin D

    ... D? We get vitamin D from three sources—food, supplements, and sunlight. Sunlight When exposed to sunlight, the ... dark skin get extra vitamin D from fortified foods or supplements. How much is too much? Vitamin D toxicity ...

  12. D-D tokamak reactor studies

    A tokamak D-D reactor design, utilizing the advantages of a deuterium-fueled reactor but with parameters not unnecessarily extended from existing D-T designs, is presented. Studies leading to the choice of a design and initial studies of the design are described. The studies are in the areas of plasma engineering, first-wall/blanket/shield design, magnet design, and tritium/fuel/vacuum requirements. Conclusions concerning D-D tokamak reactors are stated

  13. Unsuccessful vitamin D treatment

    Schmedes, Anne; Hey, Henrik; Larsson, Iben;

    2012-01-01

    Vitamin D3 (25-OHD3) analyses have increased exponentially and vitamin D deficiency (D2). Lack of effect of treatment can be due to: 1......) too low dose, 2) incorrect analytical methods when injection treatment (vitamin D2) is used, 3) obesity, 4) seasonal variations, and 5) poor compliance. Treatment is mandatory in order to prevent osteopenia and osteoporosis. Vitamin D3 is more potent than vitamin D2. Injections with vitamin D2 should...... be replaced by vitamin D3....

  14. Vitamin D and diabetes

    Wolden-Kirk, Heidi; Overbergh, Lut; Christesen, Henrik Thybo;

    2011-01-01

    Experimental evidence indicates that vitamin D may play a role in the defense against type 1 diabetes (T1D) as well as type 2 diabetes (T2D). Epidemiological data have established a link between vitamin D deficiency and an increased incidence of both T1D and T2D, whereas early and long-term vitamin...

  15. 6D Interpretation of 3D Gravity

    Herfray, Yannick; Scarinci, Carlos

    2016-01-01

    We show that 3D gravity, in its pure connection formulation, admits a natural 6D interpretation. The 3D field equations for the connection are equivalent to 6D Hitchin equations for the Chern-Simons 3-form in the total space of the principal bundle over the 3-dimensional base. Turning this construction around one gets an explanation of why the pure connection formulation of 3D gravity exists. More generally, we interpret 3D gravity as the dimensional reduction of the 6D Hitchin theory. To this end, we show that any SU(2) invariant closed 3-form in the total space of the principal SU(2) bundle can be parametrised by a connection together with a 2-form field on the base. The dimensional reduction of the 6D Hitchin theory then gives rise to 3D gravity coupled to a topological 2-form field.

  16. Reflection asymmetry in odd-A and odd-odd actinium nuclei

    Theoretical calculations and measurements indicate that octupole correlations are at a maximum in the ground states of the odd-proton nuclei Ac and Pa. It has been expected that odd-odd nuclei should have even larger amount of octupole-octupole correlations. We have recently made measurements on the structure of 224Ac. Although spin and parity assignments could not be made, two bands starting at 354.1 and 360.0 keV have properties characteristic of reflection asymmetric shape. These two bands have very similar rotational constants and also similar alpha decay rates, which suggest similarity between the wavefunctions of these bands. These signatures provide evidence for octupole correlations in these nuclides

  17. Bestimmung der Ionisationsenergie von Actinium und Ultraspurenanalyse von Plutonium mit resonanter Ionisationsmassenspektrometrie (RIMS)

    Waldek, Achim Marcus

    2001-01-01

    ZusammenfassungDie Resonanzionisationsmassenspektrometrie (RIMS) verbindet hohe Elementselektivität mit guter Nachweiseffizienz. Aufgrund dieser Eigenschaften ist die Methode für Ultraspurenanalyse und Untersuchungen an seltenen oder schwer handhabbaren Elementen gut geeignet. Für RIMS werden neutrale Atome mit monochromatischem Laserlicht ein- oder mehrfach resonant auf energetisch hoch liegende Niveaus angeregt und anschließend durch einen weiteren Laserstrahl oder durch ein elektrisches Fe...

  18. Radium-228 analysis of natural waters by Cherenkov counting of Actinium-228

    The activities of 228Ra in natural waters were determined by the Cherenkov counting of the daughter nuclide 228Ac. The radium was pre-concentrated on MnO2 and the radium purified via ion exchange and, after a 2-day period of incubation to allow for secular equilibrium between the parent-daughter 228Ra(228Ac), the daughter nuclide 228Ac was isolated by ion exchange according to the method of Nour et al. [2004. Radium-228 determination of natural waters via concentration on manganese dioxide and separation using Diphonix ion exchange resin. Appl. Radiat. Isot. 61, 1173-1178]. The Cherenkov photons produced by 228Ac were counted directly without the addition of any scintillation reagents. The optimum Cherenkov counting window, sample volume, and vial type were determined experimentally to achieve optimum Cherenkov photon detection efficiency and lowest background count rates. An optimum detection efficiency of 10.9±0.1% was measured for 228Ac by Cherenkov counting with a very low Cherenkov photon background of 0.317±0.013 cpm. The addition of sodium salicylate into the sample counting vial at a concentration of 0.1 g/mL yielded a more than 3-fold increase in the Cherenkov detection efficiency of 228Ac to 38%. Tests of the Cherenkov counting technique were conducted with several water standards of known activity and the results obtained compared closely with a conventional liquid scintillation counting technique. The advantages and disadvantages of Cherenkov counting compared to liquid scintillation counting methods are discussed. Advantages include much lower Cherenkov background count rates and consequently lower minimal detectable activities for 228Ra and no need for expensive environmentally unfriendly liquid scintillation cocktails. The disadvantages of the Cherenkov counting method include the need to measure 228Ac Cherenkov photon detection efficiency and optimum Cherenkov counting volume, which are not at all required when liquid scintillation analysis is used

  19. Linear free energy relationship applied to trivalent cations with lanthanum and actinium oxide and hydroxide structure

    Linear free energy relationships for trivalent cations with crystalline M2O3 and, M(OH)3 phases of lanthanides and actinides were developed from known thermodynamic properties of the aqueous trivalent cations, modifying the Sverjensky and Molling equation. The linear free energy relationship for trivalent cations is as ΔGf,MvX0=aMvXΔGn,M3+0+bMvX+βMvXrM3+, where the coefficients aMvX, bMvX, and βMvX characterize a particular structural family of MvX, rM3+ is the ionic radius of M3+ cation, ΔGf,MvX0 is the standard Gibbs free energy of formation of MvX and ΔGn,M3+0 is the standard non-solvation free energy of the cation. The coefficients for the oxide family are: aMvX=0.2705, bMvX=-1984.75 (kJ/mol), and βMvX=197.24 (kJ/molnm). The coefficients for the hydroxide family are: aMvX=0.1587, bMvX=-1474.09 (kJ/mol), and βMvX=791.70 (kJ/molnm).

  20. Actinium: A RESTful Runtime Container for Scriptable Internet of Things Applications

    Kovatsch, Matthias; Lanter, Martin; Duquennoy, Simon

    2012-01-01

    Programming Internet of Things (IoT) applications is challenging because developers have to be knowledgeable in various technical domains, from low-power networking, over embedded operating systems, to distributed algorithms. Hence, it will be challenging to find enough experts to provide software for the vast number of expected devices, which must also be scalable and particularly safe due to the connection to the physical world. To remedy this situation, we propose an architecture that pr...

  1. New method for large scale production of medically applicable Actinium-225 and Radium-223

    Alpha-emitters (211At, 212Bi, 213Bi, 223Ra, 225Ac) are promising for targeted radiotherapy of cancer. Only two alpha decays near a cell membrane result in 50% death of cancer cell and only a single decay inside the cell is required for this. 225Ac may be used either directly or as a mother radionuclide in 213Bi isotope generator. Production of 225Ac is provided by three main suppliers - Institute for Transuranium Elements in Germany, Oak Ridge National Laboratory in USA and Institute of Physics and Power Engineering in Obninsk, Russia. The current worldwide production of 225Ac is approximately 1.7 Ci per year that corresponds to only 100-200 patients that could be treated annually. The common approach for 225Ac production is separation from mother 229Th or irradiation of 226Ra with protons in a cyclotron. Both the methods have some practical limitations to be applied routinely. 225Ac can be also produced by irradiation of natural thorium with medium energy protons . Cumulative cross sections of 225Ac, 227Ac, 227Th, 228Th formations have been obtained recently. Thorium targets (1-9 g) were irradiated by 114-91 MeV proton beam (1-50 μA) at INR linear accelerator. After dissolution in 8 M HNO3 + 0.004 M HF thorium was removed by double LLX by HDEHP in toluene (1:1). Ac and REE were pre-concentrated and separated from Ra and most fission products by DGA-Resin (Triskem). After washing out by 0.01 M HNO3 Ac was separated from REE by TRU Resin (Triskem) in 3 M HNO3 media. About 6 mCi 225Ac were separated in hot cell with chemical yield 85%. The method may be upscaled for production of Ci amounts of the radionuclide. The main impurity is 227Ac (0.1% at the EOB) but it does not hinder 225Ac from being used for medical 225Ac/213Bi generators. (author)

  2. Synthesis of chelating agents for actinium 225 complexation and its application in radioimmunotherapy

    Immunotherapy with radiolabeled antibodies should allow fairly specific targeting of certain cancers. However, iodine 131 may not be the best isotope for tumor therapy because of its limited specific activity, low beta-energy, relatively long half life and strong gamma emission. Another approach to improve therapeutic efficacy is the use of replacement isotopes with better physical properties. Chelator that can hold radio-metals with high stability under physiological conditions are essential to avoid excessive damage to non-target cells; Moreover, the development of new bifunctional chelating agents is essential for this purpose. Accordingly, our efforts have been directed, for several years, to the synthesis of original chelating agents likely to form stable complexes in vivo with the numerous potential candidates for such applications. Therefore, we have developed a new simple and efficient synthesis pathway of 2-(4-iso-thio-cyanate-benzyl)-1,4,7,10,13,16- hexa-aza-cyclo-hexadecane- 1,4,7,10,13,16-hexa-acetic acid, though functionalized on the cycle by a termination allowed coupling to an antibody or any other biological substance such as a hapten. (author)

  3. Purification of selenium from thorium, uranium, radium, actinium and potassium impurities for low background measurements

    A technique of selenium purification from 232Th, 238U, 226,228Ra, 227Ac and 40K was developed. This technique is simple to perform and employs a minimum number of highly pure reagents (bidistilled water, nitric acid). Operations carried out during purification (elution, evaporation) practically exclude losses of the target product (chemical yields of Se > 99%). A test purification of 100 g of selenium was carried out using this technique. The efficiency of this technique was confirmed by low background gamma spectrometry of the purified selenium sample. Distribution coefficients of Th, U, Ra and Ac on DOWEX 50W- x 8 cation-exchange resin at different concentrations of selenium and nitric acid were experimentally determinated. Instrumental neutron activation analysis of bidistilled water, deionized water and nitric acid was performed. (orig.)

  4. Purification of selenium from thorium, uranium, radium, actinium and potassium impurities for low background measurements

    Rakhimov, A.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Uzbek Academy of Sciences, Tashkent (Uzbekistan). Inst. of Nuclear Physics (INP AS RUz); Warot, G. [CEA-CNRS, Modane (France). Laboratoire Souterrain de Modane (LSM); Karaivanov, D.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Institute for Nuclear Research and Nuclear Energy (INRNE), Sofia (Bulgaria); Kochetov, O.I.; Lebedev, N.A.; Filosofov, D.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Mukhamedshina, N.M.; Sadikov, I.I. [Uzbek Academy of Sciences, Tashkent (Uzbekistan). Inst. of Nuclear Physics (INP AS RUz)

    2013-07-01

    A technique of selenium purification from {sup 232}Th, {sup 238}U, {sup 226,228}Ra, {sup 227}Ac and {sup 40}K was developed. This technique is simple to perform and employs a minimum number of highly pure reagents (bidistilled water, nitric acid). Operations carried out during purification (elution, evaporation) practically exclude losses of the target product (chemical yields of Se > 99%). A test purification of 100 g of selenium was carried out using this technique. The efficiency of this technique was confirmed by low background gamma spectrometry of the purified selenium sample. Distribution coefficients of Th, U, Ra and Ac on DOWEX 50W- x 8 cation-exchange resin at different concentrations of selenium and nitric acid were experimentally determinated. Instrumental neutron activation analysis of bidistilled water, deionized water and nitric acid was performed. (orig.)

  5. Calcium and Vitamin D

    ... Home › Patients › Treatment › Calcium/Vitamin D Calcium/Vitamin D Getting enough calcium and vitamin D is essential ... counter medications and calcium supplements. What is Vitamin D and What Does it Do? Vitamin D plays ...

  6. Drug: D08227 [KEGG MEDICUS

    Full Text Available 303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Co...rticosteroids, potent (group III) D07AC13 Mometasone D08227 Mometasone (INN) D07X CORTICOSTEROIDS, OTHER COM

  7. Delta agent (Hepatitis D)

    Hepatitis D virus ... Hepatitis D virus (HDV) is found only in people who carry the hepatitis B virus. HDV may make liver ... B virus but who never had symptoms. Hepatitis D infects about 15 million people worldwide. It occurs ...

  8. Vitamin D Test

    ... limited. Home Visit Global Sites Search Help? Vitamin D Tests Share this page: Was this page helpful? Also known as: Ergocalciferol (Vitamin D 2 ); Cholecalciferol (Vitamin D 3 ); Calcidiol (25-hydroxyvitamin ...

  9. 3D video

    Lucas, Laurent; Loscos, Céline

    2013-01-01

    While 3D vision has existed for many years, the use of 3D cameras and video-based modeling by the film industry has induced an explosion of interest for 3D acquisition technology, 3D content and 3D displays. As such, 3D video has become one of the new technology trends of this century.The chapters in this book cover a large spectrum of areas connected to 3D video, which are presented both theoretically and technologically, while taking into account both physiological and perceptual aspects. Stepping away from traditional 3D vision, the authors, all currently involved in these areas, provide th

  10. 3D Animation Essentials

    Beane, Andy

    2012-01-01

    The essential fundamentals of 3D animation for aspiring 3D artists 3D is everywhere--video games, movie and television special effects, mobile devices, etc. Many aspiring artists and animators have grown up with 3D and computers, and naturally gravitate to this field as their area of interest. Bringing a blend of studio and classroom experience to offer you thorough coverage of the 3D animation industry, this must-have book shows you what it takes to create compelling and realistic 3D imagery. Serves as the first step to understanding the language of 3D and computer graphics (CG)Covers 3D anim

  11. Vitamin D and Aging

    Gallagher, J. Christopher

    2013-01-01

    Aging affects the formation of 1,25-dihydroxyvitamin D (1,25[OH]2D; calcitriol), the active form of vitamin D. Production of 1,25(OH)2D is reduced by 50% as a result of an age-related decline in renal function, although serum 1,25(OH)2D levels are maintained in part by secondary hyperparathyroidism. Aging also causes a decrease in calcium absorption that precedes the decrease in 1,25(OH)2D by 10 to 15 years. Because 1,25(OH)2D is dependent on an adequate supply of the substrate vitamin D, the...

  12. Fission multipliers for D-D/D-T neutron generators

    A compact D-D/D-T fusion based neutron generator is being designed at the Lawrence Berkeley National Laboratory to have a potential yield of 1012 D-D n/s and 1014 D-T n/s. Because of its high neutron yield and compact size (∼20 cm in diameter by 4 cm long), this neutron generator design will be suitable for many applications. However, some applications required higher flux available from nuclear reactors and spallation neutron sources operated with GeV proton beams. In this study, a subcritical fission multiplier with keff of 0.98 is coupled with the compact neutron generators in order to increase the neutron flux output. We have chosen two applications to show the gain in flux due to the use of fission multipliers--in-core irradiation and out-of-core irradiation. For the in-core irradiation, we have shown that a gain of ∼25 can be achieved in a positron production system using D-T generator. For the out-of-core irradiation, a gain of ∼17 times is obtained in Boron Neutron Capture Therapy (BNCT) using a D-D neutron generator. The total number of fission neutrons generated by a source neutron in a fission multiplier with keff is ∼50. For the out-of-core irradiation, the theoretical maximum net multiplication is ∼30 due to the absorption of neutrons in the fuel. A discussion of the achievable multiplication and the theoretical multiplication will be presented in this paper

  13. Drug: D04221 [KEGG MEDICUS

    Full Text Available ne D04221 Fluorometholone acetate (USAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, D...ERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D...07AB06 Fluorometholone D04221 Fluorometholone acetate (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB

  14. Drug: D09101 [KEGG MEDICUS

    Full Text Available D09101 Formula, Drug Kosharikkunshito Ginseng [DR:D06772], (Atractylodes lancea rhizome ... [DR:D067 ... 52] | Atractylodes rhizome ... [DR:D06780]), Poria sclerotium [DR:D06783], Jujube ... R:D06778], Citrus unshiu peel [DR:D06764], Cyperus rhizome ... [DR:D06719], Amomum seed [DR:D06743], Patchouli [D ...

  15. Drug: D10037 [KEGG MEDICUS

    Full Text Available D10037 Formula, Drug Kamishimotsuto Japanese angelica root [DR:D06768], Cnidium rhizome ... [DR:D067 ... , Rehmannia root [DR:D06736], (Atractylodes lancea rhizome ... [DR:D06752] | Atractylodes rhizome ... [DR:D06780]), O ... [DR:D06689], Schisandra fruit [DR:D06724], Coptis rhizome ... [DR:D00092], Anemarrhena rhizome ... [DR:D06761], Euco ...

  16. Solid works 3D

    This book explains modeling of solid works 3D and application of 3D CAD/CAM. The contents of this book are outline of modeling such as CAD and 2D and 3D, solid works composition, method of sketch, writing measurement fixing, selecting projection, choosing condition of restriction, practice of sketch, making parts, reforming parts, modeling 3D, revising 3D modeling, using pattern function, modeling necessaries, assembling, floor plan, 3D modeling method, practice floor plans for industrial engineer data aided manufacturing, processing of CAD/CAM interface.

  17. [Vitamin D and pregnancy].

    Benachi, Alexandra; Cordier, Anne-Gael; Courbebaisse, Marie; Souberbielle, Jean-Claude

    2013-10-01

    Vitamin D insufficiency is characterized, since 2005, by 25(OH)D concentration less than 75 nmol/L (or 30 ng/mL). Vitamin D could interfere with many mechanisms involved in preeclampsia's pathogenesis including trophoblastic invasion and immunomodulation as well as blood pressure control and proteinuria. Occurrence of preeclampsia and gestational diabetes seems to be linked to vitamin D deficiency but recent data in the literature are contradictory. Vitamin D supplementation during pregnancy is controversial. Some societies consider it unnecessary and others recommend up to 2000 UI/d. There is no reported case of teratogenicity linked with vitamin D intake. PMID:24054765

  18. Vitamin D Insufficiency

    THACHER, Tom D; Clarke, Bart L.

    2011-01-01

    Vitamin D deficiency, which classically manifests as bone disease (either rickets or osteomalacia), is characterized by impaired bone mineralization. More recently, the term vitamin D insufficiency has been used to describe low levels of serum 25-hydroxyvitamin D that may be associated with other disease outcomes. Reliance on a single cutoff value to define vitamin D deficiency or insufficiency is problematic because of the wide individual variability of the functional effects of vitamin D an...

  19. En performers død

    Kuhlmann, Annelis

    Graven som nærvær for identiteten og borgeren i den politiske performance Funus Imaginarium (2010) udfolder sit fokus i en mise en abyme konstruktion som en konsekvens af en teatraliseret kunstnerhunger, udtrykt som en performers død. Det mimede begravelsesritual bringer forholdet mellem deltager...

  20. Drug: D08714 [KEGG MEDICUS

    Full Text Available D08714 Mixture, Drug d-Camphor - mentha oil mixt d-Camphor [DR:D06392], Mentha oil ... Peppermint rubber and camphor peppermint D08714 d-Camphor - mentha oil mixt PubChem: 96025397 ...

  1. Drug: D03697 [KEGG MEDICUS

    Full Text Available R:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...one (USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07

  2. Drug: D02287 [KEGG MEDICUS

    Full Text Available emical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, D...ERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D

  3. Drug: D04761 [KEGG MEDICUS

    Full Text Available D04761 Mixture, Drug d-Camphor - ethanol mixt; Camphor (TN) d-Camphor [DR:D06392], (Ethanol [DR: ... ringents, anti-inflammatory agents 2645 Peppermint rubber ... and camphor peppermint D04761 d-Camphor - ethanol ...

  4. Drug: D08510 [KEGG MEDICUS

    Full Text Available azole derivatives D01AC14 Sertaconazole D08510 Sertacona...cation [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tri

  5. Drug: D08245 [KEGG MEDICUS

    Full Text Available hemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR D...ERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D01AE22 Naftifine

  6. EUROPEANA AND 3D

    D. Pletinckx

    2012-09-01

    Full Text Available The current 3D hype creates a lot of interest in 3D. People go to 3D movies, but are we ready to use 3D in our homes, in our offices, in our communication? Are we ready to deliver real 3D to a general public and use interactive 3D in a meaningful way to enjoy, learn, communicate? The CARARE project is realising this for the moment in the domain of monuments and archaeology, so that real 3D of archaeological sites and European monuments will be available to the general public by 2012. There are several aspects to this endeavour. First of all is the technical aspect of flawlessly delivering 3D content over all platforms and operating systems, without installing software. We have currently a working solution in PDF, but HTML5 will probably be the future. Secondly, there is still little knowledge on how to create 3D learning objects, 3D tourist information or 3D scholarly communication. We are still in a prototype phase when it comes to integrate 3D objects in physical or virtual museums. Nevertheless, Europeana has a tremendous potential as a multi-facetted virtual museum. Finally, 3D has a large potential to act as a hub of information, linking to related 2D imagery, texts, video, sound. We describe how to create such rich, explorable 3D objects that can be used intuitively by the generic Europeana user and what metadata is needed to support the semantic linking.

  7. Drug: D03812 [KEGG MEDICUS

    Full Text Available DS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, ...potent (group III) D07AC06 Diflucortolone D03812 Diflucortolone (USAN) D07X CORTICOSTEROIDS...icoid ATC code: D07AC06 D07XC04 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROI

  8. Drug: D03813 [KEGG MEDICUS

    Full Text Available DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticos...teroids, potent (group III) D07AC06 Diflucortolone D03813 Diflucortolone pivalate (USAN) D07X CORTICOSTERO...IDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC04 D

  9. Drug: D10045 [KEGG MEDICUS

    Full Text Available D10045 Formula, Drug Chibakujiogan Rehmannia root [DR:D06736], Cornus fruit [DR:D06732], Dioscor ... ea rhizome ... [DR:D06735], Alisma rhizome ... [DR:D06759], Poria scl ... [DR:D06783], Moutan bark [DR:D06788], Anemarrhena rhizome ... [DR:D06761], Phellodendron bark [DR:D06689] PubChe ...

  10. Drug: D09114 [KEGG MEDICUS

    Full Text Available D09114 Formula, Drug Jingyobofuto Gentiana macrophylla root [DR:D10233], Alisma rhizome ... [DR:D067 ... se angelica root [DR:D06768], (Atractylodes lancea rhizome ... [DR:D06752] | Atractylodes rhizome ... [DR:D06780]), G ... 04365], Phellodendron bark [DR:D06689], Cimicifuga rhizome ... [DR:D06745], Rhubarb [DR:D06756], Peach kernel [DR ...

  11. Drug: D09064 [KEGG MEDICUS

    Full Text Available D09064 Formula, Drug Kyukichoketsuindaiichikagen Japanese angelica root [DR:D06768], Cnidium rhizome ... , Rehmannia root [DR:D06736], (Atractylodes lancea rhizome ... [DR:D06752] | Atractylodes rhizome ... [DR:D06780]), P ... eel [DR:D06764], Lindera root [DR:D06696], Cyperus rhizome ... [DR:D06719], Moutan bark [DR:D06788], Leonuri herb ...

  12. The D0-D8 system revisited

    Lu, J X

    2009-01-01

    We address a few subtle issues regarding the interacting D0-D8 system. There are two existing interpretations for the counter-intuitive non-vanishing attractive cylinder-diagram R-R potential. We improve them each by properly dealing with the divergence of potential in the R-R as well as the NS-NS sector, which has been ignored so far. We further test them by considering the D8 to carry a flux, electric or magnetic. We find that the improved interpretations continue to hold. We resolve a subtle issue regarding the regularization of fermionic zero-modes in the R-R sector when the D8 carries an electric flux so that a meaningful result for the potential can be calculated. The persistence of divergence for the potential in either sector in the presence of a flux on the D8 brane indicates that adding a flux/fluxes on the D8 brane doesn't help to improve its nature of existence as an independent object, therefore reenforcing the previous assertion on D8 branes.

  13. JANUS reactor d and d project

    Argonne National Laboratory (ANL-E) has recently completed the decontamination and decommissioning (D and D) of the JANUS Reactor Facility located in Building 202. The 200 KW reactor operated from August 1963 to March 1992. The facility was used to study the effects of both high and low doses of fission neutrons in animals. There were two exposure rooms on opposite sides of the reactor and the reactor was therefore named after the two-faced Roman god. The High Dose Room was capable of specimen exposure at a dose rate of 3,600 rads per hour. During calendar year 1996 a detailed characterization of the facility was performed by ANL-E Health Physics personnel. ANL-E Analytical Services performed the required sample analysis. An Auditable Safety Analysis and an Environmental Assessment were completed. D and D plans, procedures and procurement documents were prepared and approved. A D and D subcontractor was selected and a firm, fixed price contract awarded for the field work and final survey effort. The D and D subcontractor was mobilized to ANL-E in January 1997. Electrical isolation of all reactor equipment and control panels was accomplished and the equipment removed. A total of 207,230 pounds (94,082 Kg) of lead shielding was removed, surveyed and sampled, and free-released for recycle. All primary and secondary piping was removed, size reduced and packaged for disposal or recycled as appropriate. The reactor vessel was removed, sized reduced and packaged as radioactive waste in April. The activated graphite block reflector was removed next, followed by the bioshield concrete and steel. All of this material was packaged as low level waste. Total low level radioactive waste generation was 4002.1 cubic feet (113.3 cubic meters). Mixed waste generation was 538 cubic feet (15.2 cubic meters). The Final Release Survey was completed in September. The project field work was completed in 38 weeks without any lost-time accidents, personnel contaminations or unplanned

  14. The dS/dS correspondence

    We present a holographic duality for the de Sitter static patch which consolidates basic features of its geometry and the behavior of gravity and brane probes, valid on timescales short compared to the decay or Poincare recurrence times. Namely de Sitter spacetime dSd(R) in d dimensions with curvature radius R is holographically dual to two conformal field theories on dSd-l (R), cut off at an energy scale 1/R where they couple to each other and to d-1 dimensional gravity. As part of our analysis, we study brane probes in de Sitter and thermal Anti de Sitter spaces, and interpret the terms in the corresponding DBI action via strongly coupled thermal field theory. This provides a dual field theoretic interpretation of the fact that probes take forever to reach a horizon in general relativity. (author)

  15. Breastfeeding: Vitamin D Supplementation

    ... Weight Breastfeeding Micronutrient Malnutrition State and Local Programs Vitamin D Supplementation Recommend on Facebook Tweet Share Compartir ... not provide infants with an adequate intake of vitamin D. Most breastfed infants are able to synthesize ...

  16. D-xylose absorption

    D-xylose absorption is a laboratory test to determine how well the intestines absorb a simple sugar (D-xylose). The test ... test is primarily used to determine if nutrient absorption problems are due to a disease of the ...

  17. D-xylose absorption

    ... this page: //medlineplus.gov/ency/article/003606.htm D-xylose absorption To use the sharing features on this page, please enable JavaScript. D-xylose absorption is a laboratory test to determine ...

  18. D and C - slideshow

    ... this page: //medlineplus.gov/ency/presentations/100013.htm D and C - series—Normal anatomy To use the ... Update Date 6/11/2014 Updated by: Cynthia D. White, MD, Fellow American College of Obstetricians and ...

  19. Vitamin D Pooling Project

    The Vitamin D Pooling Project of Rarer Cancers brought together investigators from 10 cohorts to conduct a large prospective epidemiologic study of the association between vitamin D status and seven rarer cancers.

  20. D and C

    D and C is a procedure to scrape and collect the tissue (endometrium) from inside the uterus. Dilation ("D") is a ... cervix to allow instruments into the uterus. Curettage ("C") is the scraping of the walls of the ...

  1. Vitamin D derivatives

    The preparation is described of specified vitamin D3 esters containing alkyl and hydroxy groups. They can be used, in particular, for preparing radiolabeled vitamin D3 compounds of high specific activity. (U.K.)

  2. Vitamin D derivatives

    The chemical preparation of 26,27-isotopically labelled vitamin D3 derivatives of high specific activity is described. These labelled vitamin D derivatives are useful in the determination of vitamin D metabolite levels in the blood and tissues of man and animals. (U.K.)

  3. Nonclassical Vitamin D Actions

    Armin Zittermann

    2010-03-01

    Full Text Available It is becoming increasingly clear that vitamin D has a broad range of actions in the human body. Besides its well-known effects on calcium/phosphate homeostasis, vitamin D influences muscle function, cardiovascular homeostasis, nervous function, and the immune response. Vitamin D deficiency/insufficiency has been associated with muscle weakness and a high incidence of various chronic diseases such as cardiovascular disease, cancer, multiple sclerosis, and type 1 and 2 diabetes. Most importantly, low vitamin D status has been found to be an independent predictor of all-cause mortality. Several recent randomized controlled trials support the assumption that vitamin D can improve muscle strength, glucose homeostasis, and cardiovascular risk markers. In addition, vitamin D may reduce cancer incidence and elevated blood pressure. Since the prevalence of vitamin D deficiency/insufficiency is high throughout the world, there is a need to improve vitamin D status in the general adult population. However, the currently recommended daily vitamin D intake of 5–15 µg is too low to achieve an adequate vitamin D status in individuals with only modest skin synthesis. Thus, there is a need to recommend a vitamin D intake that is effective for achieving adequate circulating 25-hydroxyvitamin D concentrations (>75 nmol/L.

  4. Enterovirus D68

    ... Related Links Water-related Hygiene Viral Conjunctivitis Hand, Foot, and Mouth Disease Viral Meningitis What is ... D68 Enterovirus D68 (EV-D68) is one of more than 100 non-polio enteroviruses. This virus was first identified in California in 1962. What ...

  5. Enterovirus D68 Infection

    Esposito, Susanna; Bosis, Samantha; Niesters, Hubert; Principi, Nicola

    2015-01-01

    First described in 1962 in children hospitalized for pneumonia and bronchiolitis, the Enterovirus D68 (EV-D68) is an emergent viral pathogen. Since its discovery, during the long period of surveillance up to 2005, EV-D68 was reported only as a cause of sporadic outbreaks. In recent years, many repor

  6. Vitamin D and diabetes

    On the basis of evidence from animal and human studies, vitamin D has emerged as a potential risk modifier for type 1 and type 2 diabetes (t1DM and t2DM). Vitamin D is thought to have both direct (through activation of the vitamin D receptor) and indirect (via regulation of calcium homeostasis) eff...

  7. Open 3D Projects

    Felician ALECU

    2010-01-01

    Full Text Available Many professionals and 3D artists consider Blender as being the best open source solution for 3D computer graphics. The main features are related to modeling, rendering, shading, imaging, compositing, animation, physics and particles and realtime 3D/game creation.

  8. Drug: D07201 [KEGG MEDICUS

    Full Text Available classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICA...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB07 Flupr...ednidene D07201 Fluprednidene (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderate

  9. Drug: D04208 [KEGG MEDICUS

    Full Text Available ssification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PR...ne D04208 Flumethasone (USAN); Flumetasone (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticostero...EPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB03 Flumetaso

  10. Drug: D04495 [KEGG MEDICUS

    Full Text Available D04495 Drug Ictasol (USAN) Disinfectant ATC code: D10BX01 Anatomical Therapeutic Chemical (ATC) ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10B ANTI-ACNE ... PREPARATIONS FOR SYSTE ... MIC USE D10BX Other anti-acne ... preparations for systemic use D10BX01 Ichtasol D04 ...

  11. Drug: D10048 [KEGG MEDICUS

    Full Text Available D10048 Formula, Drug Tokishakuyakusankaninjin Japanese angelica root [DR:D06768], Alisma rhizome ... [DR:D06759], Cnidium rhizome ... [DR:D06748], Peony root [DR:D06739], Poria sclerot ... ium [DR:D06783], (Atractylodes rhizome ... [DR:D06780] | Atractylodes lancea rhizome ... [DR:D067 ...

  12. Drug: D10047 [KEGG MEDICUS

    Full Text Available D10047 Formula, Drug Tokishakuyakusankaogichoto Japanese angelica root [DR:D06768], Alisma rhizome ... me [DR:D06759], Cnidium rhizome ... [DR:D06748], Peony root [DR:D06739], Poria sclerot ... ium [DR:D06783], (Atractylodes rhizome ... [DR:D06780] | Atractylodes lancea rhizome ... [DR:D067 ...

  13. Drug: D09091 [KEGG MEDICUS

    Full Text Available D09091 Formula, Drug Seijokentsuto; Kufushokutsuto Ophiopogon tuber [DR:D06775], Scutellaria roo ... t [DR:D06688], Notopterygium rhizome ... [DR:D06707], Araliae cardatae rhizoma [DR:D06909], ... poshnikovia root [DR:D06787], (Atractylodes lancea rhizome ... [DR:D06752] | Atractylodes rhizome ... [DR:D06780]), J ...

  14. Drug: D07719 [KEGG MEDICUS

    Full Text Available ication [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROI...DS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB21 Clocortolone

  15. Drug: D04723 [KEGG MEDICUS

    Full Text Available D04723 Mixture, Drug Iodine tincture (JP16); Iodine tincture (TN) Iodine [DR:D00108], Potassium ... iodine [DR:D01016], (Ethanol ... [DR:D00068] | Isopropanol [DR:D00137]) Therapeutic ...

  16. Drug: D10301 [KEGG MEDICUS

    Full Text Available D10301 Mixture, Drug Chlorhexidine gluconate - alcohol mixt; Prevantics (TN) Chlorhexidine gluco ... [DR:D00858], (Isopropanol [DR:D00137] | Anhydrous ethanol ... [DR:D00068] | Ethanol ... for disinfection [DR:D04855] ...

  17. Drug: D05463 [KEGG MEDICUS

    Full Text Available matologicals D11AX03 Calcium gluconate D05463 Calcium gluconate hydrate (JP16) PubC...RMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other der

  18. Drug: D00882 [KEGG MEDICUS

    Full Text Available midazole derivatives A07AC01 Miconazole D00882 Miconazole nitrate (JP16/USP) D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tr

  19. Drug: D01046 [KEGG MEDICUS

    Full Text Available cal (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFU...NGALS FOR TOPICAL USE D01AE Other antifungals for topical use D01AE02 Methylrosanil

  20. Drug: D08313 [KEGG MEDICUS

    Full Text Available cal (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFU...NGALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D01AC11 Oxiconazole

  1. Drug: D10053 [KEGG MEDICUS

    Full Text Available D10053 Formula, Drug Renjuin Japanese angelica root [DR:D06768], (Atractylodes rhizome ... [DR:D0678 ... 0] | Atractylodes lancea rhizome ... [DR:D06752]), Cnidium rhizome ... [DR:D06748], Glycyrr ...

  2. Drug: D01910 [KEGG MEDICUS

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA13 Iodofo...10 Iodoform (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  3. IZDELAVA TISKALNIKA 3D

    Brdnik, Lovro

    2015-01-01

    Diplomsko delo analizira trenutno stanje 3D tiskalnikov na trgu. Prikazan je razvoj in principi delovanja 3D tiskalnikov. Predstavljeni so tipi 3D tiskalnikov, njihove prednosti in slabosti. Podrobneje je predstavljena zgradba in delovanje koračnih motorjev. Opravljene so meritve koračnih motorjev. Opisana je programska oprema za rokovanje s 3D tiskalniki in komponente, ki jih potrebujemo za izdelavo. Diploma se oklepa vprašanja, ali je izdelava 3D tiskalnika bolj ekonomična kot pa naložba v ...

  4. Vitamin D-mangel

    Hey, Henrik; Schmedes, Anne; Horn, Peer;

    2009-01-01

    The importance of vitamin D for osteoporosis and fractures has been known for more than 40 years. Vitamin D deficiency is diagnosed by measuring 25-hydroxyvitamin D (25-OHD), which should be > 50 nmol/l year round. Recent research suggests that a number of severe diseases could be prevented by...... increasing 25-OHD to 80 nmol/l. Despite a strong focus on such increase, recommendations for intake of Vitamin D have not been changed and the present recommendations are too low even to ensure > 50 nmol/l. To achieve optimal concentrations > 80 nmol/l, we estimate that 50-70 microgram of vitamin D per day...

  5. Pragmatic and cost efficient D and D

    A great deal of effort is expended by remediation professionals in the pursuit of new technologies to assist them in performing their tasks more efficiently. These individuals understand the cost savings associated with volume reduction and waste minimization and routinely incorporate these practices into their planning. However, the largest cost component on many D and D projects is labor. Increasing the efficiency of work force utilization is frequently the most overlooked technique that can be instituted and which can easily offer major cost savings. Granted, some D and D jobs require highly specialized tools and equipment which are quite expensive. Decreasing these costs is often not an option or will yield minimal results. Conversely, the increase in worker efficiency can usually decrease costs dramatically. During the performance of the Safe Shutdown Project at the Fernald Environmental Management Project (the Fernald site), a process improvement initiative was instituted in support of the development of the Ten Year Plan. Costs associated with the removal of hundreds of thousands of pounds of nuclear material from formerly utilized equipment piping, and ductwork in nuclear facilities at the Fernald site were analyzed. This analysis indicated that the labor component was large enough to merit further inspection. A new approach to the activities was instituted and the results were significant. A macroscopic overview of all work activities utilized work evolution control (sequencing), building segmentation, and efficient use of engineering controls to streamline the D and D process. Overall costs on the first facility were reduced by over 20%. The increased labor efficiency resulted in decreased Personal Protective Equipment costs for field personnel. This approach will be discussed in detail

  6. D ampersand D screening risk evaluation guidance

    The Screening Risk Evaluation (SRE) guidance document is a set of guidelines provided for the uniform implementation of SREs performed on decontamination and decommissioning (D ampersand D) facilities. Although this method has been developed for D ampersand D facilities, it can be used for transition (EM-60) facilities as well. The SRE guidance produces screening risk scores reflecting levels of risk through the use of risk ranking indices. Five types of possible risk are calculated from the SRE: current releases, worker exposures, future releases, physical hazards, and criticality. The Current Release Index (CRI) calculates the current risk to human health and the environment, exterior to the building, from ongoing or probable releases within a one-year time period. The Worker Exposure Index (WEI) calculates the current risk to workers, occupants and visitors inside contaminated D ampersand D facilities due to contaminant exposure. The Future Release Index (FRI) calculates the hypothetical risk of future releases of contaminants, after one year, to human health and the environment. The Physical Hazards Index (PHI) calculates the risks to human health due to factors other than that of contaminants. Criticality is approached as a modifying factor to the entire SRE, due to the fact that criticality issues are strictly regulated under DOE. Screening risk results will be tabulated in matrix form, and Total Risk will be calculated (weighted equation) to produce a score on which to base early action recommendations. Other recommendations from the screening risk scores will be made based either on individual index scores or from reweighted Total Risk calculations. All recommendations based on the SRE will be made based on a combination of screening risk scores, decision drivers, and other considerations, as determined on a project-by-project basis

  7. D & D screening risk evaluation guidance

    Robers, S.K.; Golden, K.M.; Wollert, D.A.

    1995-09-01

    The Screening Risk Evaluation (SRE) guidance document is a set of guidelines provided for the uniform implementation of SREs performed on decontamination and decommissioning (D&D) facilities. Although this method has been developed for D&D facilities, it can be used for transition (EM-60) facilities as well. The SRE guidance produces screening risk scores reflecting levels of risk through the use of risk ranking indices. Five types of possible risk are calculated from the SRE: current releases, worker exposures, future releases, physical hazards, and criticality. The Current Release Index (CRI) calculates the current risk to human health and the environment, exterior to the building, from ongoing or probable releases within a one-year time period. The Worker Exposure Index (WEI) calculates the current risk to workers, occupants and visitors inside contaminated D&D facilities due to contaminant exposure. The Future Release Index (FRI) calculates the hypothetical risk of future releases of contaminants, after one year, to human health and the environment. The Physical Hazards Index (PHI) calculates the risks to human health due to factors other than that of contaminants. Criticality is approached as a modifying factor to the entire SRE, due to the fact that criticality issues are strictly regulated under DOE. Screening risk results will be tabulated in matrix form, and Total Risk will be calculated (weighted equation) to produce a score on which to base early action recommendations. Other recommendations from the screening risk scores will be made based either on individual index scores or from reweighted Total Risk calculations. All recommendations based on the SRE will be made based on a combination of screening risk scores, decision drivers, and other considerations, as determined on a project-by-project basis.

  8. Pragmatic and cost efficient D and D

    Morris, M. [Nuclear Fuel Services, Erwin, TN (United States)

    1998-03-01

    A great deal of effort is expended by remediation professionals in the pursuit of new technologies to assist them in performing their tasks more efficiently. These individuals understand the cost savings associated with volume reduction and waste minimization and routinely incorporate these practices into their planning. However, the largest cost component on many D and D projects is labor. Increasing the efficiency of work force utilization is frequently the most overlooked technique that can be instituted and which can easily offer major cost savings. Granted, some D and D jobs require highly specialized tools and equipment which are quite expensive. Decreasing these costs is often not an option or will yield minimal results. Conversely, the increase in worker efficiency can usually decrease costs dramatically. During the performance of the Safe Shutdown Project at the Fernald Environmental Management Project (the Fernald site), a process improvement initiative was instituted in support of the development of the Ten Year Plan. Costs associated with the removal of hundreds of thousands of pounds of nuclear material from formerly utilized equipment piping, and ductwork in nuclear facilities at the Fernald site were analyzed. This analysis indicated that the labor component was large enough to merit further inspection. A new approach to the activities was instituted and the results were significant. A macroscopic overview of all work activities utilized work evolution control (sequencing), building segmentation, and efficient use of engineering controls to streamline the D and D process. Overall costs on the first facility were reduced by over 20%. The increased labor efficiency resulted in decreased Personal Protective Equipment costs for field personnel. This approach will be discussed in detail.

  9. 3d-3d correspondence revisited

    Chung, Hee-Joong; Dimofte, Tudor; Gukov, Sergei; Sułkowski, Piotr

    2016-04-01

    In fivebrane compactifications on 3-manifolds, we point out the importance of all flat connections in the proper definition of the effective 3d {N}=2 theory. The Lagrangians of some theories with the desired properties can be constructed with the help of homological knot invariants that categorify colored Jones polynomials. Higgsing the full 3d theories constructed this way recovers theories found previously by Dimofte-Gaiotto-Gukov. We also consider the cutting and gluing of 3-manifolds along smooth boundaries and the role played by all flat connections in this operation.

  10. 3D and Education

    Meulien Ohlmann, Odile

    2013-02-01

    Today the industry offers a chain of 3D products. Learning to "read" and to "create in 3D" becomes an issue of education of primary importance. 25 years professional experience in France, the United States and Germany, Odile Meulien set up a personal method of initiation to 3D creation that entails the spatial/temporal experience of the holographic visual. She will present some different tools and techniques used for this learning, their advantages and disadvantages, programs and issues of educational policies, constraints and expectations related to the development of new techniques for 3D imaging. Although the creation of display holograms is very much reduced compared to the creation of the 90ies, the holographic concept is spreading in all scientific, social, and artistic activities of our present time. She will also raise many questions: What means 3D? Is it communication? Is it perception? How the seeing and none seeing is interferes? What else has to be taken in consideration to communicate in 3D? How to handle the non visible relations of moving objects with subjects? Does this transform our model of exchange with others? What kind of interaction this has with our everyday life? Then come more practical questions: How to learn creating 3D visualization, to learn 3D grammar, 3D language, 3D thinking? What for? At what level? In which matter? for whom?

  11. Offshoring R&D

    Hansen, Zaza Nadja Lee; Rasmussen, Lauge Baungaard

    2010-01-01

    Companies are increasingly offshoring R&D activities. Many firms, however, experience difficulties related to virtual teamwork across cultures and time zones. The research question is: How does increasing R&D offshoring impact transparency of communication structures and knowledge sharing? Using...... case studies from Danish multinational corporations with R&D activities in China, India or Eastern Europe this paper analyses the impact observed in these companies in regard to communication structures and knowledge sharing in management of offshored R&D activities. The findings show that companies...... complexity of the R&D activity. This paper shows that management of offshored R&D activities touches upon many key management dilemmas like trust, control and knowledge sharing....

  12. 4-D Photoacoustic Tomography

    Xiang, Liangzhong; Wang, Bo; Ji, Lijun; Jiang, Huabei

    2013-01-01

    Photoacoustic tomography (PAT) offers three-dimensional (3D) structural and functional imaging of living biological tissue with label-free, optical absorption contrast. These attributes lend PAT imaging to a wide variety of applications in clinical medicine and preclinical research. Despite advances in live animal imaging with PAT, there is still a need for 3D imaging at centimeter depths in real-time. We report the development of four dimensional (4D) PAT, which integrates time resolutions with 3D spatial resolution, obtained using spherical arrays of ultrasonic detectors. The 4D PAT technique generates motion pictures of imaged tissue, enabling real time tracking of dynamic physiological and pathological processes at hundred micrometer-millisecond resolutions. The 4D PAT technique is used here to image needle-based drug delivery and pharmacokinetics. We also use this technique to monitor 1) fast hemodynamic changes during inter-ictal epileptic seizures and 2) temperature variations during tumor thermal therapy.

  13. Outsourcing R&D

    Hsuan, Juliana; Mahnke, Volker

    2011-01-01

    Outsourcing R&D is an increasingly explored corporate practice. Extant research advanced our initial understanding of its increasing importance and benefits. While the associated literature has blossomed, the enthusiasm of R&D managers is tenured by an increasing realization of the possible...... downsides, risks, and costs that come with increasing use of external sources of innovation. Here, we suggest that research on outsourcing R&D has to move towards a balanced view on the profitability of such arrangements. To this end, we offer a review of what we know and need to know about outsourcing R......&D, suggest a simple, yet integrative model on the relation between outsourcing R&D and performance, and offer a research agenda that is instrumental in guiding companies’ process-management and design strategies when seeking to benefit from the outsourcing of R&D....

  14. D-Matter

    Shiu, G; Shiu, Gary; Wang, Lian-Tao

    2003-01-01

    We study the properties and phenomenology of particle-like states originating from D-branes whose spatial dimensions are all compactified. They are non-perturbative states in string theory and we refer to them as D-matter. In contrast to other non-perturbative objects such as 't Hooft-Polyakov monopoles, D-matter states could have perturbative couplings among themselves and with ordinary matter. The lightest D-particle (LDP) could be stable because it is the lightest state carrying certain (integer or discrete) quantum numbers. Depending on the string scale, they could be cold dark matter candidates with properties similar to that of wimps or wimpzillas. The spectrum of excited states of D-matter exhibits an interesting pattern which could be distinguished from that of Kaluza-Klein modes, winding states, and string resonances. We speculate about possible signatures of D-matter from ultra-high energy cosmic rays and colliders.

  15. Vitamin D and Skin

    Ibrahim Ozmen

    2008-09-01

    Full Text Available Vitamin D was originally discovered as a factor that regulates calcium and bone metabolism. Recent advances in investigation have shown that vitamin D also functions as a regulator of cellular growth and differentiation in various tissues. Evidence has accumulated showing that the active form of vitamin D and its analogs suppress growth and stimulate the terminal differentiation of keratinocytes. Also, vitamin D stimulates the synthesis of melanin and release of interleukins. On the other hand, vitamin D has been used in the treatment of psoriasis, vitiligo and morfea for a long time. In this review, we summarize the fundamental features of vitamin D and the clinical application for psoriasis and other dermatological disorders.

  16. Underwater 3D filming

    Roberto Rinaldi

    2014-12-01

    Full Text Available After an experimental phase of many years, 3D filming is now effective and successful. Improvements are still possible, but the film industry achieved memorable success on 3D movie’s box offices due to the overall quality of its products. Special environments such as space (“Gravity” and the underwater realm look perfect to be reproduced in 3D. “Filming in space” was possible in “Gravity” using special effects and computer graphic. The underwater realm is still difficult to be handled. Underwater filming in 3D was not that easy and effective as filming in 2D, since not long ago. After almost 3 years of research, a French, Austrian and Italian team realized a perfect tool to film underwater, in 3D, without any constrains. This allows filmmakers to bring the audience deep inside an environment where they most probably will never have the chance to be.

  17. Drug: D07041 [KEGG MEDICUS

    Full Text Available D07041 Formula, Drug Bofutsushosan Japanese angelica root [DR:D06768], Peony root [DR:D06739], C ... arb [DR:D06756], Atractylodes rhizome [DR:D06780], Platycodon ... root [DR:D06703], Scutellaria root [DR:D06688], Gl ...

  18. Drug: D06956 [KEGG MEDICUS

    Full Text Available D06956 Formula, Drug Goshakusan Citrus unshiu peel [DR:D06764], Poria sclerotium [DR:D06783], Pi ... e [DR:D06748], Angelica dahurica root [DR:D06779], Platycodon ... root [DR:D06703], Cinnamon bark [DR:D06712], Ephed ...

  19. Drug: D09066 [KEGG MEDICUS

    Full Text Available D09066 Formula, Drug Kyososan Perilla herb [DR:D06755], Schisandra fruit [DR:D06724], Areca peel ... ernel [DR:D06708], Citrus unshiu peel [DR:D06764], Platycodon ... root [DR:D06703], Ephedra herb [DR:D06791], Mulber ...

  20. Drug: D09054 [KEGG MEDICUS

    Full Text Available D09054 Formula, Drug Kakkoshokisan Atractylodes rhizome [DR:D06780], Pinellia tuber [DR:D06778], ... bark [DR:D06720], Citrus unshiu peel [DR:D06764], Platycodon ... root [DR:D06703], Angelica dahurica root [DR:D0677 ...

  1. Drug: D09095 [KEGG MEDICUS

    Full Text Available D09095 Formula, Drug Keibohaidokusan Schizonepeta spike [DR:D06711], Saposhnikovia root [DR:D067 ... ppermint [DR:D05431], Forsythia fruit [DR:D04674], Platycodon ... root [DR:D06703], Immature orange [DR:D06706], (Cn ...

  2. Drug: D09094 [KEGG MEDICUS

    Full Text Available D09094 Formula, Drug Jinreibyakujutsusan Ginseng [DR:D06772], Poria sclerotium [DR:D06783], (Atr ... lichos seed [DR:D06813], Nelumbo seed [DR:D06803], Platycodon ... root [DR:D06703], Amomum seed [DR:D06743], Glycyrr ...

  3. Drug: D06986 [KEGG MEDICUS

    Full Text Available D06986 Formula, Drug Shosaikotokakikyosekko Gypsum [DR:D01728], Bupleurum root [DR:D06727], Pine ... a tuber [DR:D06778], Scutellaria root [DR:D06688], Platycodon ... root [DR:D06703], Jujube [DR:D06758], Ginseng [DR: ...

  4. Drug: D01764 [KEGG MEDICUS

    Full Text Available alerate (JP16) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III...) D07AC06 Diflucortolone D01764 Diflucortolone valerate (JP16) D07X CORTICOSTEROIDS

  5. Drug: D07980 [KEGG MEDICUS

    Full Text Available IDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids,... moderately potent (group II) D07AB07 Fluprednidene D07980 Fluprednidene acetate D07X CORTICOSTEROIDS, OTHER...ction Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTERO

  6. Drug: D01464 [KEGG MEDICUS

    Full Text Available utic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (grou...p II) D07AB03 Flumetasone D01464 Flumetasone pivalate (JAN/BAN); Flumethasone pivalate (USP) D07X CORTICOSTEROIDS

  7. Drug: D03325 [KEGG MEDICUS

    Full Text Available hydrate (JAN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticos...teroids, potent (group III) D07AC13 Mometasone D03325 Mometasone furoate hydrate (JAN) D07X CORTICOSTEROIDS,

  8. Drug: D08407 [KEGG MEDICUS

    Full Text Available D08407 Drug Pramocaine (INN) C17H27NO3 293.1991 293.4012 D08407.gif Local anestheti... TOPICAL USE C05AD Local anesthetics C05AD07 Pramocaine D08407 Pramocaine (INN) D...STAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB07 Pramocaine D08407 Pramocaine (INN) CAS

  9. Drug: D04707 [KEGG MEDICUS

    Full Text Available D04707 Mixture, Drug Lithospermum root extract - ethyl aminobenzoate - dibucaine hydrochloride - diphenhydr...amine hydrochloride - cetrimide mixt; Borraginol N (TN) Lithospermum root extract [D...R:D04705], Ethyl aminobenzoate [DR:D00552], Dibucaine hydrochloride [DR:D02220], Diphenhydramine hydrochloride [DR:D00669], Cetrimide [DR:D02164] PubChem: 17398145 ...

  10. Drug: D02132 [KEGG MEDICUS

    Full Text Available D02132 Drug Clindamycin hydrochloride (JP16/USP); Cleocin hydrochloride (TN); Dalacin (TN) C18H3 ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF01 Clindamycin D02132 Clindamycin hydrochlori ...

  11. Drug: D00104 [KEGG MEDICUS

    Full Text Available D00104 Drug Chloramphenicol (JP16/USP/INN); CP; Amphicol (TN); Chloromycetin (TN); Econochlor (T ... col D00104 Chloramphenicol (JP16/USP/INN) D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF03 Chloramphenicol D00104 Chloramphenicol (JP ...

  12. Drug: D01361 [KEGG MEDICUS

    Full Text Available D01361 Drug Erythromycin ethylsuccinate (JP16/USP); E.E.S. (TN); Eryped (TN); Erythrocin W (TN) ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF02 Erythromycin D01361 Erythromycin ethylsucc ...

  13. Drug: D06971 [KEGG MEDICUS

    Full Text Available D06971 Formula, Drug Jiinshihoto Cyperus rhizome [DR:D06719], Bupleurum root [DR:D06727], Lycium ... D04365], Peppermint [DR:D05431] Chronic sputum and cough ... Therapeutic category: 5200 Therapeutic category of ... ing Ying D06971 *Jiinshihoto Formulas for dampness Cough ... suppressant and expectorant formulas D06971 *Jiins ...

  14. Drug: D02375 [KEGG MEDICUS

    Full Text Available Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGAL...ine D02375 Terbinafine (USAN/INN) D01B ANTIFUNGALS FOR SYSTEMIC USE D01BA Antifungals for systemic use D01BA

  15. Drug: D00209 [KEGG MEDICUS

    Full Text Available ation [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGAL...S FOR TOPICAL USE D01AA Antibiotics D01AA08 Griseofulvin D00209 Griseofulvin (JP16/USP/INN) D01B ANTIFUNGAL

  16. Drug: D10052 [KEGG MEDICUS

    Full Text Available D10052 Formula, Drug Yokukansankashakuyakuoren Japanese angelica root [DR:D06768], Uncaria hook ... [DR:D06762], Cnidium rhizome ... [DR:D06748], (Atractylodes rhizome ... [DR:D06780] | A ... tractylodes lancea rhizome ... [DR:D06752]), Poria sclerotium [DR:D06783], Bupleu ...

  17. Drug: D04044 [KEGG MEDICUS

    Full Text Available D04044 Mixture, Drug Chlorpheniramine maleate - acetaminophen ... - salicylamide - anhydrous caffein ... ixt; LL (TN) Chlorpheniramine maleate [DR:D00665], Acetaminophen ... [DR:D00217], Salicylamide [DR:D01811], Anhydrous c ... 4 Mixture of Chlorpheniramine maleate [DR:D00665], Acetaminophen ... [DR:D00217], Salicylamide [DR:D01811] and Anhydrou ...

  18. Drug: D02863 [KEGG MEDICUS

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA08 Aluminium chlorohydrate D02863 Aluminum sesquichlorohydrate (USP) PubChem: 17397020 ... ...ode: D09AA08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  19. Drug: D02856 [KEGG MEDICUS

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA08 Aluminium chlorohydrate D02856 Aluminum dichlorohydrate (USP) PubChem: 17397013 ... ...: D09AA08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  20. Nonclassical Vitamin D Action

    Armin Zittermann; Jan F Gummert

    2010-01-01

    It is becoming increasingly clear that vitamin D has a broad range of actions in the human body. Besides its well-known effects on calcium/phosphate homeostasis, vitamin D influences muscle function, cardiovascular homeostasis, nervous function, and the immune response. Vitamin D deficiency/insufficiency has been associated with muscle weakness and a high incidence of various chronic diseases such as cardiovascular disease, cancer, multiple sclerosis, and type 1 and 2 diabetes. Most important...

  1. Drug: D01615 [KEGG MEDICUS

    Full Text Available AA Corticosteroids C05AA09 Dexamethasone D01615 Dexamethasone palmitate (JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticoste...roids, moderately potent (group II) D07AB19 Dexamethasone D01615 Dexamethasone palmitate (JAN) D07X CORTICOSTEROIDS...e D01615 Dexamethasone palmitate (JAN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H0

  2. Drug: D08412 [KEGG MEDICUS

    Full Text Available 8412 Prednisolone pivalate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL ...PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Prednisolone D08412 P...rednisolone pivalate D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combination...OIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC ...THALMOLOGICAL AND OTOLOGICAL PREPARATIONS S03B CORTICOSTEROIDS S03BA Corticosteroids S03BA02 Prednisolone D0

  3. D^- mesic atoms

    García Recio, Carmen; Nieves Pamplona, Juan Miguel; Salcedo, Lorenzo Luis; Tolós Rigueiro, Laura

    2011-01-01

    The anti-D meson self-energy is evaluated self-consistently, using unitarized coupled-channel theory, by computing the in-medium meson-baryon T-matrix in the C=-1,S=0 sector. The heavy pseudo-scalar and heavy vector mesons, anti-D and anti-D^*, are treated on equal footing as required by heavy quark spin symmetry. Results for energy levels and widths of D^- mesic atoms in 12C, 40Ca, 118Sn and 208Pb are presented. The spectrum contains states of atomic and of nuclear types for all nuclei. anti...

  4. Vitamin D and cancer

    LauraVuolo

    2012-04-01

    Full Text Available Vitamin D system is a complex pathway that includes precursors, active metabolites, enzymes and receptors activating several molecular pathways and mediating a multitude of functions. In addition to the classical role of vitamin D metabolites in calcium and bone homeostasis, many in vitro and in vivo studies recognized several "non calcemic" effects involved in host defence, inflammation, immunity and cancer processes. The aim of this review is to highlight the relationship between vitamin D and cancer, summarizing several mechanisms proposed to explain the potential protective effect of vitamin D against the development and progression of cancer. Vitamin D acts like a transcription factor that influences central mechanisms of tumorigenesis: growth, cell differentiation and apoptosis. In addition to cellular and molecular studies, epidemiological surveys have shown that sunlight exposure and consequent increased circulating levels of vitamin D are associated not only with reduced occurrence but also with reduced mortality for different histological types of cancer. Another recent field of interest concerns polymorphisms of vitamin D receptor: in this context, preliminary data suggest that vitamin D receptor polymorphisms more frequently associated with tumorigenesis are Fok1, Bsm1, Taq1, Apa1, EcoRV, Cdx2, although further studies are needed to clarify any discrepancies. In this review, the relationship between vitamin D and cancer is discussed.

  5. Sunshine and vitamin D.

    Saraff, Vrinda; Shaw, Nick

    2016-02-01

    Vitamin D is vital for bone health and its deficiency deemed as a disease of the past has re-emerged as an important health concern. Exposure of the skin to solar ultraviolet B radiation is the major source of vitamin D and only a small proportion is derived from dietary intake. We review the various factors that influence the cutaneous synthesis of vitamin D and the recommendations regarding safe sun exposure and dietary supplementation to achieve adequate vitamin D levels proposed for optimal bone health. PMID:26323284

  6. Hyperelliptic plane curves of type (d,d-2)

    Sakai, Fumio; Saleem, Mohammad; Tono, Keita

    2008-01-01

    In a previous paper, we classified and constructed all rational plane curves of type (d,d-2). In this paper, we generalize these results to irreducible plane curves of type (d,d-2) with positive genus.

  7. Alternative D and D Planning Tool - 12466

    On August 1, 2011, URS - CH2M Oak Ridge LLC (UCOR) began cleanup of the East Tennessee Technology Park (ETTP). UCOR's $2.2 billion contract has an initial five-year term and a four-year option period for completing the cleanup of ETTP and performing surveillance and maintenance and waste management operations at both the Oak Ridge National Laboratory and the Y-12 National Security Complex. ETTP D and D work includes disposition of large, complex, contaminated, Manhattan Project-era facilities such as the K-25 and K-27 uranium enrichment facilities. At ETTP, UCOR views the D and D process as a 'Waste Factory' with waste production lines from the point-of-generation to the point-of-disposal. Safely transforming vertically-standing buildings into horizontally-lying waste in a disposal facility is the primary cleanup objective. Whereas a factory produces widgets, D and D produces waste-lots of waste. In support of the Waste Factory view, UCOR is developing a systems planning tool to help better plan how to effect cleanup by improving waste planning, uniting waste generator with waste dis-positioner, and represent the 'waste factory' in a computer model that allows the D and D and waste management teams to better understand available disposal paths, waste uncertainties and potential consequences, driving variables, and sensitivity to changes. Any model of reality represents a compromise. Part of the Waste Factory Model's value may be in providing standardization and relative direction for assisting decision making as opposed to absolute cost or schedule answers. From that relative direction, management can commission detailed planning and estimating. Also, the model's output credibility is tied directly to its input quality. That is why, as discussed above, the Waste Factory Model's key informational component will be the standardized waste streams (e.g., Structure/Debris disposed at EMWMF) and associated standardized unit costs. The model development process generally

  8. ACTINOMYCIN D ANALOGUES

    1997-01-01

    The present invention relates to new compounds being structurally and functionally similar to Actinomycin D and to combinatorial libraries of such compounds. The Actinomycin D analogues according to the present invention comprise two linear or cyclic peptide moieties constituted by $g...

  9. Beyond Type D personality

    Pelle, Aline J; Pedersen, Susanne S.; Szabó, Balázs M;

    2009-01-01

    Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important.......Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important....

  10. Pau D'arco

    Pau d'arco is a tree with extremely hard wood. Its name is the Portuguese word for “bow stick,” ... Though possibly unsafe, especially at higher doses, pau d'arco is used to treat a wide range ...

  11. HYBRID R&D

    Goyal, Sanjeev; Moraga González, José; Konovalov, Alexander

    2008-01-01

    We develop a model of R&D collaboration in which individual firms carry out in-house research on core activities and undertake bilateral joint projects on non-core activities with other firms. We develop conditions on the profit functions of the firm under which R&D investments in different projects

  12. 3D virtuel udstilling

    Tournay, Bruno; Rüdiger, Bjarne

    2006-01-01

    3d digital model af Arkitektskolens gård med virtuel udstilling af afgangsprojekter fra afgangen sommer 2006. 10 s.......3d digital model af Arkitektskolens gård med virtuel udstilling af afgangsprojekter fra afgangen sommer 2006. 10 s....

  13. D2-tree

    Brodal, Gerth Stølting; Sioutas, Spyros; Pantazos, Kostas;

    2015-01-01

    We present a new overlay, called the Deterministic Decentralized tree (D2-tree). The D2-tree compares favorably to other overlays for the following reasons: (a) it provides matching and better complexities, which are deterministic for the supported operations; (b) the management of nodes (peers...

  14. Calcium D-saccharate

    Garcia, André Castilho; Hedegaard, Martina Vavrusova; Skibsted, Leif Horsfelt

    2016-01-01

    Molar conductivity of saturated aqueous solutions of calcium d-saccharate, used as a stabilizer of beverages fortified with calcium d-gluconate, increases strongly upon dilution, indicating complex formation between calcium and d-saccharate ions, for which, at 25 °C, Kassoc = 1032 ± 80, ΔHassoc......° = -34 ± 6 kJ mol-1, and ΔSassoc° = -55 ± 9 J mol-1 K-1, were determined electrochemically. Calcium d-saccharate is sparingly soluble, with a solubility product, Ksp, of (6.17 ± 0.32) × 10-7 at 25 °C, only moderately increasing with the temperature: ΔHsol° = 48 ± 2 kJ mol-1, and ΔSassoc° = 42 ± 7 J mol-1...... K-1. Equilibria in supersaturated solutions of calcium d-saccharate seem only to adjust slowly, as seen from calcium activity measurements in calcium d-saccharate solutions made supersaturated by cooling. Solutions formed by isothermal dissolution of calcium d-gluconate in aqueous potassium d...

  15. Enterovirus D68 Infection

    Susanna Esposito

    2015-11-01

    Full Text Available First described in 1962 in children hospitalized for pneumonia and bronchiolitis, the Enterovirus D68 (EV-D68 is an emergent viral pathogen. Since its discovery, during the long period of surveillance up to 2005, EV-D68 was reported only as a cause of sporadic outbreaks. In recent years, many reports from different countries have described an increasing number of patients with respiratory diseases due to EV-D68 associated with relevant clinical severity. In particular, an unexpectedly high number of children have been hospitalized for severe respiratory disease due to EV-D68, requiring intensive care such as intubation and mechanical ventilation. Moreover, EV-D68 has been associated with acute flaccid paralysis and cranial nerve dysfunction in children, which has caused concerns in the community. As no specific antiviral therapy is available, treatment is mainly supportive. Moreover, because no vaccines are available, conventional infection control measures (i.e., standard, for contacts and droplets in both community and healthcare settings are recommended. However, further studies are required to fully understand the real importance of this virus. Prompt diagnosis and continued surveillance of EV-D68 infections are essential to managing and preventing new outbreaks. Moreover, if the association between EV-D68 and severe diseases will be confirmed, the development of adequate preventive and therapeutic approaches are a priority.

  16. An upper limit on D0-anti D0mixing

    We have searched for D0-anti D0 mixing in the cascade decay of D*+, using the excellent particle identification of the ARGUS detector. No mixing was observed, leading to an upper limit of 1.4% (90% CL) for Γ(D0 → anti D0 → X')/Γ(D0 → X). (orig.)

  17. Conic D-branes

    Hashimoto, Koji; Murata, Keiju

    2015-01-01

    The shape of D-branes is of fundamental interest in string theory. We find that generically D-branes in trivial spacetime can form a conic shape under external uniform forces. Surprisingly, the apex angle is found to be unique, once the spatial dimensions of the cone is given. In particular it is universal irrespective of the external forces. The quantized angle is reminiscent of Taylor cones of hydrodynamic electrospray. We provide explicit D-brane solutions as well as the mechanism of a force balance on the cone, for D-branes in RR and NSNS flux backgrounds. Critical embedding of probe D-branes in AdS/CFT with electric and magnetic fields is in the same category, for which we give an analytic proof of a power-low spectrum of "turbulent meson condensation."

  18. Drug: D10040 [KEGG MEDICUS

    Full Text Available ], Immature orange [DR:D06706], Glycyrrhiza [DR:D04365], Cyperus rhizome [DR:D06719], Cnidium rhizome [DR:D06748], Citrus immature fruit and fruit peel [ED:E00338] PubChem: 135626760 ...

  19. Drug: D08809 [KEGG MEDICUS

    Full Text Available D08809 Formula, Drug Aromatic powder; Cinnamon bark - zanthoxylum fruit - ginger mi...xt; Aromatic powder (TN) Cinnamon bark [DR:D06712], Zanthoxylum fruit [DR:D06733], Ginger [DR:D06744] Therap

  20. Drug: D09110 [KEGG MEDICUS

    Full Text Available D09110 Formula, Drug Shakosaito; Sammishakosaito Digenea [DR:D06792], Rhubarb [DR:D...elling parasites Anthelmintic formulas D09110 Shakosaito; Sammishakosaito PubChem: 96025790 ...

  1. Drug: D00979 [KEGG MEDICUS

    Full Text Available 08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA .../USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS

  2. Drug: D10299 [KEGG MEDICUS

    Full Text Available iasis ATC code: D07CB01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07C CORTICOSTEROIDS, COMBINATIO

  3. Vitamin D and Disease Prevention

    Vitamin D and Disease Prevention Why is vitamin D important for health? Vitamin D is a hot topic in the news, thanks ... is controversy, though, over the effects of vitamin D on health other than the bones. Doctors have ...

  4. Drug: D06250 [KEGG MEDICUS

    Full Text Available D06250 Mixture, Drug Trisulfapyrimidines (USP); Lantrisul (TN) Sulfamerazine [DR:D0...2435], Sulfadiazine [DR:D00587], Sulfamethazine [DR:D02436] Antibacterial CAS: 8017-57-0 PubChem: 47207908 ...

  5. Drug: D09062 [KEGG MEDICUS

    Full Text Available D04365], Jujube [DR:D06758], Coptis rhizome [DR:D00092] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for stomach Antidiarrheal formulas D09062 Kanzoshashinto PubChem: 96025743 ...

  6. Drug: D09053 [KEGG MEDICUS

    Full Text Available :D06712], Ginger [DR:D06744], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for dampness Diuretic formulas D09053 Bukuryotakushato PubChem: 96025734 ...

  7. Drug: D09040 [KEGG MEDICUS

    Full Text Available D06712], Glycyrrhiza [DR:D04365], Jujube [DR:D06758] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for Qi Sedative formulas D09040 *Ryokeikansoto PubChem: 96025723 ...

  8. Drug: D07031 [KEGG MEDICUS

    Full Text Available oria sclerotium [DR:D06783], Moutan bark [DR:D06788], Cinnamon bark [DR:D06712], Processed aconite root [DR:D06784] Nephritis; Diabet...es; Oscheitis; Sciatic pain; High pressure (HP); Geriatr

  9. Drug: D02120 [KEGG MEDICUS

    Full Text Available D02120 Mixture, Drug Citric acid monohydrate - potassium bicarbonate mixt; K-lyte (...TN) Citric acid monohydrate [DR:D01222], Potassium bicarbonate [DR:D02077] PubChem: 7849181 LigandBox: D02120 ...

  10. Drug: D09102 [KEGG MEDICUS

    Full Text Available D09102 Formula , Drug Kobokushokyohangeninjinkanzoto Magnolia bark [DR:D06720], Ginger [DR:D06744 ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for stomach Antiemetic formula s D09102 K ...

  11. Drug: D00097 [KEGG MEDICUS

    Full Text Available FUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPI...c acids D00097 Salicylic acid (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTI

  12. Drug: D02923 [KEGG MEDICUS

    Full Text Available s map07026 Antifungal agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01A

  13. Drug: D00381 [KEGG MEDICUS

    Full Text Available P/INN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS F...OR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals fo

  14. Drug: D02582 [KEGG MEDICUS

    Full Text Available hesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FO...R DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazol

  15. Drug: D01093 [KEGG MEDICUS

    Full Text Available ne hydrochloride (JP16/USAN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01A

  16. Drug: D00886 [KEGG MEDICUS

    Full Text Available azole nitrate (JAN/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imi

  17. Drug: D04624 [KEGG MEDICUS

    Full Text Available l agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGA...LS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tria

  18. Drug: D00881 [KEGG MEDICUS

    Full Text Available e (JAN/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and t

  19. Drug: D01094 [KEGG MEDICUS

    Full Text Available 1AA07 natural product Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antib

  20. Drug: D02557 [KEGG MEDICUS

    Full Text Available 026 Antifungal agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imida

  1. Drug: D01664 [KEGG MEDICUS

    Full Text Available Steroid biosynthesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imida

  2. Drug: D00323 [KEGG MEDICUS

    Full Text Available 3 Flucytosine (JP16/USP/INN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01A

  3. Drug: D00883 [KEGG MEDICUS

    Full Text Available agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals f

  4. Drug: D04366 [KEGG MEDICUS

    Full Text Available D04366 Mixture, Drug Pipethanate hydrochloride - magnesium aluminometasilicate - liqourice extract... mixt; Geschwur (TN) Pipethanate hydrochloride [DR:D01521], Magunesium aluminometasilicate [DR:D03242], Crude glycyrrhiza extract [DR:D06811] PubChem: 17398077 ...

  5. Drug: D00378 [KEGG MEDICUS

    Full Text Available nzyme: CYP2D6 [HSA:1565] Genomic biomarker: CYP2D6 [HSA:1565] map07054 Antiglaucoma...ic Blocking Agents Timolol D00378 Timolol (USAN) Ophthalmic Agents Ophthalmic Antiglaucoma Agents Timolol D0

  6. Vitamin D and cancer

    Ali Minu

    2007-01-01

    Full Text Available Vitamin D, a fat-soluble prohormone is synthesized in response to sunlight. Experimental evidence suggests that vitamin D may reduce the risk of cancer through regulation of cellular proliferation and differentiation as well as inhibition of angiogenesis. These anticancer properties have been attributed primarily to 1,25-dihydroxyvitamin D [1,25(OH 2 D] (calcitriol, the hormonal form of vitamin D. Extensive research has shown that cells, including cancer cells, express specific receptors (VDR for 1,25-dihydroxyvitamin D. When bound to the VDR, 1,25-dihydroxyvitamin D regulates> 60 genes that exert prodifferentiating, antiproliferative and antimetastatic effects on cells, including effects on cell cycle. The amount of exposure to the sun has been found to correlate inversely with cancer mortality and survival in numerous epidemiological studies. An inverse relationship between solar ultraviolet-B (UV-B exposure and non-skin cancer mortality has long been reported. Several ecological studies suggest that sunlight may protect against prostate, colon, rectal, female breast and ovarian cancer, all diseases that contribute to a substantially higher proportion of cancer mortality in the western industrialized world. Some analytical studies also suggest a protective association between circulating vitamin D in blood, which is largely derived from sunlight, or dietary vitamin D. Paricalcitol (calcitriol analogue is as effective as 1,25-dihydroxyvitamin D in transactivating the prostatic VDR and in inhibiting the growth of prostate cancer cell lines and primary cultures of prostate cancer cells in vitro. Promising preclinical evaluations of calcitriol and analogues have appeared in prostate cancer animal models.

  7. Drug: D07798 [KEGG MEDICUS

    Full Text Available icosteroids C05AA09 Dexamethasone D07798 Dexamethasone sodium hemisulfate D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group... II) D07AB19 Dexamethasone D07798 Dexamethasone sodium hemisulfate D07X CORTICOSTEROIDS, OTHER COMBINATIONS ...dium hemisulfate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H0

  8. Drug: D00984 [KEGG MEDICUS

    Full Text Available E C05AA Corticosteroids C05AA12 Triamcinolone D00984 Triamcinolone diacetate (JAN/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB C...orticosteroids, moderately potent (group II) D07AB09 Triamcinolone D00984 Triamcinolone diacetate (JAN/USP) D07X CORTICOSTEROIDS...S AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYST

  9. Drug: D01948 [KEGG MEDICUS

    Full Text Available TOPICAL USE C05AA Corticosteroids C05AA09 Dexamethasone D01948 Dexamethasone valerate (JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D...07AB Corticosteroids, moderately potent (group II) D07AB19 Dexamethasone D01948 Dexamethasone valerate (JAN) D07X CORTICOSTEROIDS...IDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC U...48 Dexamethasone valerate (JAN) S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS S03B CORTICOSTEROIDS S03BA

  10. Drug: D03127 [KEGG MEDICUS

    Full Text Available GICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AC Medicated shampo...D03127 Drug Biphenamine hydrochloride (USAN); Xenysalate hydrochloride C19H23NO3. H...Cl 349.1445 349.8518 D03127.gif Anesthetic [topical]; Antibacterial; Antifungal ATC code: D11AC09 Biphenamin...os D11AC09 Xenysalate D03127 Biphenamine hydrochloride (USAN) CAS: 5560-62-3 PubChe

  11. Drug: D00277 [KEGG MEDICUS

    Full Text Available D00277 Drug Clindamycin (USAN/INN); CLDM; Cleocin (TN) C18H33ClN2O5S 424.1799 424.983 D00277.gif ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF01 Clindamycin D00277 Clindamycin (USAN/INN) ...

  12. Drug: D01621 [KEGG MEDICUS

    Full Text Available D01621 Drug Retinol acetate (JP16) C22H32O2 328.2402 328.4883 D01621.gif Vitamin A; Antiacne ... ATC ... Retinol acetate (JP16) D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AD Retinoids for topical use in acne ... D10AD02 Retinol D01621 Retinol acetate (JP16) R RE ...

  13. Drug: D07674 [KEGG MEDICUS

    Full Text Available D07674 Drug Chloramphenicol stearate; Quemicetina (TN) C29H46Cl2N2O6 588.2733 589.5913 D07674.gi ... mphenicol D07674 Chloramphenicol stearate D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF03 Chloramphenicol D07674 Chloramphenicol ste ...

  14. Drug: D01516 [KEGG MEDICUS

    Full Text Available D01516 Drug Tretinoin tocoferil (JAN); Tocoretinate C49H76O3 712.5794 713.1259 D01516.gif Same a ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AD Retinoids for topical use in acne ... D10AD01 Tretinoin D01516 Tretinoin tocoferil (JAN) ...

  15. Drug: D00348 [KEGG MEDICUS

    Full Text Available D00348 Drug Isotretinoin (USP); Absorica (TN); Accutane (TN); Sotret (TN) C20H28O2 300.2089 300. ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AD Retinoids for topical use in acne ... D10AD04 Isotretinoin D00348 Isotretinoin (USP) D10 ...

  16. Drug: D02393 [KEGG MEDICUS

    Full Text Available D02393 Drug Resorcinol monoacetate (USP); Euresol (TN) C8H8O3 152.0473 152.1473 D02393.gif Antis ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AX Other anti-acne ... preparations for topical use D10AX02 Resorcinol D0 ...

  17. Drug: D00133 [KEGG MEDICUS

    Full Text Available D00133 Drug Resorcin (JAN); Resorcinol (USP); Resorcin (TN) C6H6O2 110.0368 110.1106 D00133.gif ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AX Other anti-acne ... preparations for topical use D10AX02 Resorcinol D0 ...

  18. Drug: D02476 [KEGG MEDICUS

    Full Text Available D02476 Drug Meclocycline (USAN/INN) C22H21ClN2O8 476.0986 476.8637 D02476.gif Antibacterial ATC ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF04 Meclocycline D02476 Meclocycline (USAN/INN ...

  19. Drug: D05082 [KEGG MEDICUS

    Full Text Available D05082 Drug Motretinide (USAN/INN); Tasmaderm (TN) C23H31NO2 353.2355 353.4977 D05082.gif Kerato ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AD Retinoids for topical use in acne ... D10AD05 Motretinide D05082 Motretinide (USAN/INN) ...

  20. Drug: D09100 [KEGG MEDICUS

    Full Text Available D09100 Formula, Drug Koshayoito Ginseng [DR:D06772], Atractylodes rhizome ... [DR:D06780], Poria scl ... 4365], Dry ginger [DR:D06744], Atractylodes lancea rhizome ... [DR:D06752], Magnolia bark [DR:D06720], Citrus uns ... 06795], Amomi rotundi fructus [ED:E00344], Cyperus rhizome ... [DR:D06719], Amomum seed [DR:D06743] Traditional C ...

  1. Drug: D06226 [KEGG MEDICUS

    Full Text Available D06226 Drug Triclosan ... (USP/INN); Stri-Dex cleansing bar (TN) C12H7Cl3O2 287.9512 289.5418 D06226 ... DISINFECTANTS D08AE Phenol and derivatives D08AE04 Triclosan ... D06226 Triclosan ... (USP/INN) D09 MEDICATED DRESSINGS ... AA Medicated dressings with antiinfectives D09AA06 Triclosan ... D06226 Triclosan ... (USP/INN) CAS: 3380-34-5 PubChem: ...

  2. INEL D ampersand D long-range plan

    This Long-Range Plan presents the Decontamination and Dismantlement (D ampersand D) Program planning status for facilities at the Idaho National Engineering Laboratory (INEL). The plan provides a general description of the D ampersand D Program objectives, management criteria, and policy; discusses current activities; and documents the INEL D ampersand D Program cost and schedule estimate projections for the next 15 years. Appendices are included that provide INEL D ampersand D project historical information, a comprehensive descriptive summary of each current D ampersand D surplus facility, and a summary database of all INEL contaminated facilities awaiting or undergoing the facility transition process

  3. Drug: D00128 [KEGG MEDICUS

    Full Text Available lassification [BR:br08303] D DERMATOLOGICALS D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06A ANTIBIOT...ICS FOR TOPICAL USE D06AX Other antibiotics for topical use D06AX05 Bacitracin D00128 Bacitracin ... R RESPIRATORY SYSTEM R02 THROAT PREPARATIONS R02A THROAT PREPARATIONS R02AB Antibiotics R02AB04 Bacitracin

  4. Drug: D00526 [KEGG MEDICUS

    Full Text Available TIONS D11AH Agents for dermatitis, excluding corticosteroids D11AH03 Cromoglicic acid D00526 Sodium cromogli...ation [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARA

  5. Drug: D07540 [KEGG MEDICUS

    Full Text Available ication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other derma...tologicals D11AX21 Brimonidine D07540 Brimonidine (INN) S SENSORY ORGANS S01 OPHTHA

  6. Drug: D07214 [KEGG MEDICUS

    Full Text Available fication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other derm...atologicals D11AX08 Tiratricol D07214 Tiratricol (INN) H SYSTEMIC HORMONAL PREPARAT

  7. Drug: D01768 [KEGG MEDICUS

    Full Text Available D01768 Drug Oxybuprocaine hydrochloride (JP16); Benoxinate hydrochloride (USP); Ben...1 Ophthalmic agents 1313 Ophthalmic local anesthetics D01768 Oxybuprocaine hydrochloride (JP16); Benoxinate ...ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB03 Oxybuprocaine D01768 Oxybuprocai...ESTHETICS S01HA Local anesthetics S01HA02 Oxybuprocaine D01768 Oxybuprocaine hydr

  8. Drug: D06661 [KEGG MEDICUS

    Full Text Available D06661 Drug Dimethisoquin hydrochloride (USAN); Quinisocaine hydrochloride C17H24N2...O. HCl 308.1655 308.8462 D06661.gif ATC code: D04AB05 Dimethisoquin is called Quinisocaine in INN. Anatomica...ETC. D04AB Anesthetics for topical use D04AB05 Quinisocaine D06661 Dimethisoquin hydrochloride (USAN) CAS: 2

  9. Drug: D03965 [KEGG MEDICUS

    Full Text Available D03965 Mixture, Drug Salsocain; Salsocain (TN) Sulpyrine [DR:D01762], Sodium salicy...late [DR:D00566], Allobarbital [DR:D02817], Procaine hydrochloride [DR:D00740], Caffeine [DR:D01453] CAS: 85886-25-5 PubChem: 47205951 ...

  10. Drug: D07195 [KEGG MEDICUS

    Full Text Available D07195 Drug Chloropyramine (INN) C16H20ClN3 289.1346 289.8031 D07195.gif ATC code: D04AA09 R06AC ... ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC . D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHE ... TICS, ETC . D04AA Antihistamines for topical use D04AA09 Chlo ...

  11. Drug: D07196 [KEGG MEDICUS

    Full Text Available D07196 Drug Tolpropamine (INN) C18H23N 253.1831 253.3819 D07196.gif ATC code: D04AA12 Anatomical ... ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC . D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHE ... TICS, ETC . D04AA Antihistamines for topical use D04AA12 Tolp ...

  12. Drug: D07194 [KEGG MEDICUS

    Full Text Available D07194 Drug Thenalidine (INN) C17H22N2S 286.1504 286.435 D07194.gif ATC code: D04AA03 R06AX03 An ... ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC . D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHE ... TICS, ETC . D04AA Antihistamines for topical use D04AA03 Then ...

  13. Drug: D10520 [KEGG MEDICUS

    Full Text Available D10520 Mixture, Drug Rabeprazole - amoxicillin - metronidazole mixt; Rabefine (TN) ...(Sodium rabeprazole [DR:D00724] | Trimethobenzamide [DR:D08643]), (Amoxicillin hydrate [DR:D00229] | Amoxici...llin [DR:D07452]), Metronidazole [DR:D00409] [DS:H00320] Therapeutic category: 6199 Therapeutic category of dr

  14. Drug: D02185 [KEGG MEDICUS

    Full Text Available D02185 Drug Chloramphenicol sodium succinate (JP16/USP); CP; Chloromycetin succinate (TN) C15H15 ... loramphenicol sodium succinate (JP16/USP) D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF03 Chloramphenicol D02185 Chloramphenicol sod ...

  15. Drug: D07211 [KEGG MEDICUS

    Full Text Available D07211 Drug Tioxolone (INN/BAN) C7H4O3S 167.9881 168.1699 D07211.gif ATC code: D10AB03 Anatomica ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ...

  16. Drug: D00416 [KEGG MEDICUS

    Full Text Available le (JP16/USP/INN) D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triaz...ole derivatives D01AC02 Miconazole D00416 Miconazole (JP16/USP/INN) G GENITO URINAR

  17. Drug: D09075 [KEGG MEDICUS

    Full Text Available icine in Japan [BR:br08304] Formulas Formulas for Qi Sedative formulas D09075 Hachimishoyosan PubChem: 96025756 ... ...[DR:D06780]), Bupleurum root [DR:D06727], Glycyrrhiza [DR:D04365], Ginger [DR:D06744], Peppermint [DR:D05431] Traditional Chinese Med

  18. Drug: D09085 [KEGG MEDICUS

    Full Text Available D09085 Formula , Drug Daihangeto Pinellia tuber [DR:D06778], Ginseng [DR:D06772], Honey [DR:D0677 ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for stomach Antiemetic formula s D09085 D ...

  19. Drug: D06816 [KEGG MEDICUS

    Full Text Available D06816 Mixture, Drug Arsenical paste (JP16) Arsenic trioxide [DR:D02106], Procaine hydrochloride [DR:D00740], Hydrophilic ointment [DR:D05237], Clove oil [DR:D06823], Medicinal carbon [DR:D03251] PubChem: 47208467 ...

  20. Drug: D06139 [KEGG MEDICUS

    Full Text Available ATC code: D01AE08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D0

  1. Drug: D02219 [KEGG MEDICUS

    Full Text Available ification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGAL...ne hydrochloride (JP16/USP) D01B ANTIFUNGALS FOR SYSTEMIC USE D01BA Antifungals for systemic use D01BA02 Ter

  2. Drug: D08894 [KEGG MEDICUS

    Full Text Available ATC code: D01AE04 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D

  3. Drug: D00282 [KEGG MEDICUS

    Full Text Available s for local oral treatment A01AB18 Clotrimazole D00282 Clotrimazole (JP16/USP/INN) D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D0

  4. Drug: D00202 [KEGG MEDICUS

    Full Text Available IVES A07AA Antibiotics A07AA02 Nystatin D00202 Nystatin (JP16/USP/INN) D DERMATOLOGICALS D01 ANTIFUNGALS FOR... DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antibiotics D01AA01 Ny

  5. Drug: D10300 [KEGG MEDICUS

    Full Text Available D10300 Mixture, Drug Clotrimazole - betamethasone ... mixt; Lotrisone (TN) Clotrimazole [DR:D00282], ... (Betamethasone ... dipropionate [DR:D01637] | Betamethasone ... [DR:D0024 ... ids, potent, combinations with antibiotics D07CC01 Betamethasone ... and antibiotics D10300 Clotrimazole - betamethason ...

  6. Drug: D04447 [KEGG MEDICUS

    Full Text Available D04447 Mixture, Drug Betamethasone ... - d-chlorpheniramine maleate mixt; Celestamine (TN) Betamethasone ... 45 Adrenal hormone preparations 2459 Others D04447 Betamethasone ... - d-chlorpheniramine maleate mixt Anatomical Thera ... amines R06AB54 Chlorphenamine, combinations D04447 Betamethasone ... - d-chlorpheniramine maleate mixt PubChem: 1739810 ...

  7. Drug: D00056 [KEGG MEDICUS

    Full Text Available D00056 Drug Trypsin (JAN); Trypsin, crystallized (USP); Parenzyme (TN) Enzyme [proteolytic] Same ... GICAL AGENTS B06A OTHER HEMATOLOGICAL AGENTS B06AA Enzymes ... B06AA07 Trypsin D00056 Trypsin (JAN); Trypsin, cry ... EPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS D03B ENZYMES ... D03BA Proteolytic enzymes ... D03BA01 Trypsin D00056 T ...

  8. Drug: D10250 [KEGG MEDICUS

    Full Text Available D10250 Mixture, Drug Buprenorphine - naloxone ... mixt; Suboxone (TN) (Buprenorphine hydrochloride [ ... DR:D00836] | Buprenorphine [DR:D07132]), (Naloxone ... hydrochloride [DR:D01340] | Naloxone ... [DR:D08249]) ... Buprenorphine, combinations D10250 Buprenorphine - naloxone ... mixt USP drug classification [BR:br08302] Anti-Add ...

  9. Vitamin D and Hypertension

    Zamzam Paknahad

    2014-06-01

    Full Text Available Nowadays, hypertension is one of the most important causes of death all over the world because of its adverse effects on cardiovascular system. For this reason its study is very valuable. Vitamin D is one of the important factors that may influence blood pressure. Many studies have shown the modulatory effect of this vitamin on rennin-angiotensin system as well as its inhibitory effect on vascular smooth muscle hypertrophy. According to the fact that vitamin receptors are distributed in almost all organs of human body, we can't consider its role just as factor in calcium homeostasis. Therefore many other important roles could be attributed to it. So vitamin D deficiency could arise many problems. There are many causes for vitamin D deficiency. The most important is insufficient exposure to UV-B. In epidemiological studies the vitamin D deficiency is considered to be associated with high blood pressure, as emphasized in many cross-sectional studies. Concerning the cohort prospective studies, the relationship between vitamin D deficiency and hypertension is reported in some cases. The interventional studies about the association between vitamin D and hypertension are not many and the results are different or contradictory. Controversial results might be due to differences in dose of supplements or duration of supplement therapy. The aim of this systematic review is to assess the researches about the association between vitamin D deficiency and hypertension and discuss the power of them. This can be helpful to lighten the path to prospective investigations.

  10. Vitamin D intoxication.

    Ozkan, Behzat; Hatun, Sükrü; Bereket, Abdullah

    2012-01-01

    Vitamin D intoxication (VDI) may result from supplementation rarely, but it has been reported more frequently in recent years. This may be attributable to an increase in vitamin D supplement intake due to an understanding of the role of vitamin D (25OHD) in the pathogenesis of several diseases. The symptoms and findings associated with VDI are closely related to serum calcium concentration and duration of hypercalcemia. In patients with VDI, hypercalcemia, normal or high serum phosphorus levels, normal or low levels of alkaline phosphatase (ALP), high levels of serum 25OHD, low serum parathyroid hormone (PTH), and high urine calcium/creatinine are usually present. Serum 25OHD levels above 150 ng/ml are considered as VDI. The main goal of treatment for VDI is correction of the hypercalcemia. When the calcium concentration exceeds 14 mg/dl, emergency intervention is necessary because of the adverse effects of hypercalcemia on cardiac, central nervous system, renal, and gastrointestinal functions. However, since vitamin D is stored in fat tissues, effects of toxicity may last for months despite the removal of the exogenous source of vitamin D. Treatment for VDI includes: discontinuation of intake, a diet with low calcium and phosphorus content, intravenous hydration with saline, loop diuretics, glucocorticoids, calcitonin, and bisphosphonates. In conclusion, the diagnosis of vitamin D deficiency rickets (VDDR) without checking serum 25OHD level may cause redundant treatment that leads to VDI. All patients who are clinically suspected of VDDR should be checked for serum vitamin D status and questioned for previous vitamin D administration before starting vitamin D therapy. On the other hand, parents of all infants should be asked whether they are using dietary or oral supplements, and serial questioning may be required during supplementation to avoid excessive intake. PMID:22734293

  11. X(3872) and Bound State Problem of D~0(D)*~0((D)~0D*~0)

    LIU Tan-rui; LIU Xiang; DENG Wei-zhen

    2009-01-01

    We have performed a dynamical calculation of the bound state problem of D~0(D)~(*0) by considering the pion and sigma meson exchange potential.Our preliminary analysis disfavors the molecular interpretation of X(3872) if we use the experimental D~* Dπ coupling constant g=0.59 and a reasonable cutoff around 1 GeV,which is the typical hadronic scale.In contrast,there probably exists a loosely bound S-wave B (-B)~* molecular state.Such a molecular state would be rather stable since its dominant decay mode is the radiative decay through B~*→Bγ.

  12. Blender 3D cookbook

    Valenza, Enrico

    2015-01-01

    This book is aimed at the professionals that already have good 3D CGI experience with commercial packages and have now decided to try the open source Blender and want to experiment with something more complex than the average tutorials on the web. However, it's also aimed at the intermediate Blender users who simply want to go some steps further.It's taken for granted that you already know how to move inside the Blender interface, that you already have 3D modeling knowledge, and also that of basic 3D modeling and rendering concepts, for example, edge-loops, n-gons, or samples. In any case, it'

  13. TOWARDS: 3D INTERNET

    Ms. Swapnali R. Ghadge

    2013-01-01

    In today’s ever-shifting media landscape, it can be a complex task to find effective ways to reach your desired audience. As traditional media such as television continue to lose audience share, one venue in particular stands out for its ability to attract highly motivated audiences and for its tremendous growth potential the 3D Internet. The concept of '3D Internet' has recently come into the spotlight in the R&D arena, catching the attention of many people, and leading to a lot o...

  14. Drug: D00976 [KEGG MEDICUS

    Full Text Available cortisone cypionate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS,... PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D00976 Hydrocortisone cypionate D07X CORTICOSTEROIDS...AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucoco...ortisone cypionate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA01 Hydrocortisone D00976 ...D07XA01 Hydrocortisone D00976 Hydrocortisone cypionate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES

  15. Drug: D04467 [KEGG MEDICUS

    Full Text Available Hydrocortisone D04467 Hydrocortisone hemisuccinate (USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGIC...AL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D04...467 Hydrocortisone hemisuccinate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D...SP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...2 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA01 Hydrocortisone D04467 Hydrocortisone hemisu

  16. Drug: D00165 [KEGG MEDICUS

    Full Text Available tisone D00165 Hydrocortisone acetate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROI...cortisone acetate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corti...MIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS... S01CB03 Hydrocortisone D00165 Hydrocortisone acetate (JP16/USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS...DS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D00165 Hydro

  17. Drug: D09796 [KEGG MEDICUS

    Full Text Available AA01 Hydrocortisone D09796 Hydrocortisone caproate (JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGIC...AL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D09...796 Hydrocortisone caproate (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, othe...EMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...3 Hydrocortisone D09796 Hydrocortisone caproate (JAN) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  18. Drug: D08415 [KEGG MEDICUS

    Full Text Available nisolone D08415 Prednisolone steaglate (BAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Pre...dnisolone D08415 Prednisolone steaglate (BAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids...ARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...02 Prednisolone D08415 Prednisolone steaglate (BAN) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroi

  19. Drug: D01442 [KEGG MEDICUS

    Full Text Available 1 Hydrocortisone D01442 Hydrocortisone succinate (JP16) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICA...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D014...42 Hydrocortisone succinate (JP16) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA...YSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...s/mydriatics in combination S01CB03 Hydrocortisone D01442 Hydrocortisone succinate (JP16) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  20. Drug: D01775 [KEGG MEDICUS

    Full Text Available D01775 Drug Bifonazole (JP16/USAN/INN); Mycospor (TN) C22H18N2 310.147 310.3917 D0177...ntiparasitic dermatosis agents 2655 Imidazoles D01775 Bifonazole (JP16/USAN/INN) Anatomical Therapeutic Chem...GALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D01AC10 Bifonazole D0177...sterol 14alpha-demethylase inhibitor [KO:K05917] Imidazoles Bifonazole [ATC:D01AC10] D01775 Bifonazole (JP16.../USAN/INN) CAS: 60628-96-8 PubChem: 7848838 LigandBox: D01775 NIKKAJI: J17.988D A

  1. Drug: D00129 [KEGG MEDICUS

    Full Text Available Japan [BR:br08301] 3 Agents affecting metabolism 31 Vitamins 311 Vitamins A and D preparations 3112 Synthetic vitami...29.gif Regulator [calcium] Same as: C01673 Therapeutic category: 3112 ATC code: A11CC04 D05AX03 vitamin D re...:br08310] Nuclear receptors Thyroid hormone like receptors Vitamin D3 like receptor vitamin D receptor [HSA:7421] [KO:K08539] Calcit...1C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO A11CC Vitamin D and analogues A11CC04 Calcitriol D00129 Calcit...n D preparations D00129 Calcitriol (JAN/USP/INN) Anatomical Therapeutic Chemical (A

  2. $X(3872)$ production from reactions involving $D$ and $D^*$ mesons

    Torres, A Martinez; Navarra, F S; Nielsen, M; Abreu, Luciano M

    2014-01-01

    In this proceeding we show the results found for the cross sections of the processes $\\bar D D\\to\\pi X(3872)$, $\\bar D^* D\\to \\pi X(3872)$ and $\\bar D^* D^*\\to\\pi X(3872)$, information needed for calculations of the $X(3872)$ abundance in heavy ion collisions. Our formalism is based on the generation of $X(3872)$ from the interaction of the hadrons $\\bar D^0 D^{*0} - \\textrm{c.c}$, $D^- D^{*+} - \\textrm{c.c}$ and $D^-_s D^{*+}_s - \\textrm{c.c}$. The evaluation of the cross section associated with processes having $D^*$ meson(s) involves an anomalous vertex, $X\\bar D^* D^*$, which we have determined by considering triangular loops motivated by the molecular nature of $X(3872)$. We find that the contribution of this vertex is important. Encouraged by this finding we estimate the $X\\bar D^* D^*$ coupling, which turns out to be $1.95\\pm 0.22$. We then use it to obtain the cross section for the reaction $\\bar D^* D^*\\to\\pi X$ and find that the $X\\bar D^* D^*$ vertex is also relevant in this case. We also discuss t...

  3. Donato D'Urbino

    2005-01-01

    Itaalia arhitektide-disainerite Jonathan De Pasi, Donato D'Urbino, Paolo Lomazzi ja Carla Scolari kavandatud ning Itaalia firmas Zanotta S.p.A. toodetud täispuhutavast plastikust tugitoolist "Blow" (1967)

  4. 3D Digital Modelling

    Hundebøl, Jesper

    wave of new building information modelling tools demands further investigation, not least because of industry representatives' somewhat coarse parlance: Now the word is spreading -3D digital modelling is nothing less than a revolution, a shift of paradigm, a new alphabet... Research qeustions. Based...... on empirical probes (interviews, observations, written inscriptions) within the Danish construction industry this paper explores the organizational and managerial dynamics of 3D Digital Modelling. The paper intends to - Illustrate how the network of (non-)human actors engaged in the promotion (and arrest) of 3......D Modelling (in Denmark) stabilizes - Examine how 3D Modelling manifests itself in the early design phases of a construction project with a view to discuss the effects hereof for i.a. the management of the building process. Structure. The paper introduces a few, basic methodological concepts...

  5. Professional Papervision3D

    Lively, Michael

    2010-01-01

    Professional Papervision3D describes how Papervision3D works and how real world applications are built, with a clear look at essential topics such as building websites and games, creating virtual tours, and Adobe's Flash 10. Readers learn important techniques through hands-on applications, and build on those skills as the book progresses. The companion website contains all code examples, video step-by-step explanations, and a collada repository.

  6. Reflectometry on D17

    Cubitt, R. [Institut Max von Laue - Paul Langevin (ILL), 38 - Grenoble (France)

    1997-04-01

    As part of the package of instrument upgrades planned over the next few years, D17 is based on a straightened cold neutron-guide and converted into a dedicated and versatile reflectometer. In the meantime, in order for ILL to become as fully involved as possible in this growing area of activity, the current D17 has been optimised for reflectometry. Results of this project are presented. (author).

  7. Drug: D07001 [KEGG MEDICUS

    Full Text Available [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]), (Glehnia root [DR:D06777] | Saposhnikovia root [DR:D06787]) Arthralgia...otium [DR:D06783], Achyranthes root [DR:D06722], Citrus unshiu peel [DR:D06764], Sinomenium stem [DR:D06785], Japanese gentian...c category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chi...D07001 Formula, Drug Sokeikakketsuto Peony root [DR:D06739], Rehmannia root [DR:D06...736], Cnidium rhizome [DR:D06748], Japanese angelica root [DR:D06768], Peach kernel [DR:D06769], Poria scler

  8. Tachyon condensation in unbalanced D-anti D system

    Ishida, Akira; Uehara, Shozo; Yada, Tomoki

    2006-01-01

    The tachyon condensation is studied in asymmetric D-anti D systems. Taking a system of two pairs of D5-anti D5 in type IIB superstring theory in the background of large N D5-branes, we show that one BPS D1-brane comes out after the condensation. It is also seen that the BPS D1-brane feels no force from the background D5-branes. We also show that the inclusion of the fluctuation fields gives an expected Dirac-Born-Infeld (DBI) action of the resultant D1-brane. On the other hand, in the case of...

  9. Observation of the Radiative Decay D*+→D

    We have observed a signal for the decay D*+→D+γ at a significance of 4standard deviations. From the measured branching ratio B(D*+→D+γ) /B(D*+→D+π0)=0.055±0.014±0.010 we find B(D*+→D+γ) =0.017±0.004±0.003, where the first uncertainty is statistical and the second is systematic. We also report the highest precision determination of the remaining D*+ branching fractions. copyright 1998 The American Physical Society

  10. Cosmic D--term Strings as Wrapped D3 Branes

    Halyo, E

    2004-01-01

    We describe cosmic D--term strings as D3 branes wrapped on a resolved conifold. The matter content that gives rise to D--term strings is shown to describe the world--volume theory of a space--filling D3 brane transverse to the conifold which itself is a wrapped D5 brane. We show that, in this brane theory, the tension of the wrapped D3 brane mathces that of the D--term string. We argue that there is a new type of cosmic string which arises from fractional D1 branes on the world--volume of a fractional D3 brane.

  11. Drug: D06216 [KEGG MEDICUS

    Full Text Available ATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...nide sodium phosphate (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately pote...IC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR... SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H02AB08 Triamcinolone D0621...SE C05AA Corticosteroids C05AA12 Triamcinolone D06216 Triamcinolone acetonide sodium phosphate (USAN) D DERM

  12. Drug: D02288 [KEGG MEDICUS

    Full Text Available e D02288 Hydrocortisone valerate (USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS... valerate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, w...ARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYST...on S01CB03 Hydrocortisone D02288 Hydrocortisone valerate (USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Co

  13. Drug: D00385 [KEGG MEDICUS

    Full Text Available e (JP16/USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PL...AIN D07AB Corticosteroids, moderately potent (group II) D07AB09 Triamcinolone D00385 Triamcinolone (JP16/USP/INN) D07X CORTICOSTEROID...PARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYS

  14. Drug: D04819 [KEGG MEDICUS

    Full Text Available D04819 Mixture, Drug Arsenic trioxide - dibucaine hydrochloride - dl-methylephedrine hydr...ochloride - p-butylaminobenzoyldiethylaminoethyl hydrochloride - benzyl alcohol mixt; Neoarsen black (...TN) Arsenic trioxide [DR:D02106], Dibucaine hydrochloridide [DR:D02220], dl-Methylephedrine hydrochloride [D...R:D02109], p-Butylaminobenzoyldiethylaminoethyl hydrochloride [DR:D01967], Benzyl alcohol [DR:D00077] PubChem: 17398187 ...

  15. Drug: D01073 [KEGG MEDICUS

    Full Text Available D01073 Drug Clindamycin phosphate (JP16/USP); Cleocin (TN); Dalacin-S (TN); Evoclin (TN) C18H34C ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF01 Clindamycin D01073 Clindamycin phosphate ( ...

  16. Drug: D02184 [KEGG MEDICUS

    Full Text Available D02184 Drug Erythromycin stearate (JP16/USP); ES; Bristamycin (TN) C37H67NO13. C18H36O2 1017.732 ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF02 Erythromycin D02184 Erythromycin stearate ...

  17. Drug: D07675 [KEGG MEDICUS

    Full Text Available D07675 Drug Chloramphenicol succinate; Chloramphenicol ICN (TN) C15H16Cl2N2O8 422.0284 423.2021 ... phenicol D07675 Chloramphenicol succinate D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF03 Chloramphenicol D07675 Chloramphenicol suc ...

  18. Drug: D02523 [KEGG MEDICUS

    Full Text Available D02523 Drug Erythromycin acistrate (USAN); EA; Erasis (TN) C39H69NO14. C18H36O2 1059.7433 1060.4 ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF02 Erythromycin D02523 Erythromycin acistrate ...

  19. Drug: D02845 [KEGG MEDICUS

    Full Text Available D02845 Drug Aluminum chloride (USP) AlCl3. 6H2O 239.9515 241.4322 D02845.gif Astringent [topical ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AX Other anti-acne ... preparations for topical use D10AX01 Aluminium chl ...

  20. Drug: D00140 [KEGG MEDICUS

    Full Text Available D00140 Drug Erythromycin (JP16/USP/INN); EM; Akne-mycin (TN); Eryc (TN); Erygel (TN); Pce (TN); ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF02 Erythromycin D00140 Erythromycin (JP16/USP ...

  1. Drug: D00094 [KEGG MEDICUS

    Full Text Available D00094 Drug Tretinoin (JAN/USP/INN); Avita (TN); Renova (TN); Retin A (TN); Tretinoin (TN); Vesa ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AD Retinoids for topical use in acne ... D10AD01 Tretinoin D00094 Tretinoin (JAN/USP/INN) L ...

  2. Drug: D02477 [KEGG MEDICUS

    Full Text Available D02477 Drug Meclocycline sulfosalicylate (USP); Meclan (TN) C22H21ClN2O8. C7H6O6S 694.0872 695.0 ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF04 Meclocycline D02477 Meclocycline sulfosali ...

  3. Drug: D00890 [KEGG MEDICUS

    Full Text Available D00890 Drug Tioconazole (JAN/USP/INN); Vagistat-1 (TN) C16H13Cl3N2OS 385.9814 387.7112 D00890.gi ... LOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole ... and triazole derivatives D01AC07 Tioconazole D0089 ... ICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS G01AF Imidazole ... derivatives G01AF08 Tioconazole D00890 Tioconazole ...

  4. Drug: D03936 [KEGG MEDICUS

    Full Text Available D03936 Drug Econazole (USAN/INN) C18H15Cl3N2O 380.025 381.6835 D03936.gif Antifungal Same as: C0 ... LOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole ... and triazole derivatives D01AC03 Econazole D03936 ... ICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS G01AF Imidazole ... derivatives G01AF05 Econazole D03936 Econazole (US ...

  5. Drug: D05720 [KEGG MEDICUS

    Full Text Available D05720 Drug Retapamulin (USAN/INN); Altabax (TN) C30H47NO4S 517.3226 517.7635 D0572...S FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AX Other antibiotics for topical use D06AX13 Retapamulin D05720 Retapa...bacterials Antibacterials, Other Retapamulin D05720 Retapamulin (USAN/INN) Antiinfectives [BR:br08307] Antib...acterials Protein biosynthesis inhibitor 23S rRNA of 50S ribosomal subunit inhibitor [KO:K01980] Pleuromutilin derivatives Retapa...mulin [ATC:D06AX13] D05720 Retapamulin (USAN/INN) CAS: 22445

  6. Drug: D01510 [KEGG MEDICUS

    Full Text Available one D01510 Dexamethasone metasulfobenzoate sodium (JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICA...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately pote...nt (group II) D07AB19 Dexamethasone D01510 Dexamethasone metasulfobenzoate sodium (JAN) D07X CORTICOSTEROIDS...RMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB ...CB01 Dexamethasone D01510 Dexamethasone metasulfobenzoate sodium (JAN) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  7. Drug: D07073 [KEGG MEDICUS

    Full Text Available e D07073 Dexamethasone cipecilate (JAN/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...) D07AB19 Dexamethasone D07073 Dexamethasone cipecilate (JAN/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D...ipecilate (JAN/INN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FO...R SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids...ctives/mydriatics in combination S01CB01 Dexamethasone D07073 Dexamethasone cipecilate (JAN/INN) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  8. Drug: D00472 [KEGG MEDICUS

    Full Text Available D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Cortic...osteroids, weak (group I) D07AA03 Prednisolone D00472 Prednisolone (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHE...ne D00472 Prednisolone (JP16/USP/INN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H02AB06 .../mydriatics in combination S01CB02 Prednisolone D00472 Prednisolone (JP16/USP/INN) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  9. Drug: D00985 [KEGG MEDICUS

    Full Text Available CAL USE C05AA Corticosteroids C05AA12 Triamcinolone D00985 Triamcinolone hexacetonide (USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAI...CL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...e (USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combina...N D07AB Corticosteroids, moderately potent (group II) D07AB09 Triamcinolone D00985 Triamcinolone hexacetonid

  10. Drug: D00292 [KEGG MEDICUS

    Full Text Available ds C05AA09 Dexamethasone D00292 Dexamethasone (JP16/USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOL...OGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB19 ...Dexamethasone D00292 Dexamethasone (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHER COM...IC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR... SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H02AB02 Dexamethasone D0029

  11. Drug: D07799 [KEGG MEDICUS

    Full Text Available 05AA09 Dexamethasone D07799 Dexamethasone 21-tebutate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL ...PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB19 Dexamet...hasone D07799 Dexamethasone 21-tebutate D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, mode...ARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...sone 21-tebutate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA

  12. Drug: D07800 [KEGG MEDICUS

    Full Text Available 21-valerate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D...07AB Corticosteroids, moderately potent (group II) D07AB19 Dexamethasone D07800 Dexamethasone 21-valerate D07X CORTICOSTEROIDS...ethasone D07800 Dexamethasone 21-valerate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN...s/mydriatics in combination S01CB01 Dexamethasone D07800 Dexamethasone 21-valerate S02 OTOLOGICALS S02B CORTICOSTEROIDS

  13. Drug: D08414 [KEGG MEDICUS

    Full Text Available AA04 Prednisolone D08414 Prednisolone 21-(sodium tetrahydrophthalate) D DERMATOLOGICALS D07 CORTICOSTEROID...S, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, w...eak (group I) D07AA03 Prednisolone D08414 Prednisolone 21-(sodium tetrahydrophthalate) D07X CORTICOSTEROIDS,...ONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Gl...Prednisolone D08414 Prednisolone 21-(sodium tetrahydrophthalate) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA

  14. Drug: D07796 [KEGG MEDICUS

    Full Text Available steroids C05AA09 Dexamethasone D07796 Dexamethasone 21-acetate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMAT...OLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB1...9 Dexamethasone D07796 Dexamethasone 21-acetate D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroi...L PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...thasone 21-acetate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02

  15. Drug: D06876 [KEGG MEDICUS

    Full Text Available drocortisone D06876 Hydrocortisone aceponate (INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTE...drocortisone aceponate D06876 Hydrocortisone aceponate (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA ...TEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS ...FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H02AB09 Hydrocortisone D...driatics in combination S01CB03 Hydrocortisone D06876 Hydrocortisone aceponate (INN) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  16. Drug: D02164 [KEGG MEDICUS

    Full Text Available OLOGICAL PREPARATIONS D11AC Medicated shampoos D11AC01 Cetrimide D02164 Cetrimide (JAN) CAS: 8044-71-1 PubCh...ICS AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AJ Quaternary ammonium compo...D02164 Drug Cetrimide (JAN) C17H38N. Br 335.2188 336.3943 D02164.gif Same as: C1127...9 ATC code: D08AJ04 D11AC01 alkyl chain length may range form C12 to C16 (see [CPD:C11275], [CPD:C11279], [C

  17. Drug: D00733 [KEGG MEDICUS

    Full Text Available D00733 Drug Dibucaine (USP); Cinchocaine (INN); Nupercaine (TN) C20H29N3O2 343.226 ...l anesthetics C05AD04 Cinchocaine D00733 Dibucaine (USP); Cinchocaine (INN) D DERMATOLOGICALS D04 ANTIPRURIT...AB Anesthetics for topical use D04AB02 Cinchocaine D00733 Dibucaine (USP); Cinchocaine (INN) N NERVOUS SYSTE...M N01 ANESTHETICS N01B ANESTHETICS, LOCAL N01BB Amides N01BB06 Cinchocaine D00733...l anesthetics S01HA06 Cinchocaine D00733 Dibucaine (USP); Cinchocaine (INN) S02 OTOLOGICALS S02D OTHER OTOLO

  18. Drug: D02435 [KEGG MEDICUS

    Full Text Available D02435 Drug Sulfamerazine (INN) C11H12N4O2S 264.0681 264.3036 D02435.gif Antibacter...CAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BA Sulfonamides D06BA06 Sulfamerazine D02435 Sulfamerazine...RIM J01ED Long-acting sulfonamides J01ED07 Sulfamerazine D02435 Sulfamerazine (IN...ibitor [KO:K00796] Sulfonamides Sulfamerazine [ATC:D06BA06 J01ED07] D02435 Sulfamerazine (INN) CAS: 127-79-7

  19. Drug: D01468 [KEGG MEDICUS

    Full Text Available D01468 Drug Nemonapride (JAN/INN); Emilace (TN) C21H26ClN3O2 387.1714 387.903 D0146...ting central nervous system 117 Psychotropics 1179 Others D01468 Nemonapride (JAN...e dopamine D2-receptor [HSA:1813] [KO:K04145] Nemonapride D01468 Nemonapride (JAN/INN) dopamine D3-receptor ...[HSA:1814] [KO:K04146] Nemonapride D01468 Nemonapride (JAN/INN) dopamine D4-recep...tor [HSA:1815] [KO:K04147] Nemonapride D01468 Nemonapride (JAN/INN) CAS: 75272-39-8 PubChem: 7848531 LigandB

  20. Drug: D07578 [KEGG MEDICUS

    Full Text Available Japan [BR:br08301] 3 Agents affecting metabolism 31 Vitamins 311 Vitamins A and D preparations 3112 Synthetic vitamin...f Dermatological, antipsoriatic Therapeutic category: 3112 Vitamin D3 [DR:D00188] analogue vitamin D recepto...br08310] Nuclear receptors Thyroid hormone like receptors Vitamin D3 like receptor vitamin... D preparations D07578 Eldecalcitol (JAN/INN) Target-based classification of drugs [BR:...D07578 Drug Eldecalcitol (JAN/INN); Edirol (TN) C30H50O5 490.3658 490.715 D07578.gi

  1. Drug: D06392 [KEGG MEDICUS

    Full Text Available D06392 Drug d-Camphor (JP16); d-Camphor (TN) C10H16O 152.1201 152.2334 D06392.gif Cinnamomum...phenic (TN), Sulfur and camphor [DR:D04811] In case of crude: Lauraceae (laurel family) Cinnamomum camphora

  2. Drug: D04218 [KEGG MEDICUS

    Full Text Available ocortolone D04218 Fluocortolone (USAN/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...luocortolone D04218 Fluocortolone (USAN/INN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H

  3. Drug: D04219 [KEGG MEDICUS

    Full Text Available 08 Fluocortolone D04219 Fluocortolone caproate (USAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL ...PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III...MONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB G

  4. Drug: D05000 [KEGG MEDICUS

    Full Text Available Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DE...RMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylpr...ORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB

  5. Drug: D00863 [KEGG MEDICUS

    Full Text Available ONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AC Medicated shampoos D11AC06 Povid...D00863 Drug Povidone-Iodine (JP16/USP); Betadine (TN) xI2. (C6H9NO)n D00863.gif Anti-infective, topical Sam

  6. Drug: D08789 [KEGG MEDICUS

    Full Text Available D08789 Drug Freeze-dried human anti-D (Rho) immunoglobulin; Anti D globulin (TN) Th...anisms and parasites 63 Biological preparations 634 Human blood preparations 6343 Plasma preparations D08789 Freeze-dried human anti-D (Rho) immunoglobulin PubChem: 96025472 ...

  7. Drug: D08708 [KEGG MEDICUS

    Full Text Available D08708 Mixture, Drug Licase (alpha Amylase) - aluminum hydroxide, dried - magnesium...e) [DR:D02831], Aluminum hydroxide, dried [DR:D02416], Magnesium carbonate [DR:D01446], Sodium bicarbonate [...2339 Others D08708 Licase (alpha Amylase) - aluminum hydroxide, dried - magnesium carbonate - sodium bicarbonate - precipitated calcium carbonate mixt PubChem: 96025391 ...

  8. Drug: D04856 [KEGG MEDICUS

    Full Text Available loride - iodoform - calcium hydroxide mixt; Calvital (TN) Sulfathiazole [DR:D01047], Diethylaminoethyl p-but...ylaminobenzoate hydrochloride [DR:D01967], Iodoform [DR:D01910], Calcium hydroxide [DR:D01083] Therapeutic c...50 Pulp capping agents D04856 Sulfathiazole - diethylaminoethyl p-butylaminobenzoate hydrochloride - iodoform - calcium hydroxide mixt PubChem: 17398197 ...

  9. Drug: D10259 [KEGG MEDICUS

    Full Text Available D10259 Mixture, Drug Famotidine - calcium carbonate - magnesium hydroxide mixt; Com...plete (TN) Famotidine [DR:D00318], Magnesium hydroxide [DR:D00731], Precipitated calcium carbonate [DR:D0093...tagonists A02BA53 Famotidine, combinations D10259 Famotidine - calcium carbonate - magnesium hydroxide mixt PubChem: 163312290 ...

  10. Drug: D04956 [KEGG MEDICUS

    Full Text Available D04956 Mixture, Drug Ferric chloride - manganese chloride - zinc sulfate - cupric sulfate - potassium iodide... [DR:D01081], Cupric sulfate [DR:D03613], Potassium iodide [DR:D01016] Therapeutic category: 3229 Therapeuti...nts, tonics 322 Mineral preparations 3229 Others D04956 Ferric chloride - manganese chloride - zinc sulfate - cupric sulfate - potassium iodide mixt PubChem: 17398230 ...

  11. Drug: D04052 [KEGG MEDICUS

    Full Text Available D04052 Mixture, Drug Adrenaline - lidocaine hydrochloride mixt; Epinephrine - lidocai...ne hydrochloride mixt; Xylocaine (TN) Adrenaline [DR:D00095], Lidcaine hydrochloride [DR:D02086] Anestheti...ns 12 Agents affecting peripheral nervous system 121 Local anesthetics 1214 Xylidines D04052 Adrenaline - lidocai... 2710 Local anesthetics D04052 Adrenaline - lidocaine hydrochloride mixt PubChem: 17398016 ...

  12. Drug: D08462 [KEGG MEDICUS

    Full Text Available D08462 Drug Quinisocaine (INN); Dimethisoquin C17H24N2O 272.1889 272.3853 D08462.gi...INES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB05 Quinisocaine D08462 Quinisocai

  13. Drug: D07679 [KEGG MEDICUS

    Full Text Available D07679 Drug Chloropyramine hydrochloride; Avapena (TN) C16H20ClN3. HCl 325.1113 326.264 D07679.g ... ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC . D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHE ... TICS, ETC . D04AA Antihistamines for topical use D04AA09 Chlo ...

  14. Drug: D04844 [KEGG MEDICUS

    Full Text Available D04844 Mixture, Drug Paraformaldehyde - dibucaine hydrochloride mixt; Periodon (TN)... Paraformaldehyde [DR:D01494], Dibucaine hydrochloride [DR:D02220] Therapeutic category: 2730 Therapeutic category of dr...sics and sedatives 2730 Analgesics and sedatives D04844 Paraformaldehyde - dibucaine hydrochloride mixt CAS: 617-48-1 PubChem: 17398192 NIKKAJI: J237.180D ...

  15. Drug: D04930 [KEGG MEDICUS

    Full Text Available D04930 Mixture, Drug Benfotiamine - pyridoxine hydrochloride - Hydroxocobalamin hydr...ochloride mixt; Vitamedin-S (TN) Benfotiamine [DR:D01255], Pyridoxine hydrochloride [DR:D02179], Hydroxocobalamin hydrochloride [DR:D04929] See [DR:D04911] PubChem: 17398222 ...

  16. Drug: D10297 [KEGG MEDICUS

    Full Text Available D10297 Mixture, Drug Theophylline - dextrose mixt; Theophylline in dextrose (TN) (Theophylline... [DR:D00371] | Theophylline [DR:D06103]), Dextrose [DR:D02325] Treatment of bronchitis ATC code: ...EASES R03DA Xanthines R03DA54 Theophylline, combinations excl. psycholeptics D10297 Theophylline - dextrose mixt PubChem: 163312328 ...

  17. Drug: D00802 [KEGG MEDICUS

    Full Text Available D00802 Drug Bithionol (JAN/INN); Bithin (TN) C12H6Cl4O2S 353.8843 356.0518 D00802.gif Same as: C ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ...

  18. Drug: D03093 [KEGG MEDICUS

    Full Text Available D03093 Drug Benzoyl peroxide (JAN/USP) C14H10O4 242.0579 242.2268 D03093.gif Keratolytic Same as ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ...

  19. Subsidizing R&D cooperatives

    J. Hinloopen

    2001-01-01

    A framework is developed with which the implementation of two commonly used R&D-stimulating policies can be evaluated: providing R&D subsidies and sustaining the formation of R&D cooperatives. Subsidized R&D cooperatives can also be analyzed. The analysis shows that providing R&D subsidies is more e

  20. Drug: D02852 [KEGG MEDICUS

    Full Text Available sification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS D09A MEDICATED DRESSINGS D09AA Medicated d...rohydrate (USP) M MUSCULO-SKELETAL SYSTEM M05 DRUGS FOR TREATMENT OF BONE DISEASES M05B DRUGS AFFECTING BONE

  1. Drug: D09117 [KEGG MEDICUS

    Full Text Available 752]), Bupleurum root [DR:D06727], Glycyrrhiza [DR:D04365], Dry ginger [DR:D06744], Peppermint [DR:D05431] Traditional Chinese Medici...ne in Japan [BR:br08304] Formulas Formulas for Qi Sedative formulas D09117 Shoyosan PubChem: 96025797 ...

  2. Drug: D09042 [KEGG MEDICUS

    Full Text Available D09042 Formula , Drug Untanto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D06783], Ginger [D ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for Qi Formula s for regulating Qi D09042 ...

  3. Drug: D09109 [KEGG MEDICUS

    Full Text Available D09109 Formula , Drug Shiteito Clove [DR:D03570], Persimmon calyx [DR:D07154], Ginger [DR:D06744] ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for Qi Formula s for regulating Qi D09109 ...

  4. Drug: D07882 [KEGG MEDICUS

    Full Text Available imidazole, topic ATC code: D01AC17 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGA...LS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tria

  5. Drug: D01335 [KEGG MEDICUS

    Full Text Available NGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifunga....gif Same as: C12767 ATC code: D01AE09 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFU

  6. Drug: D06883 [KEGG MEDICUS

    Full Text Available al ATC code: D01AC14 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole derivative

  7. Drug: D07193 [KEGG MEDICUS

    Full Text Available TC code: D01AC16 G01AF18 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole deriva

  8. Drug: D03315 [KEGG MEDICUS

    Full Text Available Antifungal ATC code: D01AE04 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for to

  9. Drug: D00351 [KEGG MEDICUS

    Full Text Available es D00351 Ketoconazole (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazo

  10. Drug: D00339 [KEGG MEDICUS

    Full Text Available ALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals...339.gif Antifungal ATC code: D01AE11 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNG

  11. Drug: D08723 [KEGG MEDICUS

    Full Text Available D08723 Mixture, Drug dl-Camphor - capsicum extract - methyl salicylate mixt; Rakool... (TN) dl-Camphor [DR:D00098], Capsicum extract [DR:D06455], Methyl salicylate [DR:D01087] Therapeutic catego...hers D08723 dl-Camphor - capsicum extract - methyl salicylate mixt PubChem: 96025406 ...

  12. Drug: D08707 [KEGG MEDICUS

    Full Text Available D08707 Mixture, Drug l-Menthol - gentian - scopolia extract powder - sodium bicarbo...nate mixt; Bellsan (TN) l-Menthol [DR:D00064], Gentian [DR:D06716], Scopolia extract powder [DR:D06875], Sod...digestives 2339 Others D08707 l-Menthol - gentian - scopolia extract powder - sodium bicarbonate mixt PubChem: 96025390 ...

  13. Drug: D04798 [KEGG MEDICUS

    Full Text Available D04798 Mixture, Drug Zinc oxide oil (JP16); Zinc oxide oil (TN) Zinc oxide [DR:D01170], (Soybean ... 3314] | Rape seed oil | Camellia oil [DR:D05289] | Olive ... oil [DR:D03311] | Rice bran oil | Castor oil [DR:D ...

  14. Drug: D04046 [KEGG MEDICUS

    Full Text Available D04046 Mixture, Drug Salicylamide - acetaminophen ... - anhydrous caffeine - promethazine methylened ... salicylate mixt; PL (TN) Salicylamide [DR:D01811], Acetaminophen ... [DR:D00217], Anhydrous caffeine [DR:D00528], Prome ... drugs 1180 Common cold drugs D04046 Salicylamide - acetaminophen ... - anhydrous caffeine - promethazine methylenedisal ...

  15. Drug: D08695 [KEGG MEDICUS

    Full Text Available D08695 Mixture, Drug dl-Methylephedrine hydrochloride - dihydrocodeine phosphate - diprophylline ... - diphenhydramine salicylate - acetaminophen ... - bromovalerylurea mixt; Coughcode N (TN) dl-Methy ... R:D00691], Diphenhydramine salicylate [DR:D02419], Acetaminophen ... [DR:D00217], Bromovalerylurea [DR:D01391] Therapeu ...

  16. Drug: D04967 [KEGG MEDICUS

    Full Text Available D04967 Mixture, Drug Carbazochrome - phytonadione ... - ascorbic acid mixt; Ophthalm K (TN) Carbazoc ... hrome [DR:D01864], Phytonadione ... [DR:D00148], Ascorbic acid [DR:D00018] Hemostatics ... 332 Hemostatics 3329 Others D04967 Carbazochrome - phytonadione ... - ascorbic acid mixt PubChem: 17398238 ...

  17. Ph.D. shortage

    The late 1990s will see a shortage of Ph.D. graduates, according to the Association of American Universities, Washington, D.C. AAU's new comprehensive study, “The Ph.D. Shortage: The Federal Role,” reports that competition for new Ph.D.s is already intense and can only intensify because demand is greater than supply in both academic and nonacademic markets.Doctoral education plays an increasingly important role in U.S. research and development programs. Students have a pivotal part in doing research and enriching it with new ideas. The AAU report says that graduate students are “major determinants of the creativity and productivity of U.S. academic research, the source of more than 50% of the nation's basic research.’ The market for doctoral education extends beyond the university. In 1985, about 43% of all Ph.D.s employed in this country were working outside higher education; the demand for doctorate recipients in nonacademic sectors continues to grow.

  18. INEL D ampersand D Long-Range Plan

    This Long-Range Plan presents the Decontamination and Decommissioning (D ampersand D) Program planning status for facilities at the Idaho National Engineering Laboratory (INEL). The plan provides a general description of the D ampersand D Program objectives, management criteria, and philosophy; discusses current activities; and documents the INEL D ampersand D Program cost and schedule estimate projections for the next 15 years. appendices are included that provide INEL D ampersand D project historical information and a comprehensive descriptive summary of each current surplus facility

  19. 3D Spectroscopic Instrumentation

    Bershady, Matthew A

    2009-01-01

    In this Chapter we review the challenges of, and opportunities for, 3D spectroscopy, and how these have lead to new and different approaches to sampling astronomical information. We describe and categorize existing instruments on 4m and 10m telescopes. Our primary focus is on grating-dispersed spectrographs. We discuss how to optimize dispersive elements, such as VPH gratings, to achieve adequate spectral resolution, high throughput, and efficient data packing to maximize spatial sampling for 3D spectroscopy. We review and compare the various coupling methods that make these spectrographs ``3D,'' including fibers, lenslets, slicers, and filtered multi-slits. We also describe Fabry-Perot and spatial-heterodyne interferometers, pointing out their advantages as field-widened systems relative to conventional, grating-dispersed spectrographs. We explore the parameter space all these instruments sample, highlighting regimes open for exploitation. Present instruments provide a foil for future development. We give an...

  20. 3D Projection Installations

    Halskov, Kim; Johansen, Stine Liv; Bach Mikkelsen, Michelle

    2014-01-01

    Three-dimensional projection installations are particular kinds of augmented spaces in which a digital 3-D model is projected onto a physical three-dimensional object, thereby fusing the digital content and the physical object. Based on interaction design research and media studies, this article...... contributes to the understanding of the distinctive characteristics of such a new medium, and identifies three strategies for designing 3-D projection installations: establishing space; interplay between the digital and the physical; and transformation of materiality. The principal empirical case, From...... Fingerplan to Loop City, is a 3-D projection installation presenting the history and future of city planning for the Copenhagen area in Denmark. The installation was presented as part of the 12th Architecture Biennale in Venice in 2010....

  1. RGB-D SLAM

    García Bueno, Jorge

    2011-01-01

    This project has been developed as an implementation of a SLAM technique called GraphSLAM. This technique applies the theory of graphs to create an on-line optimization system that allows robots to map the scenario and locate themselves using a Time of Flight camera as the input source. To do that, a RGB-D system has been calibrated and used to create color 3D point clouds. With this information, the feature detector module estimates, as a first approximation, the pose of the camera. Therefor...

  2. β-d-Gulose

    Tomohiko Ishii

    2014-05-01

    Full Text Available The title compound, C6H12O6, a C-3 position epimer of d-galactose, crystallized from an aqueous solution, was confirmed as β-d-pyranose with a 4C1 (C1 conformation. In the crystal, O—H...O hydrogen bonds between the hydroxy groups at the C-1 and C-6 positions connect molecules into a tape structure with an R33(11 ring motif running along the a-axis direction. The tapes are connected by further O—H...O hydrogen bonds, forming a three-dimensional network.

  3. Herramientas SIG 3D

    Francisco R. Feito Higueruela

    2010-04-01

    Full Text Available Applications of Geographical Information Systems on several Archeology fields have been increasing during the last years. Recent avances in these technologies make possible to work with more realistic 3D models. In this paper we introduce a new paradigm for this system, the GIS Thetrahedron, in which we define the fundamental elements of GIS, in order to provide a better understanding of their capabilities. At the same time the basic 3D characteristics of some comercial and open source software are described, as well as the application to some samples on archeological researchs

  4. Bootstrapping 3D fermions

    Iliesiu, Luca; Kos, Filip; Poland, David; Pufu, Silviu S.; Simmons-Duffin, David; Yacoby, Ran

    2016-03-01

    We study the conformal bootstrap for a 4-point function of fermions in 3D. We first introduce an embedding formalism for 3D spinors and compute the conformal blocks appearing in fermion 4-point functions. Using these results, we find general bounds on the dimensions of operators appearing in the ψ × ψ OPE, and also on the central charge C T . We observe features in our bounds that coincide with scaling dimensions in the GrossNeveu models at large N . We also speculate that other features could coincide with a fermionic CFT containing no relevant scalar operators.

  5. Interaktiv 3D design

    Villaume, René Domine; Ørstrup, Finn Rude

    2002-01-01

    Projektet undersøger potentialet for interaktiv 3D design via Internettet. Arkitekt Jørn Utzons projekt til Espansiva blev udviklet som et byggesystem med det mål, at kunne skabe mangfoldige planmuligheder og mangfoldige facade- og rumudformninger. Systemets bygningskomponenter er digitaliseret som...... 3D elementer og gjort tilgængelige. Via Internettet er det nu muligt at sammenstille og afprøve en uendelig  række bygningstyper som  systemet blev tænkt og udviklet til....

  6. 3D Dental Scanner

    Kotek, L.

    2015-01-01

    This paper is about 3D scan of plaster dental casts. The main aim of the work is a hardware and software proposition of 3D scan system for scanning of dental casts. There were used camera, projector and rotate table for this scanning system. Surface triangulation was used, taking benefits of projections of structured light on object, which is being scanned. The rotate table is controlled by PC. The camera, projector and rotate table are synchronized by PC. Controlling of stepper motor is prov...

  7. Drug: D05820 [KEGG MEDICUS

    Full Text Available D05820 Drug Semduramicin (USAN/INN) C45H76O16 872.5133 873.0753 D05820.gif Coccidiostat ionophore... Antiinfectives [BR:br08307] Antibacterials Others Others Polyether ionophores Semduramicin D0

  8. Drug: D06982 [KEGG MEDICUS

    Full Text Available D06982 Formula, Drug Jumihaidokuto Bupleurum root [DR:D06727], Platycodon root [DR:D06703], Cnid ... sease; Urticarial eruption; Acute eczema; Athletic foot ... Therapeutic category: 5200 Therapeutic category of ...

  9. Drug: D07049 [KEGG MEDICUS

    Full Text Available Insomnia; Night cry in childhood Therapeutic category: 5200 Therapeutic category...a [DR:D04365], (Atractylodes rhizome [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]) Nervous disease;

  10. Drug: D06965 [KEGG MEDICUS

    Full Text Available adenoiditis; Ecozema in childhood Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08...Trichosanthes root [DR:D06701], Burdock fruit [DR:D06723], Glycyrrhiza [DR:D04365] Nervous disease; Chronic

  11. Drug: D09069 [KEGG MEDICUS

    Full Text Available D09069 Formula, Drug Keikangan Powdered dioscorea rhizome [DR:D06735] Traditional Chinese Medicine in... Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09069 Keikangan PubChem: 96025750 ...

  12. Drug: D09067 [KEGG MEDICUS

    Full Text Available D09067 Formula, Drug Kujinto Sophora root [DR:D06710] Traditional Chinese Medicine in... Japan [BR:br08304] Formulas Formulas for external use Formulas for external use D09067 Kujinto PubChem: 96025748 ...

  13. Drug: D03091 [KEGG MEDICUS

    Full Text Available D03091 Crude, Drug Benzoin (JP16/USP); Benzoin tincture; Anxixang (TN) Benzoic acid [CPD:C00180] ... sifying agents D03091 Benzoin (JP16/USP) 73 Public health ... agents 731 Antiseptics 7319 Others D03091 Benzoin ...

  14. Drug: D09105 [KEGG MEDICUS

    Full Text Available D09105 Formula, Drug Saishakurikkunshito Ginseng [DR:D06772], (Atractylodes lancea ...pan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09105 Saishakurikkunshito PubChem: 96025785 ...

  15. Drug: D07203 [KEGG MEDICUS

    Full Text Available classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A

  16. Drug: D04732 [KEGG MEDICUS

    Full Text Available D04732 Mixture, Drug Isopropanol - methylated alcohol mixt; Alcohol (TN) Isopropanol [DR:D00137] ... , (Methylated alcohol | Ethanol ... [DR:D06542]) Therapeutic category: 2619 Therapeuti ...

  17. Vitamin D and Breast Cancer

    Shao, Theresa; Klein, Paula; Grossbard, Michael L.

    2012-01-01

    Vitamin D metabolism and its mechanism of action, the current evidence on the relationship between vitamin D and breast cancer, and the optimal dosing of vitamin D for breast cancer prevention are summarized.

  18. Drug: D10243 [KEGG MEDICUS

    Full Text Available DR:D00523], Amlodipine besilate [DR:D00615] Antihypertensive Therapeutic category: 2149 ATC code: C09DB05 En...gans 21 Cardiovascular agents 214 Antihypertensives 2149 Others D10243 Irbesartan

  19. Drug: D09196 [KEGG MEDICUS

    Full Text Available ); Ecard LD (TN) Candesartan cilexetil [DR:D00626], Hydrochlorothiazide [DR:D00340] Antihypertensive Therape... individual organs 21 Cardiovascular agents 214 Antihypertensives 2149 Others D09

  20. Drug: D06716 [KEGG MEDICUS

    Full Text Available D06716 Crude, Drug Gentian (JP16); Powdered gentian (JP16); Gentian (TN) Gentiopicr...tions 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06716 Gentian (JP16); Powdered gentian (JP16) Crude d

  1. Drug: D07028 [KEGG MEDICUS

    Full Text Available D07028 Formula, Drug Ninjinyoeito Ginseng [DR:D06772], (Atractylodes rhizome [DR:D06780] | Atrac ... hysical strength after illness; Tired and fatigue; Anorexia ; Night sweat; Cold limbs; Anemia Therapeutic categ ...

  2. Drug: D07039 [KEGG MEDICUS

    Full Text Available D07039 Formula, Drug Heiisan Atractylodes lancea rhizome [DR:D06752], Magnolia bark [DR:D06720], ... onic catarrhal gastritis; Gastroatonia; Dyspepsia; Anorexia ... Therapeutic category: 5200 Therapeutic category of ...

  3. Drug: D04249 [KEGG MEDICUS

    Full Text Available D04249 Mixture, Drug Oxytetracycline hydrochloride - hydrocortisone acetate mixt; T...erra-cortril (TN); Tetrazol (TN) Oxytetracycline hydrochloride [DR:D01596], Hydrocortisone acetate [DR:D00165] combination adrenocorticoid and antibiotic PubChem: 17398033 ...

  4. Drug: D04809 [KEGG MEDICUS

    Full Text Available D04809 Mixture, Drug Glycerin and potash solution (JP16); Glycerin and potash solution (TN) Potassium hydrox...ide [DR:D01168], Glycerin [DR:D00028] Therapeutic category: 2662 Therapeutic catego

  5. Drug: D09061 [KEGG MEDICUS

    Full Text Available :D06772], Pinellia tuber [DR:D06778] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic form...ulas D09061 Kankyoninjinhangegan PubChem: 96025742 ...

  6. Drug: D09116 [KEGG MEDICUS

    Full Text Available R:D06744], Poria sclerotium [DR:D06783] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09116 Bukuryukanto PubChem: 96025796 ...

  7. Drug: D06620 [KEGG MEDICUS

    Full Text Available D06620 Mixture, Drug dl-Camphor - ethanol mixt; Camphor (TN) dl-Camphor [DR:D00098], Ethanol [DR ... ringents, anti-inflammatory agents 2645 Peppermint rubber ... and camphor peppermint D06620 dl-Camphor - ethanol ...

  8. Vitamin D and Your Child

    ... 5 Things to Know About Zika & Pregnancy Vitamin D and Your Child KidsHealth > For Parents > Vitamin D ... to get it. Who's at Risk for Vitamin D Deficiency? Things like a lack of direct sunlight ...

  9. Drug: D09076 [KEGG MEDICUS

    Full Text Available Ginger [DR:D06744], Jujube [DR:D06758] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge... Formulas for pus discharge D09076 Hainoto PubChem: 96025757 ...

  10. Drug: D09073 [KEGG MEDICUS

    Full Text Available Oryzae semen [DR:D06900], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for clearing heat Formulas for clearing heat D09073 Byakkoto PubChem: 96025754 ...

  11. Drug: D09084 [KEGG MEDICUS

    Full Text Available eric [DR:D06695], Phellodendron bark [DR:D06689] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for external use Formulas for external use D09084 Chuoko PubChem: 96025765 ...

  12. Drug: D09082 [KEGG MEDICUS

    Full Text Available ractylodes lancea rhizome [DR:D06752] | Atractylodes rhizome [DR:D06780]) Traditional Chinese Medicine in Japan [BR:br08304] Formulas... Formulas for blood Formulas for replenishing blood D09082 Tokisan PubChem: 96025763 ...

  13. Drug: D09093 [KEGG MEDICUS

    Full Text Available ea [DR:D06792], Ophiopogon tuber [DR:D06775] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for expelling parasites Anthelmintic formulas D09093 Seikiankaito PubChem: 96025773 ...

  14. Drug: D09090 [KEGG MEDICUS

    Full Text Available as Formulas for blood Formulas for removing blood stasis D09090 Sesshoin PubChem: 96025770 ... ...yranthes root [DR:D06722], Safflower [DR:D06717] Traditional Chinese Medicine in Japan [BR:br08304] Formul

  15. Drug: D09080 [KEGG MEDICUS

    Full Text Available llaria bulb [DR:D06774], Sophora root [DR:D06710] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for clearing heat Formulas for clearing heat D09080 Tokibaimokujinganryo PubChem: 96025761 ...

  16. Drug: D09113 [KEGG MEDICUS

    Full Text Available ocessed ginger [DR:D06702], Ginger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for stomach Antidiarrheal formulas D09113 Shokyoshashinto PubChem: 96025793 ...

  17. Drug: D06938 [KEGG MEDICUS

    Full Text Available D06938 Formula, Drug Keigairengyoto Scutellaria root [DR:D06688], Phellodendron bark [DR:D06689] ... ]) Empyema; Chronic rhinitis; Chronic adenoiditis; Acne ... Therapeutic category: 5200 Therapeutic category of ...

  18. Drug: D09039 [KEGG MEDICUS

    Full Text Available :D06783], Cinnamon bark [DR:D06712], Millet Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09039 Ifuto PubChem: 96025722 ...

  19. Drug: D09052 [KEGG MEDICUS

    Full Text Available DR:D06744], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09052 Kashokuyohito PubChem: 96025733 ...

  20. Drug: D09071 [KEGG MEDICUS

    Full Text Available D09071 Formula , Drug Bukuryoinkahange Poria sclerotium [DR:D06783], (Atractylodes lancea rhizome ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for stomach Antiemetic formula s D09071 B ...

  1. Drug: D09120 [KEGG MEDICUS

    Full Text Available D09120 Formula , Drug Shoseiryutokasekko Ephedra herb [DR:D06791], Peony root [DR:D06739], Proces ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Diaphoretic formula s Diaphoretic dformula s pungen ...

  2. Drug: D02583 [KEGG MEDICUS

    Full Text Available 0100(K05917) Steroid biosynthesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE

  3. Drug: D08296 [KEGG MEDICUS

    Full Text Available UNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPIC...7] ko00100(K05917) Steroid biosynthesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIF

  4. Drug: D08696 [KEGG MEDICUS

    Full Text Available D08696 Mixture, Drug Acetaminophen - ephedra herb - scopolia extract - caffeine and... sodium benzoate - magnesium oxide mixt; Asgen (TN) Acetaminophen [DR:D00217], Ephedra herb [DR:D06791], Scopolia extract

  5. Drug: D04311 [KEGG MEDICUS

    Full Text Available D04311 Mixture, Drug dl-Methylephedrine hydrochloride - diphenhydramine hydrochloride mixt; Asdr...in (TN) dl-Methylephedrine hydrochloride [DR:D02109], Diphenhydramine hydrochloride [DR:D00669] PubChem: 17398049 ...

  6. Drug: D08600 [KEGG MEDICUS

    Full Text Available [HSA:1565] Genomic biomarker: CYP2D6 [HSA:1565] map07054 Antiglaucoma agents Anat...s Timolol D08600 Timolol (INN) Ophthalmic Agents Ophthalmic Antiglaucoma Agents Timolol D08600 Timolol (INN)

  7. Drug: D02135 [KEGG MEDICUS

    Full Text Available pa [DR:D00059], Benserazide hydrochloride [DR:D01653] Antiparkinsonian [DS:H00057] Therapeutic category: 116...d sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian

  8. Drug: D08753 [KEGG MEDICUS

    Full Text Available D08753 Mixture, Drug Bromelain - trypsin, crystallized mixt; Bromelains - trypsin, crystal...lized mixt; Kimotab (TN) Bromelain [DR:D03162], Trypsin, crystallized [DR:D00056] PubChem: 96025436 ...

  9. Drug: D02153 [KEGG MEDICUS

    Full Text Available D02153 Mixture, Drug Acetaminophen ... - oxycodone hydrochloride mixt; Percocet (TN); Roxicet 5/500 ... ); Tylox (TN) Oxycodone hydrochloride [DR:D00847], Acetaminophen ... [DR:D00217] Analgesic PubChem: 7849214 ...

  10. Drug: D07004 [KEGG MEDICUS

    Full Text Available D07004 Formula, Drug Daisaikoto Bupleurum root [DR:D06727], Pinellia tuber [DR:D06778], Scutella ... Cerebral hemorrhage; Stomach acid; Acute catarrhal gastritis ; Diabetes; Insomnia; Adipositas Therapeutic catego ...

  11. Drug: D02100 [KEGG MEDICUS

    Full Text Available D02100 Drug Ziprasidone mesylate (USAN); Ziprasidone mesylate hydrate; Geodon (TN) C21H21ClN4OS. ... cal Ziprasidone D02100 Ziprasidone mesylate (USAN) Bipolar ... Agents Bipolar ... Agents, Other Ziprasidone D02100 Zi ...

  12. Drug: D05255 [KEGG MEDICUS

    Full Text Available D05255 Mixture, Drug Omega-3 -acid ethyl esters (USAN); Omacor (TN) Ethyl icosapentate [DR:D01892 ... r08302] Cardiovascular Agents Dyslipidemics, Other Omega-3 -acid ethyl esters D05255 Omega-3 -acid ethyl esters ...

  13. Search for the Decays B0→D(*)+D(*)-

    Using the CLEO-II data set we have searched for the decays B0→D(*)+D(*)- . We observe one candidate signal event for the decay B0→D*+D*- with an expected background of 0.022±0.011 events. This yield corresponds to a branching fraction of B(B0→D*+D*- )=[5.3+7.1-3.7(stat )±1.0(syst)]x 10-4 and an upper limit of B(B0→D*+D*- )-3 at the 90% C.L. We see no significant excess of signal above the expected background level in the other modes, and we calculate the 90% C.L.upper limits on the branching fractions to be B(B0→D*±Dminus-plus)-3 and B(B0→D+D-)-3 . copyright 1997 The American Physical Society

  14. Drug: D04408 [KEGG MEDICUS

    Full Text Available Therapeutic category: 2359 Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 23 Digestive... organ agents 235 Purgatives, clysters 2359 Others D04408 Carlsbad salt CAS: 8007-49-6 PubChem: 17398096 ... ...D04408 Mixture, Drug Carlsbad salt; Artificial carlsbad salt (TN) Sodium sulfate, dried [DR:D01732], Sodi...um bicarbonate [DR:D01203], Sodium chloride [DR:D02056], Potassium sulfate [DR:D01726

  15. Drug: D02676 [KEGG MEDICUS

    Full Text Available D02676 Drug Oxiperomide (USAN/INN) C20H23N3O2 337.179 337.4155 D02676.gif Antipsychotic dopamine ... D1 receptor antagonist [HSA:1812] [KO:K04144]; dopamine ... D2 receptor antagonist [HSA:1813] [KO:K04145]; dop ... ine D3 receptor antagonist [HSA:1814] [KO:K04146]; dopamine ... D4 receptor antagonist [HSA:1815] [KO:K04147]; dop ...

  16. Drug: D03047 [KEGG MEDICUS

    Full Text Available ichyl phosphatase inhibitor Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D06 ANTIBIOT...ICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06A ANTIBIOTICS... FOR TOPICAL USE D06AX Other antibiotics for topical use D06AX05 Bacitracin D03047 Bacitracin methylene disa...licylate (USP) R RESPIRATORY SYSTEM R02 THROAT PREPARATIONS R02A THROAT PREPARATIONS R02AB Antibiotics R02AB

  17. Drug: D08288 [KEGG MEDICUS

    Full Text Available D08288 Drug Nortriptyline (INN); Nortrilen (TN) C19H21N 263.1674 263.3767 D08288.gif Antidepress...ant, tricyclic Same as: C07274 ATC code: N06AA10 Tricyclic antidepressants serotonin transporte... Serotonergic synapse Enzyme: CYP2D6 [HSA:1565] Genomic biomarker: CYP2D6 [HSA:1565] map07027 Antidepress... D08288 Nortriptyline (INN) USP drug classification [BR:br08302] Antidepressants Tricyclics Nortriptyline D0

  18. Drug: D00983 [KEGG MEDICUS

    Full Text Available ROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS,...ide (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other comb...IC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...OR TOPICAL USE C05AA Corticosteroids C05AA12 Triamcinolone D00983 Triamcinolone acetonide (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTE

  19. Drug: D07801 [KEGG MEDICUS

    Full Text Available xamethasone phenylpropionate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...ne phenylpropionate D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other...EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...methasone phenylpropionate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticoster...oids S02BA06 Dexamethasone D07801 Dexamethasone phenylpropionate S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS S03B CORTICOSTEROID

  20. Drug: D00977 [KEGG MEDICUS

    Full Text Available drocortisone sodium phosphate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...ne sodium phosphate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Cor...SP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS... phosphate (JP16/USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA01 Hydrocortisone D009

  1. Drug: D02798 [KEGG MEDICUS

    Full Text Available D02798 Drug Alcohol diluted (NF) Pharmaceutic aid [solvent] Same as: C00469 ATC code: D08AX08 V0 ... D08AX Other antiseptics and disinfectants D08AX08 Ethanol ... D02798 Alcohol diluted (NF) V VARIOUS V03 ALL OTHE ... OTHER THERAPEUTIC PRODUCTS V03AB Antidotes V03AB16 Ethanol ... D02798 Alcohol diluted (NF) V03AZ Nerve depressant ...

  2. Drug: D06772 [KEGG MEDICUS

    Full Text Available D06772 Crude, Drug Ginseng (JP16); Powdered ginseng (JP16); Ginseng (TN) Ginsenosid...icine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06772 Ginseng (JP16); Powdered ginseng (...d antidiarrheal drugs Stomachic and antidiarrheal drugs D06772 *Ginseng; Powdered ginseng; Ginseng Drugs for... Qi Drugs for replenishing Qi D06772 *Ginseng; Powdered ginseng; Ginseng Crude drugs [BR:br08305] Dicot plants: asterids Araliaceae (ginseng family) D06772 Ginseng PubChem: 47208423 ...

  3. Drug: D00023 [KEGG MEDICUS

    Full Text Available D00023 Drug Urea ... (JP16/USP); Carbamide; Pastaron (TN) CH4N2O 60.0324 60.0553 D00023.gif Diuretic ... s 26 Epidermides 266 Emollients 2669 Others D00023 Urea ... (JP16/USP) Anatomical Therapeutic Chemical (ATC) c ... roducing osmotic diuresis B05BC02 Carbamide D00023 Urea ... (JP16/USP) D DERMATOLOGICALS D02 EMOLLIENTS AND PR ...

  4. Drug: D10511 [KEGG MEDICUS

    Full Text Available D10511 Drug Afamelanotide (INN) C78H111N21O19 1645.8365 1646.8452 D10511.gif ATC co...TS AND PROTECTIVES D02B PROTECTIVES AGAINST UV-RADIATION D02BB Protectives against UV-radiation for systemic use D02BB02 Afame...lanotide D10511 Afamelanotide (INN) CAS: 75921-69-6 PubChem: 17

  5. Drug: D04054 [KEGG MEDICUS

    Full Text Available D04054 Drug Erythromycin salnacedin (USAN); Erythromycin salnacedin dihydrate C37H67NO13. C12H13 ... NO5S. 2H2O 1052.5338 1053.2577 D04054.gif Anti-acne , Antibacterial ATC code: D10AF02 J01FA01 23S rRNA ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ...

  6. Drug: D08477 [KEGG MEDICUS

    Full Text Available D08477 Drug Retinol propionate; Microvit a dlc [veterinary] (TN) C23H34O2 342.2559 342.5149 D084 ... 77.gif Vitamin A; Antiacne ... ATC code: A11CA01 D10AD02 R01AX02 S01XA02 retinoic ... 8477 Retinol propionate D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ...

  7. Drug: D01072 [KEGG MEDICUS

    Full Text Available D01072 Drug Chloramphenicol palmitate (JP16/USP); Chloromycetin palmitate (TN) C27H42Cl2N2O6 560 ... 1072 Chloramphenicol palmitate (JP16/USP) D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ... AL USE D10AF Antiinfectives for treatment of acne ... D10AF03 Chloramphenicol D01072 Chloramphenicol pal ...

  8. Drug: D04917 [KEGG MEDICUS

    Full Text Available g metabolism 31 Vitamins 317 Multivitamin preparations 3179 Others D04917 Octotiami...D04917 Mixture, Drug Octotiamine - riboflavin - pyridoxine hydrochloride - cyanocobalamin mixt; Neurovita...n (TN) Octotiamine [DR:D01184], Riboflavin [DR:D00050], Pyridoxine hydrochloride [DR:D02179], Cyanocobalamin...ne - riboflavin - pyridoxine hydrochloride - cyanocobalamin mixt PubChem: 17398219 ... ... [DR:D00166] Therapeutic category: 3179 Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affectin

  9. Drug: D04935 [KEGG MEDICUS

    Full Text Available apan [BR:br08301] 3 Agents affecting metabolism 31 Vitamins 317 Multivitamin preparations...D04935 Mixture, Drug Thiamine disulfide phosphate - pyridoxine hydrochloride - cyanocobalamin mixt; Vitam...edin (TN) Thiamine disulfide phosphate [DR:D04933], Pyridoxine hydrochloride [DR:D02179], Cyanocobalamin... 3179 Others D04935 Thiamine disulfide phosphate - pyridoxine hydrochloride - cyanocobalamin mixt PubChem: 17398223 ... ... [DR:D00166] Therapeutic category: 3179 See [DR:D04911] Therapeutic category of drugs in J

  10. Drug: D04915 [KEGG MEDICUS

    Full Text Available an [BR:br08301] 3 Agents affecting metabolism 31 Vitamins 317 Multivitamin preparations...D04915 Mixture, Drug Calcium pantothenate - riboflavin - pyridoxine hydrochloride - nicotinamide mi... 3179 Others D04915 Calcium pantothenate - riboflavin - pyridoxine hydrochloride - nicotinamide mixt PubChem: 17398217 ... ...loride [DR:D02179], Nicotinamide [DR:D00036] Therapeutic category: 3179 Therapeutic category of drugs in Jap...xt; Pancal (TN) Calcium pantothenate [DR:D01082], Riboflavin [DR:D00050], Pyridoxine hydroch

  11. Drug: D04919 [KEGG MEDICUS

    Full Text Available Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 31 Vitamins 317 Multivit... acetate mixt; Vitadan (TN) Pyridoxal phosphate hydrate [DR:D00006], Fursultiamine hydroc...amin preparations 3179 Others D04919 Pyridoxal phosphate - fursultiamine hydrochloride - riboflavin - hydroxocobalamin acetate mixt PubChem: 17398220 ... ...D04919 Mixture, Drug Pyridoxal phosphate - fursultiamine hydrochloride - riboflavin - hydroxocobalamin...hloride [DR:D03321], Riboflavin [DR:D00050], Hydroxocobalami acetate [DR:D02707] Therapeutic category: 3179

  12. Drug: D08829 [KEGG MEDICUS

    Full Text Available bolism 31 Vitamins 317 Multivitamin preparations 3179 Others D08829 Hydroxocobalamin acetate -...e hydrochloride - riboflavin mixt; Vitaneurin-capsule (TN) Hydroxocobalamin acetate [DR:D02707], Pyri...D08829 Mixture, Drug Hydroxocobalamin acetate - pyridoxal phosphate hydrate - fursultiamin...doxal phosphate hydrate [DR:D00006], Fursultiamine hydrochloride [DR:D03321], Riboflavin [DR:D00050] Therape... pyridoxal phosphate hydrate - fursultiamine hydrochloride - riboflavin mixt PubChem: 96025512 ...

  13. Drug: D02136 [KEGG MEDICUS

    Full Text Available D02136 Mixture, Drug Ampicillin - dicloxacillin sodium mixt Ampicillin [DR:D00204],... J01CA Penicillins with extended spectrum J01CA51 Ampicillin, combinations D02136 Ampicillin - dicloxacillin...cillins D02136 Ampicillin - dicloxacillin sodium mixt J01R COMBINATIONS OF ANTIBA...CTERIALS J01RA Combinations of antibacterials J01RA01 Penicillins, combinations with other antibacterials D02136 Ampicillin - dicloxa...cillin sodium mixt PubChem: 7849197 LigandBox: D02136 ...

  14. Drug: D08697 [KEGG MEDICUS

    Full Text Available D08697 Mixture, Drug Platycodon fluidextract - glycyrrhiza extract - plantago herb extract - peony root extr...act - dihydrocodeine phosphate mixt; Opisezol codeine (TN) Platycodon fluidextract ...[DR:D06812], Glycyrrhiza extract [DR:D06811], Plantago herb extract [DR:D04333], Peony root extract [DR:D067... Antitussives and expectorants 2249 Others D08697 Platycodon fluidextract - glycyrrhiza extract - plantago herb extract... - peony root extract - dihydrocodeine phosphate mixt PubChem: 96025380 ...

  15. Drug: D10519 [KEGG MEDICUS

    Full Text Available D10519 Mixture, Drug Rabeprazole - amoxicillin - clarithromycin mixt; Rabecure (TN)...tibiotics 619 Miscellaneous 6199 Miscellaneous D10519 Rabeprazole - amoxicillin - clarithromycin mixt ...

  16. Drug: D01239 [KEGG MEDICUS

    Full Text Available C05AA Corticosteroids C05AA04 Prednisolone D01239 Prednisolone sodium succinate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (g...roup I) D07AA03 Prednisolone D01239 Prednisolone sodium succinate (JP16/USP) D07X CORTICOSTEROIDS...1239 Prednisolone sodium succinate (JP16/USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, P

  17. Drug: D02156 [KEGG MEDICUS

    Full Text Available ) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corti...P) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...Prednisolone D02156 Prednisolone succinate (JP16); Prednisolone hemisuccinate (USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS...nate (JP16); Prednisolone hemisuccinate (USP) S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS S03B CORTICOSTEROIDS...nate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02

  18. Drug: D00244 [KEGG MEDICUS

    Full Text Available PICAL USE C05AA Corticosteroids C05AA05 Betamethasone D00244 Betamethasone (JP16/USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (...group III) D07AC01 Betamethasone D00244 Betamethasone (JP16/USP/INN) D07X CORTICOSTEROIDS...Betamethasone (JP16/USP/INN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucoc

  19. Drug: D01998 [KEGG MEDICUS

    Full Text Available PICAL USE C05AA Corticosteroids C05AA04 Prednisolone D01998 Prednisolone farnesylate (JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (g...roup I) D07AA03 Prednisolone D01998 Prednisolone farnesylate (JAN) D07X CORTICOSTEROIDS...isolone farnesylate (JAN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocort

  20. Drug: D07802 [KEGG MEDICUS

    Full Text Available hate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Co...rticosteroids, moderately potent (group II) D07AB19 Dexamethasone D07802 Dexamethasone phosphate D07X CORTICOSTEROIDS...7802 Dexamethasone phosphate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucoc...bination S01CB01 Dexamethasone D07802 Dexamethasone phosphate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Cor

  1. Drug: D00981 [KEGG MEDICUS

    Full Text Available roids C05AA04 Prednisolone D00981 Prednisolone sodium phosphate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 ...Prednisolone D00981 Prednisolone sodium phosphate (JP16/USP) D07X CORTICOSTEROIDS...e sodium phosphate (JP16/USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Gluco

  2. Drug: D00980 [KEGG MEDICUS

    Full Text Available /USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07...te (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D...ORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FO...nisolone acetate (JP16/USP/INN) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Cortic...L PREPARATIONS S03B CORTICOSTEROIDS S03BA Corticosteroids S03BA02 Prednisolone D00980 Prednisolone acetate (

  3. Drug: D00975 [KEGG MEDICUS

    Full Text Available C05AA Corticosteroids C05AA09 Dexamethasone D00975 Dexamethasone sodium phosphate (JAN/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D...te (JAN/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combin...REPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR S...mbination S01CB01 Dexamethasone D00975 Dexamethasone sodium phosphate (JAN/USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS

  4. Drug: D00088 [KEGG MEDICUS

    Full Text Available 88 Hydrocortisone (JP16/USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...NS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC U...Hydrocortisone (JP16/USP/INN) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticos...ROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, o..., PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D00088 Hydrocortisone (JP16/USP/INN) D07X CORTICOSTE

  5. Drug: D07797 [KEGG MEDICUS

    Full Text Available Dexamethasone D07797 Dexamethasone isonicotinate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTER...ne D07797 Dexamethasone isonicotinate D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, modera...EPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS...examethasone isonicotinate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticoster...oids S02BA06 Dexamethasone D07797 Dexamethasone isonicotinate S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS S03B CORTICOSTEROIDS

  6. Drug: D00978 [KEGG MEDICUS

    Full Text Available rocortisone D00978 Hydrocortisone sodium succinate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATO...LOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortison...e D00978 Hydrocortisone sodium succinate (JP16/USP) D07X CORTICOSTEROIDS, OTHER C...ium succinate (JP16/USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorti

  7. Drug: D01596 [KEGG MEDICUS

    Full Text Available D01596 Drug Oxytetracycline hydrochloride (JP16/USP); OTC; Terramycin (TN) C22H24N2...s 2760 Antibiotics D01596 Oxytetracycline hydrochloride (JP16/USP) Anatomical Therapeutic Chemical (ATC) cla...FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AA Tetracycline and derivatives D06AA03 Oxytetracycline D01596 Oxytetracyc...OMBINATIONS WITH CORTICOSTEROIDS G01AA Antibiotics G01AA07 Oxytetracycline D01596 Oxytetracycline hydrochlor...A Tetracyclines J01AA06 Oxytetracycline D01596 Oxytetracycline hydrochloride (JP16/USP) S SENSORY ORGANS S01

  8. Drug: D00205 [KEGG MEDICUS

    Full Text Available D00205 Drug Oxytetracycline (JAN/USP/INN); Oxytetracycline dihydrate; OTC; Terramyc... FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AA Tetracycline and derivatives D06AA03 Oxytetracycline D00205 Oxytetracy...S WITH CORTICOSTEROIDS G01AA Antibiotics G01AA07 Oxytetracycline D00205 Oxytetracycline (JAN/USP/INN) J ANTI...S J01AA Tetracyclines J01AA06 Oxytetracycline D00205 Oxytetracycline (JAN/USP/INN) S SENSORY ORGANS S01 OPHT...HALMOLOGICALS S01A ANTIINFECTIVES S01AA Antibiotics S01AA04 Oxytetracycline D00205 Oxytetracycline (JAN/USP/

  9. Drug: D01600 [KEGG MEDICUS

    Full Text Available D01600 Drug Diphenylpiperidinomethyldioxolan iodide (JAN); Anacolin; Gastrophyllin-...iperidinomethyldioxolan D01600 Diphenylpiperidinomethyldioxolan iodide (JAN) CAS: 21216-78-4 PubChem: 784866

  10. Drug: D04814 [KEGG MEDICUS

    Full Text Available D04814 Mixture, Drug Ethyl aminobenzoate - p-butylaminobenzoyldiethylaminoethyl hyd...rochloride mixt; Neozalocaine (TN) Ethyl aminobenzoate [DR:D00552], p-Butylaminobenzoyldiethylaminoethyl hyd

  11. Drug: D04296 [KEGG MEDICUS

    Full Text Available D04296 Mixture, Drug Diprophylline - methoxyphenamine hydrochloride - noscapine - chlorphenirami ... ne maleate mixt; Asthma ... (TN) Diprophylline [DR:D00691], Methoxyphenamine h ...

  12. Drug: D04099 [KEGG MEDICUS

    Full Text Available D04099 Mixture, Drug Erythromycin lactobionate - colistin sodium methanesulfonate m...Others D04099 Erythromycin lactobionate - colistin sodium methanesulfonate mixt PubChem: 17398025 ...

  13. Drug: D07585 [KEGG MEDICUS

    Full Text Available D07585 Mixture, Drug Isopropylantipyrine - ergotamine tartrate - anhydrous caffeine...ers D07585 Isopropylantipyrine - ergotamine tartrate - anhydrous caffeine mixt PubChem: 96024447 ...

  14. Drug: D05480 [KEGG MEDICUS

    Full Text Available D05480 Drug Pimecrolimus (JAN/USAN/INN); Elidel (TN) C43H68ClNO11 809.4481 810.4531...ATOLOGICAL PREPARATIONS D11AH Agents for dermatitis, excluding corticosteroids D11AH02 Pimecrolimus D05480 Pimecrolimus... (JAN/USAN/INN) USP drug classification [BR:br08302] Dermatological Agents Pimecrolimus... D05480 Pimecrolimus (JAN/USAN/INN) Immunological Agents Immune Suppressants Pimecrolimus D05480 Pimecrolimus...neurin [HSA:5530 5532 5533 5534 5535 11261 63928] [KO:K04348 K06268] Pimecrolimus [ATC:D11AH02] D05480 Pim

  15. Drug: D07753 [KEGG MEDICUS

    Full Text Available D07753 Drug Cromoglicic acid (INN); Cromo-Comod (TN) C23H16O11 468.0693 468.3665 D0775...A07EB Antiallergic agents, excl. corticosteroids A07EB01 Cromoglicic acid D07753 Cromoglicic acid (INN) D DE...dermatitis, excluding corticosteroids D11AH03 Cromoglicic acid D07753 Cromoglicic...TOPICAL USE R01AC Antiallergic agents, excl. corticosteroids R01AC01 Cromoglicic acid D07753 Cromoglicic aci...E AIRWAY DISEASES, INHALANTS R03BC Antiallergic agents, excl. corticosteroids R03BC01 Cromoglicic acid D0775

  16. Drug: D01480 [KEGG MEDICUS

    Full Text Available al organ agents 2529 Others D01480 Isoconazole nitrate (JAN) 26 Epidermides 265 Antiparasitic dermatos...is agents 2655 Imidazoles D01480 Isoconazole nitrate (JAN) Anatomical Thera...TEROIDS G01AF Imidazole derivatives G01AF07 Isoconazole D01480 Isoconazole nitrate (JAN) Antiinfectives [BR:...D01480 Drug Isoconazole nitrate (JAN); Adestan-G (TN) C18H14Cl4N2O. HNO3 476.9817 4...OGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D01AC05 Isoconazole D01480 Isoconazole nitrat

  17. Drug: D00903 [KEGG MEDICUS

    Full Text Available halmic Agents Ophthalmic Anti-inflammatories Diclofenac D00903 Diclofenac potassium...00903 Diclofenac potassium (USAN) Dermatological Agents Diclofenac D00903 Diclofenac potassium (USAN) Opht

  18. Course d'Orientation

    Course d'Orientation

    2012-01-01

      Coupe de printemps La deuxième étape de la coupe de printemps organisée par le club d’orientation du CERN s’est déroulée le samedi 21 avril dans la forêt de Pougny-Challex. étant donné le temps très humide qui domine depuis début avril, les coureurs ne pouvaient trouver qu’un terrain gras et trempé, mais cela fait partie des défis de la course d’orientation. Le parcours technique long a été remporté par Yvan Balliot, CO Annecy en 51:18 devant Jean-Charles Baritaux en 56:21 et Bruno Barge, CO CERN en 59:39. La prochaine CO populaire se courra à Vulbens le samedi 28 avril. Les inscriptions et les départs se feront entre 13h et 15h. A noter les courses en mai : • Samedi 5 mai : Trelex • Samedi 12 mai : Chancy / Valleiry • Samedi 19 mai : Lausan...

  19. Bruno D'Amicis

    2008-01-01

    Bioloogist ja loodusemehest itaalia fotograafist Bruno D'Amicist, kes vaatamata oma noorusele (28), on võtnud ette suuri projekte - Berliini metropolis elutsevate loomade jäädvustamine, Kesk-Euroopa viimase metsiku mägismaa päästmine Slovakkias. Fotod, õigemini keskkonnaportreed on pärit seeriast "Intimate landscapes"

  20. Hybrid R&D

    S. Goyal (Sanjeev); A. Konovalov; J.L. Moraga-Gonzalez (José Luis)

    2003-01-01

    textabstractWe develop a model of R&D competition and collaboration in which individual firms carry out independent in-house research and also undertake joint research projects with other firms. We examine the impact of collaboration on in-house research and explore the circumstances under which a h

  1. Vann on 3D

    2006-01-01

    Aivar Habakukest, kes on 2005. aastast AS Balteco peadisainer. A. Habakukk AS Balteco tootegruppidest, tööstusdisainist. A. Habakuke projektid, objektid ja tööd. Ill.: värv. foto A. Habakukest, tema disainitud AS Balteco vann Metro

  2. Tangible 3D Modelling

    Hejlesen, Aske K.; Ovesen, Nis

    2012-01-01

    This paper presents an experimental approach to teaching 3D modelling techniques in an Industrial Design programme. The approach includes the use of tangible free form models as tools for improving the overall learning. The paper is based on lecturer and student experiences obtained through...

  3. 3D terrestrisk laserscanning

    Christoffersen, Morten Thoft

    2004-01-01

    Forfatteren til denne artikel er pr. juni 2004 påbegyndt et ph.d.-studie i terrestrisk laserscanning ved Aalborg Universitet, Institut for Samfundsudvikling og Planlægning. De næste 3 år skal derfor benyttes til forskning inden for dette fagfelt....

  4. Shaping 3-D boxes

    Stenholt, Rasmus; Madsen, Claus B.

    2011-01-01

    Enabling users to shape 3-D boxes in immersive virtual environments is a non-trivial problem. In this paper, a new family of techniques for creating rectangular boxes of arbitrary position, orientation, and size is presented and evaluated. These new techniques are based solely on position data...

  5. 3D monitor

    Szkandera, Jan

    2009-01-01

    Tato bakalářská práce se zabývá návrhem a realizací systému, který umožní obraz scény zobrazovaný na ploše vnímat prostorově. Prostorové vnímání 2D obrazové informace je umožněno jednak stereopromítáním a jednak tím, že se obraz mění v závislosti na poloze pozorovatele. Tato práce se zabývá hlavně druhým z těchto problémů. This Bachelor's thesis goal is to design and realize system, which allows user to perceive 2D visual information as three-dimensional. 3D visual preception of 2D image i...

  6. Vitamin D and you

    Public Health Agency

    2015-01-01

    This leaflet highlights the importance of Vitamin D supplements for those who may not get enough, including women who are pregnant or breastfeeding; infants and young children under five; people aged 65 years and over; people who are confined indoors or cover their skin for cultural reasons; and those with darker skins (eg African and African-Caribbean).�

  7. 3D Harmonic Echocardiography:

    M.M. Voormolen

    2007-01-01

    textabstractThree dimensional (3D) echocardiography has recently developed from an experimental technique in the ’90 towards an imaging modality for the daily clinical practice. This dissertation describes the considerations, implementation, validation and clinical application of a unique

  8. Comparison of preliminary D-T and 'catalyzed' D-D system studies

    The purpose of the research currently underway is to provide technological and eventual economic comparison of a reference D-T reactor to a 'catalyzed' D-D reactor. Two separate reactor designs are delineated and examined for this purpose. These systems include plasma parameters, blanket and shield configurations, magnetic coil configurations, and power conversion systems, including a divertor-direct convertor system for the D-D design. The initial conclusions reached are as follows: no extraordinary requirements in the D-D reactor in the areas of blanket or magnet technology, advantageous use of minimum activity blankets and shields, increased overall efficiency via introduction of divertor-direct convertor subsystem in D-D design and 65% increase in the toroidal radius of the D-D design compared to the D-T reference value

  9. Purification of radium-226 for the manufacturing of actinium-225 in a cyclotron for alpha-immunotherapy; Radium-Aufreinigung zur Herstellung von Actinium-225 am Zyklotron fuer die Alpha-Immuntherapie

    Marx, Sebastian Markus

    2014-09-23

    The thesis describes the development of methods for the purification of Ra-226. The objective was to obtain the radionuclide in the quality that is needed to be used as starting material in the manufacturing process for Ac-225 via proton-irradiated Ra-226. The radionuclide has been gained efficiently out of huge excesses of impurities. The high purity of the obtained radium affords its use as staring material in a pharmaceutical manufacturing process.

  10. 3-D Whole-Core Transport Calculation with 3D/2D Rotational Plane Slicing Method

    Use of the method of characteristics (MOC) is very popular due to its capability of heterogeneous geometry treatment and widely used for 2-D core calculation, but direct extension of MOC to 3-D core is not so attractive due to huge calculational cost. 2-D/1-D fusion method was very successful for 3-D calculation of current generation reactor types (highly heterogeneous in radial direction but piece-wise homogeneous in axial direction). In this paper, 2-D MOC concept is extended to 3-D core calculation with little modification of an existing 2-D MOC code. The key idea is to suppose 3-D geometry as a set of many 2-D planes like a phone-directory book. Dividing 3-D structure into a large number of 2-D planes and solving each plane with a simple 2-D SN transport method would give the solution of a 3-D structure. This method was developed independently at KAIST but it is found that this concept is similar with that of 'plane tracing' in the MCCG-3D code. The method developed was tested on the 3-D C5G7 OECD/NEA benchmark problem and compared with the 2-D/1-D fusion method. Results show that the proposed method is worth investigating further. A new approach to 3-D whole-core transport calculation is described and tested. By slicing 3-D structure along characteristic planes and solving each 2-D plane problem, we can get 3-D solution. The numerical test results indicate that the new method is comparable with the 2D/1D fusion method and outperforms other existing methods. But more fair comparison should be done in similar discretization level

  11. D/antiD Dark Energy in String Warped Compactification

    Piao, Y S

    2005-01-01

    We study the evolution of relic D3-branes in the bulk after D3/antiD3-brane inflation in string warped compactification. The motion of D3-branes can be frozen under certain condition during radiation/matter domination, and will be relaxed until D3/antiD3-branes potential starts to dominate the universe at late time. These relic D3-branes will be attract and move toward to antiD3-branes with the role of uplifting AdS minimum to dS's near the apex of throats. This provides a rapid channel inducing to the subsiding of dS vacuum with observed value. We discuss the required parameter spaces and calculate the decay time for this process.

  12. DISTRIBUCIJSKA LOGISTIKA V PODJETJU LAMA DEKANI, D.D.

    Segulin, Kristina

    2010-01-01

    Diplomsko delo z naslovom Distribucijska logistika v podjetju Lama Dekani, d.d., v svojem teoretičnem delu zajema opredelitev samega pojma in pomena logistike ter elementov logističnega sistema. V nadaljevanju so opredeljeni logistični podsistemi v proizvodnem podjetju, kamor spadajo nabavna, notranja, distribucijska ter poprodajna logistika. V aplikativnem delu diplomskega dela je predstavljeno podjetje Lama Dekani, d.d. ter opis panoge, v kateri podjetje deluje. Podrobneje je opisana d...

  13. D and D Knowledge Management Information Tool - 2012 - 12106

    Deactivation and decommissioning (D and D) work is a high priority activity across the Department of Energy (DOE) complex. Subject matter specialists (SMS) associated with the different ALARA (As-Low-As-Reasonably-Achievable) Centers, DOE sites, Energy Facility Contractors Group (EFCOG) and the D and D community have gained extensive knowledge and experience over the years in the cleanup of the legacy waste from the Manhattan Project. To prevent the D and D knowledge and expertise from being lost over time from the evolving and aging workforce, DOE and the Applied Research Center (ARC) at Florida International University (FIU) proposed to capture and maintain this valuable information in a universally available and easily usable system. D and D KM-IT provides single point access to all D and D related activities through its knowledge base. It is a community driven system. D and D KM-IT makes D and D knowledge available to the people who need it at the time they need it and in a readily usable format. It uses the World Wide Web as the primary source for content in addition to information collected from subject matter specialists and the D and D community. It brings information in real time through web based custom search processes and its dynamic knowledge repository. Future developments include developing a document library, providing D and D information access on mobile devices for the Technology module and Hotline, and coordinating multiple subject matter specialists to support the Hotline. The goal is to deploy a high-end sophisticated and secured system to serve as a single large knowledge base for all the D and D activities. The system consolidates a large amount of information available on the web and presents it to users in the simplest way possible. (authors)

  14. 2D vs. 3D mammography observer study

    Fernandez, James Reza F.; Hovanessian-Larsen, Linda; Liu, Brent

    2011-03-01

    Breast cancer is the most common type of non-skin cancer in women. 2D mammography is a screening tool to aid in the early detection of breast cancer, but has diagnostic limitations of overlapping tissues, especially in dense breasts. 3D mammography has the potential to improve detection outcomes by increasing specificity, and a new 3D screening tool with a 3D display for mammography aims to improve performance and efficiency as compared to 2D mammography. An observer study using a mammography phantom was performed to compare traditional 2D mammography with this ne 3D mammography technique. In comparing 3D and 2D mammography there was no difference in calcification detection, and mass detection was better in 2D as compared to 3D. There was a significant decrease in reading time for masses, calcifications, and normals in 3D compared to 2D, however, as well as more favorable confidence levels in reading normal cases. Given the limitations of the mammography phantom used, however, a clearer picture in comparing 3D and 2D mammography may be better acquired with the incorporation of human studies in the future.

  15. Drug: D08704 [KEGG MEDICUS

    Full Text Available oride - magnesium carbonate - precipitated calcium carbonate mixt; Cabagin-U (TN) Magnesium aluminometasilic...ate [DR:D03242], Methylmethionine sulfonium chloride [DR:D00177], Magnesium carbonate [DR:D01446], Precipita...cer agents 2329 Others D08704 Magnesium aluminometasilicate - methylmethionine sulfonium chloride - magnesium carbonate - precipitated calcium carbonate mixt PubChem: 96025387 ...

  16. Drug: D08582 [KEGG MEDICUS

    Full Text Available D08582 Drug Thiamphenicol glycinate acetylcysteinate; Fluimucil antibiotic (TN) C19...CTERIALS FOR SYSTEMIC USE J01B AMPHENICOLS J01BA Amphenicols J01BA02 Thiamphenicol D08582 Thiamphenicol glycinate acetylcystein...02] D08582 Thiamphenicol glycinate acetylcysteinate CAS: 75639-30-4 PubChem: 96025266 LigandBox: D08582 NIKK

  17. Drug: D04842 [KEGG MEDICUS

    Full Text Available idual organs 27 Dental preparations 273 Analgesics and sedatives 2730 Analgesics and sedatives D04842 Formalin - cresol mixt PubChem: 17398191 ... ...ol [DR:D01960] Therapeutic category: 2730 Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting indiv...D04842 Mixture, Drug Formalin - cresol mixt; Formalin cresol (TN) Formalin [DR:D00017], Cres

  18. Drug: D07703 [KEGG MEDICUS

    Full Text Available D07703 Mixture, Drug Hydroxyethyl cellulose ... - boric acid - dibasic sodium phosphate - potassium ... sodium carbonate mixt; Scopisol (TN) Hydroxyethyl cellulose ... [DR:D04474], Boric acid [DR:D01089], Dibasic sodiu ... Ophthalmic agents 1319 Others D07703 Hydroxyethyl cellulose ... - boric acid - dibasic sodium phosphate - potassiu ...

  19. Drug: D06416 [KEGG MEDICUS

    Full Text Available D06416 Mixture, Drug Cresol solution (JP16) Saponated cresol solution [DR:D06417], ...Water [DR:D00001] Cresol solution is included 1.25-1.60 volume percent Cresol [DR:D01960] PubChem: 47208072 ...

  20. Drug: D05354 [KEGG MEDICUS

    Full Text Available D05354 Mixture, Drug Absorptive ointment (JP16) White petrolatum [DR:D05304], Cetanol [DR:D00099 ... se 71 Dispensing medicines 712 Ointment bases 7122 Emulsion ... bases D05354 Absorptive ointment (JP16) PubChem: 1 ...

  1. Drug: D06700 [KEGG MEDICUS

    Full Text Available D06700 Formula, Drug Kamishoyosan extract (JP16); Kamishoyosan Japanese angelica ro...200 Traditional Chinese medicines D06700 Kamishoyosan extract (JP16) Traditional Chinese Medicine in Japan [...BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D06700 *Kamishoyosan extract; Kamishoyos...an Formulas for Qi Sedative formulas D06700 *Kamishoyosan extract; Kamishoyosan PubChem: 47208351 ...

  2. Drug: D06311 [KEGG MEDICUS

    Full Text Available ICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AX Other antibiot...X10 J01FG01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D06 ANTIBIOT

  3. Drug: D00817 [KEGG MEDICUS

    Full Text Available NO. HCl 275.0844 276.2021 D00817.gif Antidepressant ATC code: N06AX12 dopamine noradrenalin selective reupta...ANTIDEPRESSANTS N06AX Other antidepressants N06AX12 Bupropion D00817 Bupropion hydrochloride (JAN/USP) USP d...ropion D00817 Bupropion hydrochloride (JAN/USP) Antidepressants Antidepressants,

  4. Drug: D06951 [KEGG MEDICUS

    Full Text Available D06951 Formula, Drug Keishakuchimoto Cinnamon bark [DR:D06712], Anemarrhena rhizome...tional Chinese medicines 5200 Traditional Chinese medicines D06951 Keishakuchimoto Traditional Chinese Medic...ine in Japan [BR:br08304] Formulas Formulas for dampness Antirheumatic formulas D06951 Keishakuchimoto PubChem: 51091293 ...

  5. Drug: D00407 [KEGG MEDICUS

    Full Text Available mical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (grou...TIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMI

  6. Drug: D04744 [KEGG MEDICUS

    Full Text Available D04744 Mixture, Drug Sodium thiosulfate - ethanol ... mixt; Hypoethanol ... (TN) Sodium thiosulfate [DR: ... D01091], (Ethanol ... added Geraniol (flavor) | Ethanol ... [DR:D06542]) The ... ial agents 2619 Others D04744 Sodium thiosulfate - ethanol ... mixt PubChem: 17398153 ...

  7. Drug: D03365 [KEGG MEDICUS

    Full Text Available D03365 Drug Nicotine ... (USP); Habitrol (TN) C10H14N2 162.1157 162.2316 D03365.gif Smoking cessatio ... urpose 799 Miscellaneous 7990 Miscellaneous D03365 Nicotine ... (USP) Anatomical Therapeutic Chemical (ATC) classi ... GS USED IN ADDICTIVE DISORDERS N07BA Drugs used in nicotine ... dependence N07BA01 Nicotine ... D03365 Nicotine ... (USP) ...

  8. Drug: D07435 [KEGG MEDICUS

    Full Text Available D07435 Mixture, Drug Papaveretum (BAN); Omnopon (TN) Morphine hydrochloride [DR:D02...271], Papaverine hydrochloride [DR:D02218], Codeine hydrochloride [DR:D07740] ATC code: N02AA10 A mixture of 253 parts of Morphine

  9. Drug: D05165 [KEGG MEDICUS

    Full Text Available tozoal [Histomonas, for poultry] CAS: 5579-89-5 PubChem: 47206889 LigandBox: D05165 NIKKAJI: J8.000D ATOM 16...D05165 Drug Nifursemizone (USAN/INN) C8H10N4O4 226.0702 226.1894 D05165.gif Antipro

  10. Drug: D06763 [KEGG MEDICUS

    Full Text Available D06763 Crude, Drug Polyporus sclerotium (JP16); Powdered polyporus sclerotium (JP16...510 Crude drugs 5100 Crude drugs D06763 Polyporus sclerotium (JP16); Powdered pol...iuretic drugs D06763 Polyporus sclerotium; Powdered polyporus sclerotium; Chuling Crude drugs [BR:br08305] Fungi Basidiomycetes D06763 Polyporus sclerotium PubChem: 47208414 ...

  11. Drug: D06712 [KEGG MEDICUS

    Full Text Available D06712 Crude, Drug Cinnamon bark (JP16); Powdered cinnamon bark (JP16); Cinnamon ba...d Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06712 Cinnamon bark (JP16); Powdered... Crude Drugs Diaphoretic drugs Diaphoretic drugs pungent in flavor and warm in property D06712 Cinnamon bark; Powdered

  12. Drug: D06780 [KEGG MEDICUS

    Full Text Available D06780 Crude, Drug Atractylodes rhizome (JP16); Powdered atractylodes rhizome (JP16... drugs 510 Crude drugs 5100 Crude drugs D06780 Atractylodes rhizome (JP16); Powdered...pness Diuretic drugs D06780 *Atractylodes rhizome; Powdered atractylodes rhizome; Atractyloides rhizoma Drug...s for resolving dampness D06780 *Atractylodes rhizome; Powdered atractylodes rhizome; Atractyloides rhizoma

  13. Drug: D06679 [KEGG MEDICUS

    Full Text Available D06679 Crude, Drug Gambir (JP16); Powdered gambir (JP16); Gamibir (TN) (+)-Catechin...edicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D06679 Gambir (JP16); Powdered gambir (...nd expectorants D06679 Gambir; Powdered gambir; Gamibir Drugs for external use Drugs for external use D06679 *Gambir; Powdered

  14. Drug: D04173 [KEGG MEDICUS

    Full Text Available D04173 Drug Ferrous sulfate Fe 59 (USAN) SO4. Fe 154.8866 151.9076 D04173.gif Radioactive agent ... PubChem: 47206119 LigandBox: D04173 ATOM ... 6 1 S4a S 18.3400 -17.7800 2 O1d O 18.3400 -16.380 ...

  15. Drug: D03789 [KEGG MEDICUS

    Full Text Available D03789 Drug Dichlorodifluoromethane (NF) CCl2F2 119.9345 120.9135 D03789.gif Pharmaceutic aid [a ... bChem: 17397877 LigandBox: D03789 NIKKAJI: J1.462A ATOM ... 5 1 X F 12.3900 -11.8300 2 C1d C 13.7900 -11.8300 ...

  16. Drug: D02059 [KEGG MEDICUS

    Full Text Available D02059 Drug Sodium bisulfite (JP16); Sodium bisulfite (TN) HSO3. Na 103.9544 104.0609 D02059.gif ... Chem: 7849121 LigandBox: D02059 NIKKAJI: J134.329G ATOM ... 5 1 S4a S 28.0233 -18.8533 2 O1d O 28.0233 -17.453 ...

  17. Drug: D04677 [KEGG MEDICUS

    Full Text Available D04677 Mixture, Drug Paraphlebon - senna powder - sulfur - potassium hydrogen ... tartrate mixt; Cir ... powder [DR:D06751], Sulfur [DR:D00024], Potassium hydrogen ... tartrate [DR:D01561] Therapeutic category: 2559 Th ... 77 Paraphlebon - senna powder - sulfur - potassium hydrogen ... tartrate mixt PubChem: 17398137 ...

  18. Drug: D04364 [KEGG MEDICUS

    Full Text Available D04364 Mixture, Drug Dicyclomine hydrochloride - aluminium hydroxide, dried - magne...sium oxide mixt; Kolantyl (TN) Dicyclomine hydrochloride [DR:D00717], Aluminum hydroxide, dried [DR:D02416],...gents 2329 Others D04364 Dicyclomine hydrochloride - aluminium hydroxide, dried - magnesium oxide mixt PubChem: 17398075 ...

  19. Drug: D04750 [KEGG MEDICUS

    Full Text Available D04750 Drug Lithium hydroxide (USP) LiHO. H2O 42.0293 41.9636 D04750.gif Antimanic ...CHOLEPTICS N05A ANTIPSYCHOTICS N05AN Lithium N05AN01 Lithium D04750 Lithium hydroxide (USP) USP drug classif...ication [BR:br08302] Bipolar Agents Mood Stabilizers Lithium D04750 Lithium hydroxide

  20. Drug: D09074 [KEGG MEDICUS

    Full Text Available D09074 Formula, Drug Byakkokakeishito Gypsum [DR:D01728], Anemarrhena rhizome [DR:D...icine in Japan [BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D09074 Byakkokakeishito PubChem: 96025755 ...

  1. Drug: D00862 [KEGG MEDICUS

    Full Text Available asitics Agents against Leishmaniasis and Trypanosomiasis Nitrofuran derivatives Nitrofural [ATC:B05CA03 D08A...03 D08AF01 D09AA03 P01CC02 S01AX04 S02AA02]; Veterinary D00862 Nitrofurazone (USP); Nitrofural (INN) Antipar

  2. Drug: D04692 [KEGG MEDICUS

    Full Text Available D04692 Mixture, Drug Diflucortolone valerate - Lidocaine mixt; Neriproct (TN) Diflu...cortolone valerate [DR:D01764], Lidocaine [DR:D00358] Therapeutic category: 2559 Therapeutic category of dru...hoidal preparations 2559 Others D04692 Diflucortolone valerate - Lidocaine mixt PubChem: 17398140 ...

  3. Drug: D07742 [KEGG MEDICUS

    Full Text Available D07742 Mixture, Drug Ethyl aminobenzoate - lidocaine - bismuth subgallate mixt; Hel...mitin S (TN) Ethyl aminobenzoate [DR:D00552], Lidocaine [DR:D00358], Bismuth subgallate [DR:D01398] Therapeu...742 Ethyl aminobenzoate - lidocaine - bismuth subgallate mixt PubChem: 96024465 ...

  4. Drug: D02261 [KEGG MEDICUS

    Full Text Available Quinine hydrochloride (TN) C20H24N2O2. 2H2O. HCl 396.1816 396.9083 D02261.gif Antiprotozoal, Antimalarial [D... and parasites 64 Parasitics (systemic) 641 Antiprotozoans 6415 Quinines D02261 Q...ation [BR:br08302] Antiparasitics Antiprotozoals Quinine D02261 Quinine hydrochloride hydrate (JP16) Antiinf

  5. Drug: D04934 [KEGG MEDICUS

    Full Text Available D04934 Drug Mercury , ammoniated (USP); Mercury ... amide chloride; Mercuric amidochloride HgNH2Cl 25 ... ial products D08AK01 Mercuric amidochloride D04934 Mercury , ammoniated (USP) S SENSORY ORGANS S01 OPHTHALMOLO ... ANTIINFECTIVES S01AX Other antiinfectives S01AX01 Mercury ... compounds D04934 Mercury , ammoniated (USP) CAS: 10 ...

  6. Drug: D01772 [KEGG MEDICUS

    Full Text Available D01772 Drug Ether (JP16/USP); Diethyl ether C4H10O 74.0732 74.1216 D01772.gif Anest... N01AA01 Diethyl ether D01772 Ether (JP16/USP) CAS: 60-29-7 PubChem: 7848835 PDB-CCD: ETZ LigandBox: D0177

  7. Drug: D04797 [KEGG MEDICUS

    Full Text Available D04797 Mixture, Drug Zinc oxide starch ... powder (JP16); Zinc oxide starch ... powder (TN) Zinc oxide [ ... DR:D01170], Potato starch ... [DR:D05318] Therapeutic category: 2621 2649 Therap ... kin protectants 2621 Zinc oxides D04797 Zinc oxide starch ... powder (JP16) 264 Analgesics, anti-itchings, astri ...

  8. Drug: D03285 [KEGG MEDICUS

    Full Text Available D03285 Drug Diphenhydramine tannate (JP16); Restamin A (TN) Antihistaminic Therapeutic category: ... ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC . D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHE ... TICS, ETC . D04AA Antihistamines for topical use D04AA32 Diph ...

  9. Drug: D10261 [KEGG MEDICUS

    Full Text Available D10261 Mixture, Drug Metformin hydrochloride - sitagliptin phosphate mixt; Janumet (TN) Metformin hydr...ochloride [DR:D00944], Sitagliptin phosphate hydrate [DR:D06645] Antidiabetic [DS:H00409]...SULINS A10BD Combinations of oral blood glucose lowering drugs A10BD07 Metformin and sitagliptin D10261 Metformin hydrochloride - sitagliptin phosphate mixt PubChem: 163312292 ...

  10. Drug: D04817 [KEGG MEDICUS

    Full Text Available D04817 Mixture, Drug Propitocaine hydrochloride - felypressin mixt; Citanest octapr...essin (TN) Propitocaine hydrochloride [DR:D01243], Felypressin [DR:D04137] Therapeutic category: 2710 Therapeutic category of dr...1 Local anesthetics 2710 Local anesthetics D04817 Propitocaine hydrochloride - felypressin mixt PubChem: 17398185 ...

  11. Drug: D08749 [KEGG MEDICUS

    Full Text Available D08749 Mixture, Drug Hydroxocobalamin - isotonic sodium chloride solution mixt Hydr...oxocobalamin [DR:D01027], Isotonic sodium chloride solution [DR:D05352] Therapeutic category: 3929 Therapeutic category of dr...m 392 Antidotes 3929 Others D08749 Hydroxocobalamin - isotonic sodium chloride solution mixt PubChem: 96025432 ...

  12. Drug: D08754 [KEGG MEDICUS

    Full Text Available D08754 Mixture, Drug L-Arginine - L-arginine hydrochloride mixt; Argi-U (TN) L-Argi...nine [DR:D02982], L-Arginine hydrochloride [DR:D01126] Therapeutic category: 3999 Therapeutic category of dr...us 3999 Others D08754 L-Arginine - L-arginine hydrochloride mixt PubChem: 96025437 ...

  13. Drug: D03980 [KEGG MEDICUS

    Full Text Available D03980 Mixture, Drug Isopropylantipyrine - allyl isopropyl acetyl urea ... - phenacetin - caffeine m ... opylantipyrine [DR:D01380], Allyl isopropyl acetyl urea ... [DR:D03975], Phenacetin [DR:D00569], Caffeine [DR: ... 03980 Isopropylantipyrine - allyl isopropyl acetyl urea ... - phenacetin - caffeine mixt N02BE Anilides N02BE5 ...

  14. Drug: D04019 [KEGG MEDICUS

    Full Text Available D04019 Mixture, Drug Isopropylantipyrine - allyl isopropyl acetyl urea ... - phenacetin - anhydrous ... opylantipyrine [DR:D01380], Allyl isopropyl acetyl urea ... [DR:D03975], Phenacetin [DR:D00569], Anhydrous caf ... 04019 Isopropylantipyrine - allyl isopropyl acetyl urea ... - phenacetin - anhydrous caffeine mixt N02BE Anili ...

  15. Drug: D08775 [KEGG MEDICUS

    Full Text Available D08775 Mixture, Drug Abacavir sulfate - lamivudine mixt; Epzicom (TN) Abacavir sulf...emotherapeutics 625 Antivirals 6250 Antivirals D08775 Abacavir sulfate - lamivudi...ns, combinations J05AR02 Lamivudine and abacavir D08775 Abacavir sulfate - lamivu... Transcriptase Inhibitors (NRTI)v Abacavir and Lamivudine D08775 Abacavir sulfate - lamivudine mixt PubChem: 96025458 ...

  16. Drug: D10134 [KEGG MEDICUS

    Full Text Available D10134 Drug Lumacaftor (USAN) C24H18F2N2O5 452.1184 452.4069 D10134.gif Treatment o...subfamily CFTR [HSA:1080] [KO:K05031] Lumacaftor D10134 Lumacaftor (USAN) CAS: 936727-05-8 PubChem: 135626852 LigandBox: D101

  17. Drug: D06429 [KEGG MEDICUS

    Full Text Available D06429 Drug Gelatin ... sponge, absorbable; Gelfoam (TN) Hemostatic [local] ATC code: B02BC01 B05AA0 ... STATICS B02BC Local hemostatics B02BC01 Absorbable gelatin ... sponge D06429 Gelatin ... sponge, absorbable B05 BLOOD ... d substitutes and plasma protein fractions B05AA06 Gelatin ... agents D06429 Gelatin ... sponge, absorbable CAS: 9000 ...

  18. Drug: D09108 [KEGG MEDICUS

    Full Text Available rea root [DR:D06795], Ginger [DR:D06744], Rush [ED:E00299] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas... for Qi Formulas for regulating Qi D09108 *Jippiin; Jippito Formulas for dampness Diuretic formulas D09108 *Jippiin; Jippito PubChem: 96025788 ...

  19. Drug: D09055 [KEGG MEDICUS

    Full Text Available DR:D00092], Scutellaria root [DR:D06688], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for clearing heat Formulas for clearing heat D09055 Kakkon'oren'ogonto PubChem: 96025736 ...

  20. Drug: D09049 [KEGG MEDICUS

    Full Text Available [DR:D06795], Ginger [DR:D06744], Rush [ED:E00299] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formul...as for regulating Qi D09049 *Bunshoto Formulas for dampness Diuretic formulas D09049 *Bunshoto PubChem: 96025730 ...

  1. Drug: D09047 [KEGG MEDICUS

    Full Text Available ginger [DR:D06744], Immature orange [DR:D06706], Evodia fruit [DR:D00173] Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for stomach Formulas for calming stomachache D09047 En'nenhangeto PubChem: 96025728 ...

  2. Drug: D09103 [KEGG MEDICUS

    Full Text Available :D06769], Corydalis tuber [DR:D06686], Saussurea root [DR:D06795] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for blood Formulas for removing blood stasis D09103 Goshitsusan PubChem: 96025783 ...

  3. Drug: D09096 [KEGG MEDICUS

    Full Text Available lla herb [DR:D06755], Dry ginger [DR:D06744], Poria sclerotium [DR:D06783] Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for dampness Diuretic formulas D09096 Keimeisankabukuryo PubChem: 96025776 ...

  4. Drug: D09111 [KEGG MEDICUS

    Full Text Available ca root [DR:D06768], Clematis root [DR:D06694], Sophora root [DR:D06710] Traditional Chinese Medicine in Japan [BR:br08304] Formulas... Formulas for external use Formulas for external use D09111 Jashoshito PubChem: 96025791 ...

  5. Drug: D03068 [KEGG MEDICUS

    Full Text Available D03068 Drug Belimumab (genetical recombination) (JAN); Belimumab (USAN); Benlysta (...nts L04AA26 Belimumab D03068 Belimumab (genetical recombination) (JAN); Belimumab... (USAN) USP drug classification [BR:br08302] Immunological Agents Immunomodulators Belimumab D03068 Belimumab (genetica...nes TNF family BAFF [HSA:10673] [KO:K05476] Belimumab [ATC:L04AA26] D03068 Belimumab (genetica

  6. Drug: D00172 [KEGG MEDICUS

    Full Text Available D00172 Drug Eptacog alfa (activated) (genetical recombination) (JAN); Eptacog alfa ...a preparations D00172 Eptacog alfa (activated) (genetical recombination) (JAN); Eptacog alfa (INN) Anatomica...oagulation factor VII D00172 Eptacog alfa (activated) (genetical recombination) (JAN); Eptacog alfa (INN) B0...2BD08 Eptacog alfa (activated) D00172 Eptacog alfa (activated) (genetical recombi

  7. Drug: D03135 [KEGG MEDICUS

    Full Text Available D03135 Drug Bithionolate sodium (USAN); Sodium bitionolate (INN) C12H4Cl4O2S. 2Na 397.8481 400.0 ... sification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE ... PREPARATIONS D10A ANTI-ACNE ... PREPARATIONS FOR TOPIC ...

  8. Drug: D07512 [KEGG MEDICUS

    Full Text Available D07512 Drug Benproperine (INN); Cofrel (TN) C21H27NO 309.2093 309.4452 D07512.gif Antitussive AT ... assification [BR:br08303] R RESPIRATORY SYSTEM R05 COUGH ... AND COLD PREPARATIONS R05D COUGH ... SUPPRESSANTS, EXC ... L. COMBINATIONS WITH EXPECTORANTS R05DB Other cough ... suppressants R05DB02 Benproperine D07512 Benproper ...

  9. Drug: D07721 [KEGG MEDICUS

    Full Text Available D07721 Drug Clofedanol (INN); Chlophedianol; Antitussin (TN) C17H20ClNO 289.1233 289.7998 D07721 ... assification [BR:br08303] R RESPIRATORY SYSTEM R05 COUGH ... AND COLD PREPARATIONS R05D COUGH ... SUPPRESSANTS, EXC ... L. COMBINATIONS WITH EXPECTORANTS R05DB Other cough ... suppressants R05DB10 Clofedanol D07721 Clofedanol ...

  10. Drug: D08334 [KEGG MEDICUS

    Full Text Available D08334 Drug Pentoxyverine (INN); Sedotussin (TN) C20H31NO3 333.2304 333.465 D08334.gif Antitussi ... assification [BR:br08303] R RESPIRATORY SYSTEM R05 COUGH ... AND COLD PREPARATIONS R05D COUGH ... SUPPRESSANTS, EXC ... L. COMBINATIONS WITH EXPECTORANTS R05DB Other cough ... suppressants R05DB05 Pentoxyverine D08334 Pentoxyv ...

  11. Drug: D05273 [KEGG MEDICUS

    Full Text Available D05273 Drug Ormetoprim (USAN/INN) C14H18N4O2 274.143 274.3183 D05273.gif Antibacterial Component ... of Rofenaid (TN) veterinary ... medicine Trimethoprim [DR:D00145] derivative Antii ... r [KO:K13938] Trimethoprim derivatives Ormetoprim; Veterinary ... D05273 Ormetoprim (USAN/INN) CAS: 6981-18-6 PubChe ...

  12. Drug: D09595 [KEGG MEDICUS

    Full Text Available D09595 Mixture, Drug Budesonide - formoterol fumarate dihydrate mixt; Symbicort (TN...us 2290 Miscellaneous D09595 Budesonide - formoterol fumarate dihydrate mixt Anatomical Therapeutic Chemical...drugs, excl. anticholinergics R03AK07 Formoterol and budesonide D09595 Budesonide - formoterol fumarate dihy... Other Budesonide/Formoterol fumarate D09595 Budesonide - formoterol fumarate dihydrate mixt PubChem: 124490335 ...

  13. Drug: D07463 [KEGG MEDICUS

    Full Text Available D07463 Drug Arformoterol (INN) C19H24N2O4 344.1736 344.4049 D07463.gif Bronchodilat...espiratory Tract/Pulmonary Agents Bronchodilators, Sympathomimetic Arformoterol D07463 Arformoterol (INN) Ta...psin family Adrenaline beta2-adrenergic receptor [HSA:154] [KO:K04142] Arformoterol D07463 Arformoterol (INN

  14. Drug: D09106 [KEGG MEDICUS

    Full Text Available D09106 Formula, Drug Satotsuko Bitumen, , Lard [DR:D05301], Sesame oil [DR:D03314] Traditional Chinese Medic...ine in Japan [BR:br08304] Formulas Formulas for external use Formulas for external use D09106 Satotsuko PubChem: 96025786 ...

  15. Drug: D09097 [KEGG MEDICUS

    Full Text Available D09097 Formula , Drug Kenchuto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D06783], Cinnamon ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for stomach Antiemetic formula s D09097 K ...

  16. Drug: D09119 [KEGG MEDICUS

    Full Text Available D09119 Formula , Drug Shojokito Rhubarb [DR:D06756], Immature orange [DR:D06706], Magnolia bark [ ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Purgative formula s Purgative formula s D09119 Shoj ...

  17. Drug: D09057 [KEGG MEDICUS

    Full Text Available D09057 Formula , Drug Kamiuntanto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D06783], Citru ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for Qi Formula s for regulating Qi D09057 ...

  18. Drug: D09048 [KEGG MEDICUS

    Full Text Available D09048 Formula , Drug Boibukuryoto Sinomenium stem [DR:D06785], Astragalus root [DR:D06687], Cinn ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for dampness Diuretic formula s D09048 Bo ...

  19. Drug: D09070 [KEGG MEDICUS

    Full Text Available D09070 Formula , Drug Keishikashakuyakushokyoninjinto Cinnamon bark [DR:D06712], Peony root [DR:D ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for Qi Formula s for replenishing Qi D090 ...

  20. Drug: D09079 [KEGG MEDICUS

    Full Text Available D09079 Formula , Drug Dokkatsukakkonto Pueraria root [DR:D06693], Ephedra herb [DR:D06791], Cinna ... Traditional Chinese Medicine in Japan [BR:br08304] Formula s Formula s for dampness Antirheumatic formula s D090 ...